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Background: Acute respiratory failure is a life-threatening emergency. Standard prehospital
management involves controlled oxygen therapy. Continuous positive airway pressure is a potentially
beneficial alternative treatment; however, it is uncertain whether or not this treatment could improve
outcomes in NHS ambulance services.
Objectives: To assess the feasibility of a large-scale pragmatic trial and to update an existing economic
model to determine cost-effectiveness and the value of further research.
Design: (1) An open-label, individual patient randomised controlled external pilot trial. (2) Cost-effectiveness
and value-of-information analyses, updating an existing economic model. (3) Ancillary substudies, comprising
an acute respiratory failure incidence study, an acute respiratory failure diagnostic agreement study, clinicians
perceptions of a continuous positive airway pressure mixed-methods study and an investigation of
allocation concealment.
Setting: Four West Midlands Ambulance Service hubs, recruiting between August 2017 and July 2018.
Participants: Adults with respiratory distress and peripheral oxygen saturations below the British
Thoracic Society’s target levels were included. Patients with limited potential to benefit from, or with
contraindications to, continuous positive airway pressure were excluded.
Interventions: Prehospital continuous positive airway pressure (O-Two system, O-Two Medical Technologies
Inc., Brampton, ON, Canada) was compared with standard oxygen therapy, titrated to the British Thoracic
Society’s peripheral oxygen saturation targets. Interventions were provided in identical sealed boxes.
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Main outcome measures: Feasibility objectives estimated the incidence of eligible patients, the
proportion recruited and allocated to treatment appropriately, adherence to allocated treatment,
and retention and data completeness. The primary clinical end point was 30-day mortality.
Results: Seventy-seven patients were enrolled (target 120 patients), including seven patients with a
diagnosis for which continuous positive airway pressure could be ineffective or harmful. Continuous
positive airway pressure was fully delivered to 74% of participants (target 75%). There were no major
protocol violations/non-compliances. Full data were available for all key outcomes (target ≥ 90%).
Thirty-day mortality was 27.3%. Of the 21 deceased participants, 14 (68%) either did not have a
respiratory condition or had ceiling-of-treatment decision implemented that excluded hospital non-
invasive ventilation and critical care. The base-case economic evaluation indicated that standard oxygen
therapy was probably cost-effective (incremental cost-effectiveness ratio £5685 per quality-adjusted
life-year), but there was considerable uncertainty (population expected value of perfect information
of £16.5M). Expected value of partial perfect information analyses indicated that effectiveness of
prehospital continuous positive airway pressure was the only important variable. The incidence rate
of acute respiratory failure was 17.4 (95% confidence interval 16.3 to 18.5) per 100,000 persons per
year. There was moderate agreement between the primary prehospital and final hospital diagnoses
(Gwet’s AC1 coefficient 0.56, 95% confidence interval 0.43 to 0.69). Lack of hospital awareness of the
Ambulance continuous positive airway pressure (CPAP): Use, Treatment Effect and economics (ACUTE)
trial, limited time to complete trial training and a desire to provide continuous positive airway pressure
treatment were highlighted as key challenges by participating clinicians.
Limitations: During week 10 of recruitment, the continuous positive airway pressure arm equipment
boxes developed a ‘rattle’. After repackaging and redistribution, no further concerns were noted.
A total of 41.4% of ambulance service clinicians not participating in the ACUTE trial indicated a
difference between the control and the intervention arm trial boxes (115/278); of these clinician
70.4% correctly identified box contents.
Conclusions: Recruitment rate was below target and feasibility was not demonstrated. The economic
evaluation results suggested that a definitive trial could represent value for money. However, limited
compliance with continuous positive airway pressure and difficulty in identifying patients who could
benefit from continuous positive airway pressure indicate that prehospital continuous positive airway
pressure is unlikely to materially reduce mortality.
Future work: A definitive clinical effectiveness trial of continuous positive airway pressure in the NHS
is not recommended.
Trial registration: Current Controlled Trials ISRCTN12048261.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health
Technology Assessment programme and will be published in full in Health Technology Assessment;
Vol. 25, No. 7. See the NIHR Journals Library website for further project information.
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Acute respiratory failure Low oxygen levels and/or high carbon dioxide in the blood resulting from an
acute disease process involving the lungs. Type 1 respiratory failure is defined as a partial pressure of
oxygen in arterial blood of < 8 kPa with a normal or low partial pressure of carbon dioxide in arterial
blood. Type 2 failure is defined as a partial pressure of carbon dioxide of > 6.1 kPa.
Ambulance hub A central regional building in which ambulances are prepared prior to travelling to
local ambulance stations to respond to emergency calls.
Ceiling of treatment The highest level of medical intervention deemed appropriate by a medical team,
aligning with patient and family wishes, values and beliefs.
Chronic obstructive pulmonary disease A disease in which the lungs’ airways become chronically
inflamed (bronchitis) and the air sacs are damaged (emphysema).
Continuous positive airway pressure Oxygen-enriched air is delivered to lungs at increased pressure
through a tight-fitting face mask. This splints open the lungs’ airways and pushes fluid and mucus out
of the lungs’ air sacs.
Hypercarbia High levels of the waste product carbon dioxide in the body’s blood. Caused when
diseases of the lung or heart prevent the lungs from excreting carbon dioxide. Defined as a partial
pressure of carbon dioxide in arterial blood of > 6.1 kPa.
Hypoxia Low oxygen levels in the blood delivered to the body’s tissues. Can be caused by diseases of
the lung or heart, which reduce the ability of the lungs to absorb oxygen. Defined by a partial pressure
of oxygen in arterial blood of < 8 kPa.
Non-invasive ventilation An external method to support breathing by cyclically pushing air into the
lungs (bi-level positive airway pressure) or delivering oxygen at a continually increased pressure
(continuous positive airway pressure).
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3CPO Three Interventions in Cardiogenic
Pulmonary Oedema
ACUTE Ambulance CPAP: Use, Treatment
Effect and economics
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Acute respiratory failure is a life-threatening medical emergency. It occurs when heart or lungdisease suddenly develops, or deteriorates, and leads to the patient being unable to maintain
oxygen levels in their blood. Continuous positive airway pressure is a potentially useful treatment
that could be used by paramedics. It involves delivering oxygen under increased pressure through a
tight-fitting face mask. However, it is uncertain whether or not it could work effectively in NHS
ambulance services, or if it represents value for money.
The Ambulance continuous positive airway pressure (CPAP): Use, Treatment Effect and economics
(ACUTE) trial investigated whether or not it is possible and worthwhile to undertake a full-scale study
comparing continuous positive airway pressure with normal paramedic treatment. Paramedics identified
adults with acute respiratory failure when attending 999 emergency calls. Half were randomly assigned
to receive continuous positive airway pressure, whereas the other half were treated normally. Patients
were then followed up to see what happened to them.
Fewer patients than expected were entered into the trial, but paramedics were able to provide
treatment with continuous positive airway pressure, and most patients were successfully followed up.
It therefore seems possible to do a full-scale trial. A cost-effectiveness model also showed that it is
uncertain whether or not continuous positive airway pressure represents value for money for the
NHS, so further research might be worthwhile, if continuous positive airway pressure is thought to
be effective.
However, examination of patients recruited to the trial uncovered important doubts about whether or
not continuous positive airway pressure would help them. One-quarter of patients were not able to
tolerate the tight continuous positive airway pressure mask. Some of the patients had conditions that
are not usually treated by continuous positive airway pressure, or had severe underlying disease that
could not be helped by this treatment. Others had collapsed lungs that could have been made worse
by continuous positive airway pressure. This means that, although a full-scale trial may be possible,
it is difficult to see how continuous positive airway pressure could save enough lives to make a
trial worthwhile.
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Acute respiratory failure is a serious acute illness that occurs when diseases of the heart or lungs lead
to failure of the respiratory system, over minutes or hours, in one or both of its gas exchange functions
(oxygenation and carbon dioxide elimination). Common causes of acute respiratory failure include
heart failure, pneumonia, chronic obstructive pulmonary disease, pulmonary embolism and asthma.
The incidence of acute respiratory failure has been estimated at 80 cases per 100,000 per year.
The overall risk of death is high, with estimates of 30-day mortality ranging between 14% and 20%.
Acute respiratory failure has substantial health services costs, with patients often requiring prolonged
hospital stays, ventilatory support and critical care admissions. Acute respiratory failure accounts for
over 3 million NHS bed-days and hospital costs of £9.6M per year in England.
Current prehospital management of acute respiratory failure in the NHS uses a standard management
approach of controlled oxygen therapy, supplemented by specific ancillary treatments directed at the
underlying disease. Continuous positive airway pressure involves delivering oxygen-enriched air to the
lungs at increased pressure through a tight-fitting face mask. Continuous positive airway pressure is
widely used in hospitals to treat acute respiratory failure from a number of causes, and it has been
suggested that it may be more effective if delivered earlier (i.e. en route to hospital). The difficulties
of prehospital diagnosis mean that prehospital continuous positive airway pressure is likely to be
applied generally to all cases of acute respiratory failure, rather than directed towards certain patients
owing to a specific cause.
Existing research investigating prehospital continuous positive airway pressure is inconclusive. A previous
Health Technology Assessment programme evidence synthesis [Pandor A, Thokala P, Goodacre S, Poku E,
Stevens JW, Ren S, et al. Pre-hospital non-invasive ventilation for acute respiratory failure: a systematic
review and cost-effectiveness evaluation. Health Technol Assess 2015;19(42)] suggested that prehospital
continuous positive airway pressure could be effective in reducing mortality and intubation rates. However,
included studies were deemed to be at a high risk of bias and the findings were not generalisable to the
NHS. None of the included studies was undertaken in the UK and the methods used to deliver prehospital
continuous positive airway pressure (physician or paramedics with online physician support) would
not reflect normal NHS practice. An economic model developed for the same project suggested that
prehospital continuous positive airway pressure was more effective than standard care, but was also
more expensive, with an incremental cost-effectiveness ratio of £20,514 per quality-adjusted life-year.
The model also indicated that further research costing up to £22.5M could represent value for money.
Although prehospital continuous positive airway pressure is a promising therapy, further research
is needed to examine whether or not the reported clinical effectiveness and cost-effectiveness are
confirmed in the UK setting, with unsupported paramedic delivery and limited additional training.
Prior to a large pragmatic trial and economic evaluation, it is first necessary to estimate the incidence
of eligible patients to determine whether or not a trial would be feasible and cost-effective. It is
also important to determine whether or not prehospital continuous positive airway pressure can be
delivered successfully in the context of the NHS ambulance services. For these reasons, a stand-alone
feasibility study is necessary to estimate the incidence of eligible patients, to test the feasibility and
acceptability of potential definitive trial methods, and to address important uncertainties, such as
patient selection, delivery of the intervention and event rates.
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Objectives
Primary objectives were to estimate the following feasibility outcomes:
l The rate of eligible patients per 100,000 persons per year.
l The proportion of participants recruited and allocated to treatment appropriately.
l Adherence to allocated treatment.
l Retention and data completeness up to 30 days.
Secondary objectives were to estimate the following summary clinical outcome measures:
l The proportion of participants surviving to 30 days.
l The proportion of participants undergoing endotracheal intubation by 30 days.
l The proportion of participants admitted to critical care at any point up to 30 days.
l The mean and median lengths of hospital stay.
l Change in visual analogue scale dyspnoea score from presentation to immediately before
emergency department arrival.
l The mean EuroQol-5 Dimensions, five-level version, score at 30 days.
l Key elements of health-care resource use up to 30 days.
Methods
Pilot trial
An open-label, individual patient randomised, parallel-arm, controlled, external pilot trial was conducted
to determine the feasibility of a definitive trial evaluating the clinical effectiveness and cost-effectiveness
of prehospital continuous positive airway pressure compared with standard oxygen therapy in acute
respiratory failure. A sample size of 120 participants was planned, allowing mortality to be estimated
with a standard error of 2.7% for use in the sample size calculation of an eventual large-scale trial and
estimation of feasibility outcomes with a precision of < 5%.
Recruitment took place across four West Midlands Ambulance Service hubs between August 2017 and
July 2018. Adults with respiratory distress and peripheral oxygen saturation below the British Thoracic
Society’s target levels, despite supplemental oxygen, were eligible. Patients with pre-existing lack of
capacity, or with limited potential to benefit from, or contraindications to, continuous positive airway
pressure were excluded.
Participants in the intervention arm were treated with prehospital continuous positive airway pressure
(O-Two unit, O-Two Medical Technologies Inc., Brampton, ON, Canada). Participants in the control arm
received standard oxygen therapy. Ancillary condition-specific treatments were administered in both
arms according to standard practice guidelines. Interventions were provided in identical sealed boxes
to ensure allocation concealment. Participants were individually randomised in a 1 : 1 ratio using simple
randomisation, constrained by the maximum number of boxes supplied for trial use (n = 160).
Feasibility outcomes comprised incidence of eligible patients (target 120); the proportion recruited and
allocated to treatment appropriately (target ≥ 90); adherence to allocated treatment (target ≥ 75%);
and retention and data completeness (target ≥ 90%). Effectiveness outcomes were survival at 30 days
(definitive trial primary end point); endotracheal intubation; admission to critical care; length of hospital
stay; EuroQol-5 Dimensions, five-level version, score; and health-care resource use at 30 days.
Economic evaluation
Cost-effectiveness and value-of-information analyses were also performed, updating the previously
described economic model and evidence synthesis with data from the Ambulance continuous positive
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airway pressure (CPAP): Use, Treatment Effect and economics (ACUTE) pilot trial. Prehospital
continuous positive airway pressure and standard care were compared in a probabilistic sensitivity
analysis following the National Institute for Health and Care Excellence base-case recommendations.
The cost-effectiveness of the different interventions was estimated using the incremental cost-
effectiveness ratio approach. The population expected value of perfect information and expected value
of partial perfect information were calculated to indicate the cost-effectiveness of further research.
Ancillary substudies
West Midlands Ambulance Service patient records between 1 August 2017 and 31 July 2018 were
electronically screened and examined by research paramedics to identify patients presenting with
acute respiratory failure who were potentially eligible for the ACUTE trial. The incidence rate was
then calculated using a population denominator determined from Office for National Statistics data.
Agreement between the prehospital clinical impression and final hospital diagnosis was compared for
patients enrolled in the pilot trial. The experiences of ambulance service clinicians participating in the
ACUTE trial were examined in a mixed-methods study consisting of a survey and focus groups. The
robustness of allocation concealment was investigated in a convenience sample of no-trial ambulance
service clinicians from Yorkshire Ambulance Service and West Midlands Ambulance Service. Clinician
participants were asked to indicate whether or not they could differentiate between a randomly
selected pair of control and intervention arm boxes.
Results
Pilot trial
Over 12 months, 77 participants were enrolled (continuous positive airway pressure arm, n = 42;
standard oxygen control arm, n = 35; target, n = 120). Continuous positive airway pressure was fully
delivered as planned in 74% of intervention arm participants (target 75%). There were no major
protocol violations or non-compliances (target 0%). Full data were available for key outcomes, including
all feasibility end points and vital status at 30 days (targets of ≥ 90%). There was missing information
on other clinical outcomes, with data completeness ranging from 79% to 100%.
Mortality was higher than expected [overall 27.3%: continuous positive airway pressure arm, n/N = 12/42
(28.6%); standard care arm, n/N = 9/35 (25.7%)]. Of the 21 deceased participants, 14 (68%) either did
not have a respiratory condition or had explicit or implicit ceiling-of-treatment decisions, which excluded
hospital non-invasive ventilation or critical care. The risk of intubation was low (overall 4.8%: continuous
positive airway pressure arm, 6.1%; standard care arm, 3.4%) and only a small proportion of participants
were admitted to critical care (overall 9.2%: continuous positive airway pressure arm, 11.4%; standard
care arm, 6.7%).
Hospital length of stay was similar for both trial arms (continuous positive airway pressure arm, median
10 days; standard oxygen therapy arm, median 7 days). Breathlessness was similar across trial arms and
improved over the prehospital interval from an initial clinician-assessed visual analogue scale median
score of 9 out of 10 (n = 76, interquartile range 8–10) to 6 out of 10 (n = 76, interquartile range 5–8)
on arrival at hospital. The median follow-up EuroQol-5 Dimensions, five-level version, score at 30 days
was 0.82 (n = 22, interquartile range 0.58–0.95) in the continuous positive airway pressure arm and
0.73 (n = 18, interquartile range 0.43–0.89) in the standard care arm.
Adverse events related to continuous positive airway pressure comprised mild claustrophobia or distress
associated with continuous positive airway pressure mask use. Two participants were diagnosed with a
pneumothorax in the emergency department (expected related serious adverse events, neither receiving
continuous positive airway pressure). There were no other expected or unexpected related serious
adverse events.
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Economic evaluation
The base-case analysis, using continuous positive airway pressure effectiveness estimates from the
ACUTE pilot trial, indicated that a standard oxygen therapy strategy was likely to be cost-effective at a
threshold of £20,000 per quality-adjusted life-year (mean incremental cost-effectiveness ratio £5685/
quality-adjusted life-year, 67% probability). Values-of-information analyses demonstrated that there
was considerable uncertainty about whether or not to adopt prehospital continuous positive airway
pressure. Base-case population expected value of perfect information suggested that it would be worth
spending up to £16.5M on further research. Expected value of partial perfect information analysis
indicated that the effectiveness of prehospital continuous positive airway pressure on mortality was
the only important variable for future investigation (expected value of partial perfect information was
£16.5M, expected value of partial perfect information was zero for all other model parameters).
Ancillary substudies
Between 1 August 2017 and 31 July 2018, a total of 1017 patients were identified from the West
Midlands Ambulance Service with acute respiratory failure and eligibility for the ACUTE pilot trial,
giving an overall incidence rate of 17.4 per 100,000 persons per year (95% confidence interval 16.3 to
18.5 per 100,000 persons per year).
The most common final hospital diagnoses for acute respiratory failure were chronic obstructive
pulmonary disease (21/65, 32.3%) and lower respiratory tract infection (28/65, 43.1%). In seven cases
(10.8%), a final diagnosis was present in which continuous positive airway pressure would not be
expected to be effective, or could be harmful; these included myocardial infarction, ruptured abdominal
aortic aneurysm, liver failure, sepsis and pneumothorax. There was moderate agreement between
the primary prehospital and hospital diagnoses (raw agreement 58.5%, Gwet’s AC1 coefficient 0.56,
95% confidence interval 0.43 to 0.69).
Ambulance service clinicians felt confident in the diagnosis of acute respiratory failure, determining
trial eligibility and delivering continuous positive airway pressure. Important factors identified as
facilitators of participation in the pilot trial were ease of use of trial boxes and trial documentation,
and simplicity of consent processes. Conversely, lack of awareness of the ACUTE trial in receiving
hospitals, limited time to complete web-based trial training and a desire to provide continuous
positive airway pressure treatment were highlighted as important challenges.
During week 10 of recruitment, some intervention arm equipment boxes began to ‘rattle’. After repackaging
and redistribution, no further concerns were noted during weekly randomisation schedule audits. Of the
278 ambulance service clinicians participating in the allocation concealment substudy, 58.6% were unable
to distinguish a difference between control and intervention arm boxes. Of the participants indicating
a difference, 70.4% (95% confidence interval 61.1% to 78.4%) correctly chose continuous positive
airway pressure.
Conclusions
The pilot trial recruitment rate was below the target rate and feasibility was not demonstrated. The
economic evaluation results suggested that a large definitive trial could represent value for money.
However, the limited compliance with continuous positive airway pressure and the trial population,
including patients who could not benefit from continuous positive airway pressure, indicate that a
clinically significant effect size is not plausible. A definitive clinical effectiveness trial of continuous
positive airway pressure in the NHS is therefore not recommended. These findings also argue against
routine implementation of continuous positive airway pressure in NHS ambulance services, but would
not preclude a continuous positive airway pressure service provided by clinicians, with extended training
(e.g. prehospital physicians), which might allow selective targeting of treatment to an appropriate
subgroup of patients.
SCIENTIFIC SUMMARY
NIHR Journals Library www.journalslibrary.nihr.ac.uk
xxvi
Trial registration
This trial is registered as ISRCTN12048261.
Funding
This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 25, No. 7.
See the NIHR Journals Library website for further project information.
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Acute respiratory failure (ARF) is a serious acute illness that commonly occurs secondary to cardiac or
respiratory conditions.2 Early prehospital administration of continuous positive airway pressure (CPAP),
a form of non-invasive ventilation (NIV), may improve survival and reduce the need for critical care
admissions.3 The Ambulance CPAP: Use, Treatment Effect and economics (ACUTE) feasibility
trial investigated the feasibility, acceptability and cost-effectiveness of a definitive trial to evaluate
prehospital CPAP compared with standard oxygen therapy for adults presenting to emergency medical
services (EMS) with ARF.
What is acute respiratory failure?
The respiratory system is responsible for breathing, the process that brings oxygen gas from the air
into, and excretes carbon dioxide gas from, the lungs.4 Normal breathing involves the co-ordinated
action of the nervous systems, airways, respiratory muscles and chest wall, to allow gas to flow
between the lungs and external environment. In the lungs, oxygen diffuses into the bloodstream and
is transported to body tissues and organs, where it is used to produce energy. Carbon dioxide, a waste
product of this metabolism, is then carried back from the tissues by the blood and diffuses into the
lungs, before being released into the air during expiration.5
Acute respiratory failure occurs when disease of the heart or lungs leads to failure of the respiratory
system, over minutes or hours, in one or both of its gas exchange functions (oxygenation and carbon
dioxide elimination).2 This leads to inadequate blood oxygen levels (hypoxia) and/or increased blood
carbon dioxide levels (hypercarbia). Common causes of ARF include heart failure, pneumonia, chronic
obstructive pulmonary disease (COPD), pulmonary embolism (PE) and asthma. Other, less common,
causes include interstitial lung diseases (e.g. fibrosing alveolitis), central nervous system dysfunction
(e.g. opioid overdose) and trauma (e.g. pneumothorax, flail chest or haemothorax).6
These conditions can cause ARF by a number of processes, comprising shunting, diffusion abnormalities,
ventilation–perfusion mismatch or hypoventilation.7 In shunting, alveoli in the lungs are collapsed,
damaged or full of water or pus. Less air can flow into the alveoli; consequently, less gas exchange
can occur with blood leaving the lungs, resulting in hypoxia. In diffusion abnormalities, the lining of
alveoli becomes thickened, or there is increased fluid surrounding their walls. Diffusion is consequently
reduced and less oxygen enters the bloodstream. Carbon dioxide is more readily diffusible than oxygen,
so abnormal carbon dioxide levels are less common with these two processes, but can occur as the
disease progresses. In ventilation without perfusion, gas flows in and out of the alveoli normally, but the
lungs’ blood supply is abnormally reduced or absent, preventing gas exchange. Hypoventilation occurs
when the rate and/or efficiency of breathing is reduced, so that less air passes through the airways into
and out of the lungs. With these processes, there is a reduction in the transport of both carbon dioxide
and oxygen. Blood oxygen levels therefore decrease, whereas carbon dioxide levels increases.
Depending on which disease process predominates, ARF is classified as either hypoxaemic or hypercapnic.
Hypoxaemic respiratory failure (type I) is characterised by low oxygen levels (partial pressure of oxygen
of < 10.6 kPa), with normal or low carbon dioxide levels [partial pressure of carbon dioxide (PaCO2) of
< 4.7 kPa].2 This is the most common form of respiratory failure and it can be associated with most acute
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diseases of the lung. Hypercapnic respiratory failure (type II) is characterised by high carbon dioxide blood
levels (PaCO2 of > 6 kPa). Hypoxaemia is also common in patients with hypercapnic respiratory failure.
Type II respiratory failure is typically caused by diseases that result in ventilation–perfusion mismatch or
hypoventilation, with common aetiologies including drug overdose, chest wall trauma and severe COPD.8
Acute respiratory failure is a common and life-threatening medical emergency. The incidence of ARF
has been estimated at 80 cases per 100,000 persons per year, with pneumonia accounting for 60%
of all type I hypoxaemic ARF.2 By contrast, the most common cause of hypercapnic type II ARF is
COPD, with 44% of patients admitted with acute exacerbations showing a degree of hypercapnia.2
The mortality associated with ARF varies according to the underlying cause, but the overall risk of
death is high, with estimates of 30-day mortality ranging between 14% and 20%.6 ARF has substantial
health services costs, with patients often requiring prolonged hospital stays, ventilatory support and
critical care admissions.8,9 ARF was responsible for over 3 million NHS bed-days in England in 2014.10
The overall cost of ARF for EMS and hospital services has been estimated at £9.6M per year.3 It is
therefore clear that ARF represents a large burden for the NHS, with improvements in management
having the potential to improve health and reduce costs.
How is acute respiratory failure currently managed by emergency
medical services?
Current EMS management of ARF in the UK is summarised in the Joint Royal Colleges Ambulance
Liaison Committee (JRCALC) clinical practice guidelines.11 These outline four steps for the management
of any patient with ARF: (1) initial resuscitation with supportive management of any life-threatening
airway, breathing or circulation problems; (2) detailed clinical assessment once time-critical problems
have been addressed; (3) commencement of oxygen for patients with low peripheral oxygen saturations
or respiratory distress; and (4) administration of relevant disease-specific ancillary treatments.
There is an important distinction in oxygen therapy in ARF between patients with chronic type II respiratory
failure (typically caused by COPD) and those with other conditions.12,13 Normally, an increased blood carbon
dioxide level is detected by the brainstem respiratory centre, with subsequent stimulation of breathing to
excrete excess waste gas, normalise blood gas levels and maintain homeostasis.With chronic type II
respiratory failure, patients adapt over time to the altered physiology, losing this stimulus effect and
tolerating an elevated baseline level of blood carbon dioxide. Such patients then rely on low blood oxygen
levels (‘hypoxic drive’) to stimulate their breathing. Giving too much oxygen removes this impetus to breathe,
leading to hypoxaemia and further reducing the excretion of carbon dioxide.12,13 Titrated oxygen is therefore
recommended, with lower than normal peripheral oxygen saturations of 88–92% targeted. In other
conditions in which chronic carbon dioxide retention does not occur, loss of hypoxic ventilatory drive is not
an issue and oxygen is administered to target normal peripheral oxygen saturation levels of 94–98%.14
Following resuscitation, recognition of ARF and commencement on appropriate oxygen therapy,
additional treatments are delivered according to the suspected underlying cause of ARF. In suspected
exacerbations of COPD, salbutamol and ipratropium bromide nebulisers are indicated. In suspected
severe asthma, the JRCALC recommends intravenous (i.v.) hydrocortisone in addition to nebulisers,
with intramuscular adrenaline indicated in life-threatening cases. In acute heart failure causing
pulmonary oedema (when the patient is well perfused), sublingual glycerine trinitrate, i.v. furosemide
and nebulised salbutamol are advised.11
What is continuous positive airway pressure?
Non-invasive ventilation, also termed bi-level positive airway pressure (BIPAP), involves delivering
oxygen-enriched air to the lungs at increased pressure.15,16 It is termed ‘non-invasive’ because oxygen
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is delivered with a mask that is tightly fitted to the face, without the need for intubation of the
trachea, which is necessary for mechanical ventilation. NIV involves varying the pressure during a
patient’s respiratory cycle, with inhaled gases given at higher positive pressure during inspiration and
at a lower pressure during expiration (positive end-expiratory pressure). The higher external inspiratory
pressure increases ventilation of the lungs, delivering additional oxygen and removing excess carbon
dioxide, thereby reducing shunting and hypoventilation. Breathing out against a low external pressure
improves lung mechanics by moving a patient to a different part of their respiratory flow–volume
loop and helps prevent accumulation of fluid within the lung. This results in lower work of breathing,
stenting of small airways and alveoli recruiting more of the lungs’ surface for gas exchange, and
reduced pulmonary oedema. Overall, ventilation without perfusion is decreased and alveolar diffusion
is improved. However, NIV requires a machine and advanced training to generate, titrate and manage
the varying respiratory cycle pressures.
Continuous positive airway pressure, a simpler variant of NIV, was first described in the 1930s when a
modified vacuum cleaner was used to treat patients with acute heart failure.17 It uses a similar interface
to NIV to provide a continuous mild level of positive airway pressure throughout the breathing cycle
(rather than variable inspiratory and end-expiratory pressures).18 CPAP, therefore, does not significantly
increase gas flow between the lungs and external environment, and is largely ineffective if ARF is due
to hypoventilation (e.g. drug overdose with respiratory depression). However, the continuous airway
pressure provides similar benefits to the positive end-expiratory pressure given with NIV, helping to
reduce shunting and ventilation without perfusion, and improving alveolar diffusion. Several types of
CPAP are available, which can be classified according to the type of delivery system used (nasal mask,
mouth mask, full-face mask or helmet), the type of oxygen delivery system used (flow generator or
pressure compressor machine) and the characteristics of the CPAP circuit (open or closed).
Successful application of the CPAP mask may not be possible in patients with claustrophobia, facial
deformity, extensive facial hair or facial burns.16,18 There are also a number of potential side effects arising
from the delivery of increased airway pressure. In patients with decreased level of consciousness, vomiting
or nose bleeds, there is a risk of inhaling bodily secretions into the lungs, resulting in pneumonitis or
aspiration pneumonia. Moreover, increased intrathoracic pressure can lead to reduced venous return to
the heart, with consequent hypotension or pneumothorax.16
Continuous positive airway pressure is widely used in hospitals to treat ARF from a number of causes.18,19
Meta-analyses have shown that it improves outcomes in ARF due to COPD and acute cardiogenic
pulmonary oedema.20,21 In contrast, the Three Interventions in Cardiogenic Pulmonary Oedema (3CPO)
trial (the largest UK study) showed that routine use of CPAP for acute cardiogenic pulmonary oedema
did not improve mortality compared with selective use.22 It has been suggested that CPAP may be more
effective if delivered earlier,23 that is en route to hospital (prehospital CPAP). This is supported by data
from a randomised trial comparing immediate with delayed prehospital CPAP24 suggesting that a delay of
only 15 minutes was associated with worse clinical breathlessness scores and blood gas measurements
and increased risk of intubation or death.
In the NHS EMS setting, BIPAP is not feasible owing to the cost and complexity of the machines and
advanced training required to safely deliver NIV. In contrast, CPAP is cheaper and simpler to deliver.
NHS prehospital clinicians do not have access to the diagnostic tests available in hospital (e.g. arterial
blood gas analysis, chest X-ray, echocardiography), with decision-making based on the presenting
symptoms, clinical signs and physiological status.11 Previous research has shown that it is very difficult
to accurately discriminate between different underlying causes of ARF in the prehospital setting25 and
prehospital CPAP is likely to be applied generally to all cases of ARF (unless a clear contraindication is
present), rather than directed towards certain patients with ARF attributable to a specific cause.26
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What is currently known about the clinical effectiveness and
cost-effectiveness of prehospital continuous positive airway pressure?
Six previous systematic reviews3,27–31 and three meta-analyses3,30,31 have examined the effectiveness of
prehospital CPAP for ARF. A Health Technology Assessment (HTA) programme-funded evidence synthesis
review is the most recent, valid and comprehensive analysis.3 It identified 10 trials comparing prehospital
NIV (including CPAP) with standard oxygen therapy. Network meta-analysis suggested that prehospital
CPAP is an effective treatment for ARF, with evidence that it reduces mortality [odds ratio (OR) 0.41,
95% credible interval (CrI) 0.20 to 0.77] and intubation rate (OR 0.32, 95% CrI 0.17 to 0.62) compared
with standard care. These findings were consistent with the two preceding meta-analyses.30,31 However,
some included studies were deemed to be at risk of selection bias from lack of allocation concealment and
information bias secondary to unblinded outcome assessment, and the validity of the pooled effectiveness
estimate is uncertain. Furthermore, the findings may also not be generalisable to the NHS. Only one trial
included undifferentiated respiratory failure patients and most studies were small, suggesting potential
for recruitment of non-representative samples. None was undertaken in the UK and the methods used to
deliver prehospital CPAP (physician or paramedics with online physician support) would not reflect normal
NHS practice if prehospital CPAP was included in the guidelines for treatment of ARF.
A de novo economic model was developed for the HTA evidence synthesis project3 to explore the costs
and health outcomes of implementing prehospital CPAP.32 This suggested that prehospital CPAP was more
effective than standard care but was also more expensive, with an incremental cost-effectiveness ratio
(ICER) of £20,514 per quality-adjusted life-year (QALY) and a 49.5% probability of being cost-effective
at the £20,000-per-QALY threshold. Expected value of perfect information (EVPI) analyses suggested
that further research, costing up to £22.5M, could represent value for money, whereas expected value
of sample information (EVSI) analyses suggested that a randomised trial recruiting 1000 participants per
arm would be cost-effective if research costs were < £18.1M. However, these cost-effectiveness results
assume that CPAP can be successfully implemented in NHS EMS, were predicated on the accuracy of
published effectiveness data and were very sensitive to estimates for the incidence of ARF.
Why is the ACUTE trial needed?
The questionable internal and external validity of existing evidence, and the very uncertain cost-
effectiveness results, indicate that further research is necessary before prehospital CPAP is introduced
in the NHS in an attempt to mitigate the large burden of ARF. Although there is the potential to
improve mortality, there could be significant costs associated with the introduction of this health
technology and there is the potential for harm if CPAP is inappropriately administered. Our survey
of English ambulance service clinical directors found that 5 out of 10 clinical directors had already
implemented, or planned to implement, prehospital CPAP in some form. Urgent research is therefore
indicated before ad hoc implementation on the basis of the limited evidence base.
The potential need for prehospital CPAP is also likely to increase as the population ages and as acute
hospital care becomes more centralised.8,33 The risk of death among patients with respiratory problems
increases markedly with distance travelled to hospital, from 10% with distances of < 10 km to 20%
with distances of > 20 km.34 Provision of prehospital CPAP could reduce the risk of death associated
with travelling long distances to hospital. However, all assumptions of benefit from prehospital CPAP
depend on the evidence of effectiveness from existing trials being reproduced in typical NHS practice
and there being sufficient numbers of eligible patients treated.
There is strong professional and public support for research investigating prehospital NIV. Asthma,
COPD and heart failure advocacy bodies have acknowledged the importance of the research question
and have endorsed this pilot study. Patient and public involvement (PPI) groups considered this to be an
important clinical problem requiring further investigation. Moreover, prehospital CPAP was identified as
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a research priority by the 999 EMS Research Forum.35 The Royal College of Emergency Medicine and
College of Paramedics were also supportive of this pilot trial. Previous systematic reviews examining
prehospital CPAP have separately concluded that a large clinical trial is required.3,20,29–31
Although prehospital CPAP is a promising therapy, NHS experience is very limited and further research is
needed to examine whether or not the reported clinical effectiveness and cost-effectiveness are confirmed
in the UK setting, with unsupported paramedic delivery and limited additional training. Prior to
a large pragmatic trial and economic evaluation comparing prehospital CPAP with standard care,
it is first necessary to estimate the incidence of eligible patients to determine whether or not a trial
would be feasible and cost-effective. It is also important to determine whether or not prehospital
CPAP can be delivered successfully in the context of the NHS ambulance services. Furthermore,
prehospital trials need to overcome a number of potential practical barriers if they are to deliver
valid data. For these reasons, a stand-alone feasibility study is necessary to estimate the incidence
of eligible patients, to test the feasibility and acceptability of potential definitive trial methods and
to address important uncertainties, such as patient selection, delivery of the intervention and event
rates, without committing to a full trial and incurring prohibitive risks or costs.
What are the aims and objectives of the ACUTE trial?
The primary aim of the ACUTE trial was to ensure that the design and methods of a definitive trial
would be sound, practicable, safe and feasible. A secondary aim was to update an existing HTA economic
model, using an applicable effectiveness estimate and a more accurate incidence rate, to investigate the
cost-effectiveness of prehospital CPAP and to determine the value of further research. If the feasibility
and cost-effectiveness of further research can be demonstrated, a large pragmatic trial could then
definitively test the hypothesis that prehospital CPAP reduces mortality and is cost-effective, compared
with standard oxygen therapy, for the treatment of ARF.
The primary objectives were to estimate the following feasibility outcomes:
l the rate of eligible patients per 100,000 persons per year
l the proportion recruited and allocated to treatment appropriately
l adherence to allocated treatment
l retention and data completeness up to 30 days.
The secondary objectives were to estimate the following summary clinical outcome measures, across
the whole trial population and per treatment group:
l proportion surviving to 30 days
l proportion undergoing endotracheal intubation by 30 days
l proportion admitted to critical care at any point up to 30 days
l mean and median lengths of hospital stay
l change in visual analogue scale (VAS) dyspnoea score from presentation to immediately before
emergency department (ED) arrival
l mean EuroQol-5 Dimensions, five-level version (EQ-5D-5L), score at 30 days
l key elements of health-care resource use up to 30 days.
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The ACUTE trial consisted of an external pilot trial, with additional ancillary substudies investigating the
cost-effectiveness of prehospital CPAP, the incidence of ARF, agreement between prehospital and final
ARF diagnosis, ambulance service clinician perceptions of prehospital CPAP and the ACUTE trial and the
robustness of allocation concealment. The methods for each study component are detailed individually
in subsequent sections. A trial protocol was registered prior to commencement of recruitment
(ISRCTN12048261, 30 August 2017) and is published separately.36 All changes made to the prespecified
protocol and study documentation are detailed in Appendix 1 and highlighted in each relevant subsection.
The ACUTE pilot trial
Trial design
The ACUTE pilot trial was an individually randomised, parallel-group, external pilot trial to determine the
feasibility and acceptability of a definitive trial to evaluate the clinical effectiveness and cost-effectiveness
of prehospital CPAP compared with standard oxygen therapy for ARF. The pilot trial is reported in
accordance with the Consolidated Standards of Reporting Trials (CONSORT) statement and the pilot and
feasibility trials extension.37,38
Trial oversight, ethics and governance
The trial and study documents relating to enrolled participants received ethics approval from the NHS
Leeds East Research Ethics Committee (REC) (31 October 2016, reference number 16/YH/0406). All
substantial protocol amendments were approved by the NHS Leeds East REC and the Health Research
Authority (HRA) before implementation. The University of Sheffield provided sponsorship and monitoring
oversight for the project. The chief investigator and trial manager performed day-to-day management of the
trial, with support from a Trial Management Group (TMG) consisting of co-investigators. An independent
Trial Steering Committee (TSC) and Data Monitoring and Ethics Committee (DMEC) oversaw the safety,
conduct and progress of the trial. Funding was received from the National Institute for Health
Research’s HTA programme (reference 15/08/40).
Setting
The pilot trial was conducted between 1 August 2017 and 31 July 2018 in the West Midlands Ambulance
Service (WMAS), which serves a mixed urban and rural population of 5.6 million. It employs approximately
4000 staff across five divisions and operates from 15 ‘super-hubs’, each covering 5–10 community
ambulance stations. The ACUTE trial recruitment took place across four ambulance hubs (Stoke, Stafford,
Lichfield and Erdington) and their satellite community ambulance stations, covering a population of
1.5 million. Included hubs were chosen to provide a representative mixture of urban, semiurban and rural
localities. Patients presenting to participating EMS ambulance stations were conveyed to the secondary-
or tertiary-level hospital closest to the scene of incident. Included ambulance hubs, ambulance stations
and hospitals are detailed in Appendix 2.
Participants and eligibility criteria
The trial population consisted of adults transported to hospital by emergency ambulance with ARF,
regardless of suspected underlying aetiology. Potential recruits were identified by participating ambulance
service clinicians (paramedics and ambulance technicians) after assessment of trial eligibility criteria at
the scene of incident, during normal working practice. Prior management in primary care or by a rapid
response ambulance clinician did not affect recruitment. ARF was defined as respiratory distress with
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peripheral oxygen saturation below British Thoracic Society (BTS) target levels (88% for patients with
COPD, 94% for other conditions), despite supplemental oxygen (titrated low-flow oxygen for COPD,
or titrated high-flow oxygen in other conditions).14 Potential participants were excluded if any of the
following criteria were met:
l hospital CPAP treatment available within 15 minutes of eligibility assessment
l aged < 18 years
l known to have terminal illness
l known pre-existing lack of capacity (confirmed by relatives, carers or documentary evidence, such as
lasting power of attorney)
l documented not for resuscitation status
l acutely incapacitated patients with known valid advanced directive declining NIV or participation
in research
l the patient has an oxygen alert card
l anticipated inability to apply CPAP (e.g. facial deformity)
l respiratory failure due to chest trauma
l contraindication to CPAP (suspected pneumothorax, respiratory arrest, epistaxis, vomiting or hypotension)
l previous enrolment in the ACUTE trial
l pregnancy
l patient unable to communicate with ambulance service clinicians
l patient with capacity declined consent for participation at the scene of the incident.
Enrolment and consent procedures
Consent procedures were designed in accordance with the Declaration of Helsinki,39 the UK Mental
Capacity Act 200540 and Good Clinical Practice guidelines.41 Potentially eligible participants identified
by participating ambulance service clinicians were assessed for mental capacity and approached
for enrolment in the trial; the clinicians were guided by a standardised script taking approximately
2–3 minutes to deliver. For patients with mental capacity, verbal consent was obtained for participation
prior to enrolment. Eligible patients lacking mental capacity were enrolled in the trial without consent
if the treating ambulance service clinician determined that it would be in their best interests. The advice
of advanced directives, or appointees with lasting power of attorney, was followed for incapacitated
patients, if present. In all cases, a research paramedic reviewed the participant in hospital as soon as
possible after enrolment. For patients with mental capacity, the research paramedics provided verbal
and written information regarding the trial, and sought written informed consent for further data
collection and participation in the trial. In the event that a patient did not have capacity, advice was
sought from a personal consultee about their further participation in the trial.42,43 When a personal
consultee was unavailable, a nominated consultee was approached for a consent waiver.42,43 In the event
that a patient lost mental capacity after providing written consent, the existing consent was considered
to remain effective, unless a personal or nominated consultee indicated that the incapacitated patient
should be withdrawn from the trial. Initially, incapacitated enrolled patients who later regained capacity
within the 30-day follow-up period were personally approached by research paramedics to obtain informed
consent to continue in the trial. Data collection then proceeded as per the patient’s wishes and details
described above.
If a patient died prior to approach from a research paramedic, delayed written consent was not possible.
In this event, all non-identifiable data collected prior to death were retained. It was initially planned to
collect anonymised 30-day mortality data only. However, following advice from the TSC and DMEC,
and after PPI group consultation, an application was made to collect anonymised data on other hospital
management and clinical outcomes to provide sufficient information for a full assessment of the safety
of the trial interventions. Permission for the collection of these anonymised data was subsequently
provided by the HRA Confidentiality Advisory Group and a substantial protocol amendment was
approved by the Leeds East REC (substantial amendment 4, 31 July 2018). The ACUTE trial consent
procedures are summarised in Figure 1.
METHODS
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Interventions
Ambulance service clinicians (paramedics and ambulance technicians) volunteering to participate in the
ACUTE trial and trained in trial procedures delivered trial treatments. Participants in the intervention
arm were treated by CPAP with supplemental oxygen. Participants in the control arm received standard
oxygen therapy. Treatment in both arms was targeted to BTS guidelines for peripheral oxygen saturations.14
Target peripheral oxygen saturations were 88–92% for participants with known or suspected COPD and
94–98% for participants with other suspected causes of ARF. Ancillary condition-specific treatments were
administered in both trial arms in accordance with standard JRCALC practice guidelines.11
Capacity assessed by























Enrolled participants approached for written consent by













    reviewed
• 30-day quality
    of life, resource
    use, AEs
    questionnaire
30-day follow-up
• Medical records
    reviewed
• 30-day quality
    of life, resource
    use, AEs







    collected data
    retained
• Anonymised
    30-day mortality
    status collected
• No further follow-up






    collected data
    retained
• Anonymised
    30-day mortality
    status collected
• No further follow-up






    collected data
    retained
• Anonymised 
    30-day mortality
    status collected
• No further follow-up




    collected data
    retained
• Anonymised
    30-day mortality
    status collected
• 30-day questionnaire






    collected data
    retained
• Anonymised 
    30-day mortality
    status collected
• No further follow-up





    collected data
    retained
• Anonymised 
    30-day mortality
    status collected
• No further follow-up
    data collection
FIGURE 1 Flow chart detailing consent procedures for the ACUTE pilot trial. AE, adverse event.
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The ACUTE trial used the O-Two unit (O-Two Medical Technologies Inc., Brampton, ON, Canada),
a lightweight, open, single-use, low-flow CPAP system, in the intervention arm.44 This device consists
of tubing, which is connected to an oxygen source (either a portable oxygen cylinder or the usual
ambulance oxygen flow regulator), and an in-line CPAP unit connecting to a close-fitting face mask.
The CPAP unit entrains ambient air to increase local mask pressure, providing resistance for the patient
to breathe against. The level of CPAP is varied by altering the incoming oxygen flow rate. Thus, the
concentration of inspired oxygen varies according to desired degree of CPAP, as the flow rate is altered.
As an open system, with access to ambient air, the device allows unrestricted inspiratory flows and is
unaffected by respiratory rate. The O-Two CPAP device is shown in Figure 2.
Continuous positive airway pressure treatment could be commenced at the site of initial clinical
contact or after transfer to an ambulance. An appropriately sized mask was used, with CPAP started
at 5 cmH2O and then incrementally increased by 1 cmH2O every 2–5 minutes to a maximum of
15cmH2O, in accordance with BTS peripheral oxygen saturation targets,14 measured by standard
pulse oximetry. If necessary, nebuliser treatments could be positioned between the face mask and
the O-Two CPAP unit, and sublingual glycerine trinitrate could be given by lifting the face mask. CPAP
was continued until arrival at hospital, unless it was not tolerated (e.g. patient request, claustrophobia,
anxiety, significant agitation), the patient was unable to maintain their own airway, systolic blood pressure
decreased to < 90 mmHg, vomiting occurred, epistaxis occurred, the consciousness level decreased and
the patient did not respond to voice, the patient improved or a suspected pneumothorax was detected.
In the event of non-compliance with CPAP, treatment with standard oxygen therapy was provided.
In the control arm, oxygen was delivered at normal atmospheric pressure from a compressed gas tank
or portable oxygen cylinder, via a flow regulator, to the patient using nasal cannula, an air entrainment
Venturi mask, a simple face mask or a non-rebreathing reservoir face mask. The exact choice of flow
rate and oxygen delivery device was determined by ambulance service clinicians, depending on the
patient’s condition and peripheral oxygen saturation levels.
On arrival at a hospital ED, staff were informed of the trial and current treatments. Patient care was
then transferred from ambulance service clinicians to hospital clinicians in accordance to normal practice.
Subsequent care followed hospital guidelines, as implemented by the hospital clinician. For the intervention
group the hospital clinician could decide to continue CPAP using the O-Two unit, to switch to an in-hospital
CPAP or NIV system or to discontinue CPAP altogether. Participants in the control group were able to
receive in-hospital CPAP or NIV if indicated, based on assessment by the hospital clinician.
FIGURE 2 The O-Two CPAP device. Reproduced with permission from the University of Sheffield, March 2019. O-two
CPAP unit; O-Two Medical Technologies Inc.
METHODS
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Training
The WMAS ambulance service clinicians volunteered to participate in the trial and were able to enrol
participants once they had completed a programme of training. Training was offered by three approaches.
First, a 1-day ACUTE trial teaching event was held, consisting of lectures and teaching stations. Second,
research paramedics provided individual or small-group teaching, including demonstrations, hands-on
familiarisation and scenario-based practice. Third, a series of online training videos could be studied
remotely. All of these training methods covered identification of eligible patients, application of the
inclusion and exclusion criteria, providing appropriate information, seeking consent, randomisation,
delivery of CPAP, monitoring for adverse events (AEs) and data collection. Training specifically focused on
trial exclusion criteria, particularly the identification of clinical conditions (e.g. pneumothorax or vomiting),
for which administration of CPAP could be harmful. Research paramedics provided ongoing support and
education as necessary, including training of any new ambulance service clinicians starting at trial
ambulance hubs after recruitment had started.
Randomisation
Enrolled participants were individually allocated to CPAP or standard oxygen therapy in a 1 : 1 ratio,
using equipment boxes and simple randomisation constrained by the maximum number of trial devices
supplied to the WMAS for trial use (160 boxes: 80 containing CPAP masks, 80 containing standard
oxygen masks). This number allowed for trial devices to be available to all trained ambulance service
clinicians on duty at any given time, regardless of the number of participants previously recruited. The
randomisation sequence was computer generated by an independent statistician not directly involved
in the conduct of the trial. The allocation schedule was held centrally on a password-protected, access-
restricted network drive. The trial statistician did not have access to the randomisation sequence until
after data lock.
Allocation concealment
Continuous positive airway pressure devices and high-concentration oxygen therapy masks were
packaged in identical, shrink-wrapped, tamper-proof, sealed trial equipment boxes, measuring 170 mm
× 170 mm × 70 mm and weighing 0.52–0.54 kg. All boxes contained a brief letter for the receiving
hospital, providing information about the trial and the treatment arm the patient had been allocated
to. Intervention arm boxes also contained brief instructions for using CPAP. Stickers summarising trial
eligibility criteria and enrolment processes were placed on the exterior of each box. The equipment box
is presented in Figure 3.
Equipment boxes were assembled, numbered and checked for indistinguishability (including weighing)
in an audited process, in accordance with the randomisation sequence at Sheffield Clinical Trials
Research Unit (CTRU) by research assistants not directly involved in the conduct of the trial. Boxes
were then transferred to a central WMAS storage and distribution centre, where they were held in
an access-restricted research store. Boxes were supplied by the WMAS internal distribution team to
participating ambulance hubs, and subsequently held locally, unordered by number, in a designated
storage area.
Participating ambulance service clinicians selected a single box at the beginning of each shift,
regardless of box number. At the end of the shift, boxes were returned to the ambulance hub
equipment store. Boxes were signed in and out for each shift with personnel, ambulance and
equipment box details recorded in a distribution log in each hub. Participating ambulance service
clinicians identified potential participants with ARF when attending emergency 999 ambulance calls.
Immediately after enrolment, paramedics opened the trial equipment box and provided treatment
according to whether a CPAP device or high-concentration oxygen mask was supplied. It was not
possible to reseal the box. Research paramedics monitored the location and condition of all boxes,
allocation concealment (i.e. boxes had not been tampered with) and adherence to the allocation
schedule on a weekly basis. A detailed audit log was completed recording this information.
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Blinding
Because of the physical differences between the CPAP device and the standard oxygen mask, it was
not possible to blind patients, ambulance service clinicians or hospital clinicians to the treatment arms.
Research paramedics assessing outcomes were also not blinded. However, both feasibility and clinical
end points were objective measures, minimising the possibility of information bias.
Data collection
A recruitment form [case report form (CRF) A], contained in each trial equipment box, was completed
by ambulance service clinicians every time a patient was enrolled in the trial. This collected trial-specific
information, including trial number, patient identifiers, eligibility criteria, suspected prehospital diagnosis,
consent details, patient-reported and clinician-assessed VAS dyspnoea (1–10) score and prehospital
clinical and treatment data. The information contained in CRF A was relayed to the central WMAS
clinical support desk telephonically and stored centrally on a specific trial database. Routinely collected
baseline characteristics, EMS timings, details of treatments provided and vital signs (including peripheral
oxygen saturations) en route to hospital were extracted later from WMAS electronic patient records
(EPRs) and entered into trial CRF B by research paramedics.
Baseline quality-of-life assessments were performed by research paramedics shortly after hospital
admission, following confirmation of patient consent for participation in the trial. Patients, or their
representatives, were asked to estimate their current health status, using the EQ-5D-5L.45 At 30 days,
research paramedics reviewed the hospital records to collate details of subsequent progress, inpatient
FIGURE 3 The ACUTE trial intervention and control arm equipment boxes.
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treatments provided (including provision of hospital CPAP/NIV), length of hospital stay, use of critical
care, any AEs and vital status at 30 days. These data were also recorded in CRF B.
Quality of life and resource use were assessed by questionnaire at 30 days following enrolment,
either in person, if still in hospital, or by telephone or post if discharged. Vital status was checked
using hospital and summary care records prior to approach. Participants were asked for their preferred
method for data collection, either telephone or post. Initial non-responders were contacted again after
a further 2 weeks. Key elements of health-care resource recorded included hospital services and
general practitioner or community services. Participants were also asked to report any AEs in the
30-day follow-up questionnaire.
Following review of blinded outcome data during TMG meetings, an unexpectedly high mortality rate
was noted. Supported by the TSC and DMEC, a post hoc descriptive analysis of the deceased patients
was therefore planned (substantial amendment 4, 31 July 2018). Local trial collaborators were contacted
by research paramedics and asked to review clinical records to determine if a ceiling-of-treatment
decision was made during the patient’s admission. Anonymised data were coded and stored using Excel®
(Microsoft Corporation, Redmond,WA, USA). The assessments and follow-up for the ACUTE trial are
summarised in Appendix 3.
Data management
All data were collected and retained in accordance with the UK Data Protection Act 1998,46 the
European Union General Data Protection Regulation 2016/67947 and the University of Sheffield
CTRU standard operating procedures. Trial data were extracted from the WMAS clinical support desk
database, source documents and CRFs by research paramedics, and entered onto a secure CTRU data
management system. Patient-identifiable data (names, date of birth and contact details) were collected
and entered only when written informed consent was confirmed. Validation reports were run regularly
to check the data for completeness, accuracy and consistency. Any data discrepancies were monitored
and managed to resolution by research paramedics.
Outcomes
The following feasibility outcomes and targets were prespecified:
l recruitment rate per 100,000 persons per year (target eight, i.e. 120 across the 1.5 million
population of the four WMAS hubs)
l proportion recruited in error and classified as minor or major non-compliances (target 0%
and ≤ 10%)
l adherence to the allocation schedule (target ≥ 90%)
l adherence to treatment in the CPAP arm (target ≥ 75%)
l retention at 30 days (target ≥ 90%)
l data completeness (target ≥ 90%).
Secondary effectiveness outcomes were:
l proportion surviving to 30 days
l proportion undergoing endotracheal intubation by 30 days
l proportion admitted to critical care at any point up to 30 days
l mean and median lengths of hospital stay
l change in VAS dyspnoea score from initial presentation to immediately before ED arrival
l mean EQ-5D-5L score
l key elements of health-care resource use up to 30 days.
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Safety reporting
Adverse changes in the health of ACUTE trial participants were defined, monitored, recorded and
reported in accordance with CTRU standard operating procedures and HRA guidance for non-Clinical
Trial of an Investigational Medicinal Product studies. Only AEs and serious adverse events (SAEs)
related to trial interventions or procedures were recorded. The following SAEs were expected to occur
following ARF and were recorded as outcomes: death, hospitalisation, intubation and ventilation, or
admission to critical care. Expected related SAEs from CPAP administration were prespecified as
pneumothorax, aspiration, hypercapnia, progressive respiratory failure or hypotension.
Adverse health changes were identified by ambulance service clinicians during delivery of trial treatments,
local hospital trial collaborators, trial participant reports, research paramedics’ review of medical records
at 30 days or by the trial manager from the 30-day follow-up questionnaire. Adverse health changes
were assessed and classified by an appropriately qualified member of the ACUTE trial research team
or a local clinician, and reported to the chief investigator, who reviewed all relevant documentation to
determine causality, severity and expectedness to determine whether or not the AE was related and/or
was unexpected. Reporting requirements depended on the seriousness of the adverse health change and
categorisation as expected or unexpected: related AEs and expected related SAEs were regularly reported
in aggregate to the TMG, TSC, DMEC, sponsor and REC. Unexpected SAEs related to trial interventions
or procedures required expedited reporting to the sponsor, relevant NHS research and development
department, REC and DMEC within 15 days of notification, using the HRA SAE form. Full details of
safety reporting are provided in Appendix 4, Table 21 and Figure 19.
Sample size
The trial was an external pilot trial intended to explore the feasibility of conducting a future definitive
trial. The sample size for a feasibility trial should be adequate to estimate the uncertain critical
parameters needed to inform the design of the full randomised controlled trial (RCT) with sufficient
precision.48 Mortality at 30 days would be the primary end point of a definitive trial. Mortality under
standard care was estimated at 12%, and, for a full trial, a 5% absolute reduction was postulated
(i.e. to 7%) in the prehospital CPAP intervention arm.26 Given the short follow-up period, loss to
follow-up of < 5% at 30 days was envisaged.
A minimum sample size of 120 was proposed by Teare and colleagues49 for pilot studies with dichotomous
outcomes to provide sufficient precision to measure binary parameters for use in the sample size
calculation of the full trial. A pilot trial sample size of 120 would therefore allow mortality to be estimated
to within a standard error of 2.7% for use in the sample size calculation of an eventual large-scale trial.
This sample size also allowed estimation of feasibility outcomes with a precision of < 5%.
A previous evidence synthesis study3 estimated that the incidence of eligible cases ranges from 3.5 to
40.8 per 100,000 persons per year. The lowest estimates were based on actual patients treated with
prehospital CPAP in services with limited ability to deliver treatment for all eligible patients and are
likely to be underestimates. The highest estimates were based on audit data for in-hospital NIV use
among emergency admissions and are likely to be overestimates. Assuming that there are 20 eligible
cases per 100,000 persons per year and that 40% of these were recruited, we anticipate that
120 patients would be recruited from the trial’s source population of 1.5 million, over 1 year.
Statistical analyses
Participant recruitment and retention are described and summarised in a CONSORT flow diagram
(see Figure 6).38 Missing data are described for each variable by indicating the number and percentage
of observations present, and reasons for missing data. Available-case analyses were performed with
casewise omission in the event of missing data. Owing to the relatively small number of missing data,
and the focus on feasibility rather than effectiveness, sensitivity analyses for missing data were not
performed. Non-normally distributed continuous variables were summarised using the number of
observations, median and interquartile range (IQR). Categorical variables were evaluated using the
METHODS
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number of observations and percentages. All analyses were conducted in the R statistical package
(The R Foundation for Statistical Computing, Vienna, Austria) in accordance with a prespecified
statistical analysis plan and CONSORT principles.
The baseline characteristics, prehospital treatment, hospital management and AEs of enrolled participants
are reported descriptively for the whole trial population, and separately per treatment arm, using an as-
randomised analysis set (i.e. participants were analysed according to their randomisation, regardless of
compliance or completeness of follow-up) with the denominator identified throughout. Feasibility outcomes
are reported descriptively for the whole trial population, together with their 95% confidence interval (CI)
(calculated using theWilson score interval),50 using a full analysis set. Pilot trials are not hypothesis-testing
studies, and safety, efficacy and effectiveness results should, therefore, be interpreted cautiously.51,52
Consequently,only summary estimates of relative effectiveness outcomes are presented, overall and
stratified by treatment arm, without 95% CIs or p-values. An intention-to-treat, full analysis set was used for
clinical end points with complete follow-up (i.e. all randomised participants included in the group to which
they were randomly assigned, regardless of their adherence with the entry criteria, the treatment they
actually received and deviation from the protocol). A modified intention-to-treat, complete-case analysis
was performed for other clinical end points with missing outcome data (i.e. randomised participants with
complete outcome data included in the group to which they were randomly assigned, regardless of their
adherence to the entry criteria, the treatment they actually received and deviation from the protocol).53
Patient and public involvement
The public and patients were fully involved in the ACUTE trial from conception to dissemination. The
research proposal was developed in partnership with a service user co-applicant and was reviewed in
terms of feasibility and relevance by the Sheffield Emergency Care Forum, the Sheffield Cardiovascular
Patient Panel and the Barnsley Patient Advisory Group. A PPI bursary from the Yorkshire and Humber
Research Design Service was used to consult with a group of respiratory patients about their views on the
research proposal, consent procedures and how best to involve patients throughout the project. Feedback
from these groups led to a number of important changes, for example reducing the number of patient
questionnaires. A service user advisory group was enlisted during the trial set-up period for collaboration
throughout the project and helped develop patient-facing research materials. A member of the Sheffield
Emergency Care Forum (MM) was a co-applicant who provided PPI advice on trial matters, attended TMG
meetings, supported trial management, and contributed to the trial report and interpretation of results.
Two further lay PPI representatives served separately on the TSC and the DMEC. Asthma UK and PPI
co-applicant Margaret M Marsh helped write the Plain English summary. Findings from the ACUTE trial were
reported to our partner PPI groups and presented at a University of Sheffield research engagement event.
Health economic evaluation
Decision problem
The decision problem, informed by the clinical research question posed in the ACUTE pilot trial, was
‘Which is the most cost-effective treatment strategy for patients presenting to NHS ambulance
services with ARF?’.
The aim of the ACUTE trial economic evaluation was, therefore, to evaluate the cost-effectiveness of
prehospital CPAP compared with standard care for patients with ARF in the UK. Specific objectives were to:
l estimate the cost-effectiveness of prehospital CPAP compared with standard care for patients with
ARF, in terms of the costs and QALYs gained by each treatment strategy
l identify the strategy that is most likely to be cost-effective for patients with ARF, defined as the
most cost-effective strategy at a willingness-to-pay threshold of £20,000 per QALY gained
l evaluate the cost and value of undertaking further research by estimating the EVPI
l identify the critical areas of uncertainty in which future research would produce most benefit,
by calculating the expected value of partial perfect information (EVPPI) for different parameters.
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Interventions
Any potentially relevant prehospital treatments that could be feasibly be implemented in the NHS
for ARF were considered. However, owing to the complexity of alternative forms of NIV, only CPAP
was judged as being a practicable alternative to standard oxygen practice in UK ambulance services.
Therefore, interventions comprised prehospital CPAP provided by ambulance service clinicians and
standard oxygen therapy (i.e. without prehospital CPAP). Hospital management was assumed to be
identical for both comparators.
Form of economic evaluation
A cost–utility economic evaluation was performed using a probabilistic decision-analytic model to synthesise
available evidence and compare alternative management strategies.54,55 Such models offer a framework to
systematically, transparently and objectively collect all available information on a particular decision problem.
Relevant evidence can then be synthesised and translated by modelling into estimates of costs and effects,
along with an indication of the uncertainty surrounded these estimates. This allows identification of the most
cost-effective treatment options and facilitates an assessment of the benefit of performing future research.
The ability of decision-analysis models to consider all important aspects of a decision problem contrasts
with trial-based economic evaluations, which are often limited by omission of relevant treatment
options, exclusion of important external evidence, failure to capture long-term differences in economic
outcomes and inclusion of non-representative populations or treatment regimens.56
Model development and scope
A cohort model, structured as a decision tree, was used to estimate the cost–utility of alternative
treatment approaches.54 The decision tree structure was based on a previously published economic model
used for a HTA programme-funded evidence synthesis project, with updated parameter values.3 Base-case
principles for economic evaluations outlined in the National Institute for Health and Care Excellence (NICE)
Guide to the Methods of Technology Appraisal57 were followed. The economic perspective was the NHS in
England and Wales, with only direct treatment costs included. The model employed a life time horizon.
Costs and consequences
Direct treatment and Personal Social Services costs were included. The price base was assumed to be 2018;
valuations were in Great British pounds and unit costs were considered to be time divisible. When unit
costs were valued prior to 2018, the Bank of England’s Consumer Price Index data were used to inflate
costs to current value.58 All costs were applied using present values; discounting was not performed.
The consequences of alternative management strategies were measured in QALYs to allow comparison
within and across different disease areas.59 QALYs were calculated by multiplying survival duration
with an appropriate mean utility value.
Model structure
Differences between management options were accounted for by designating each chance node with a
strategy-specific probability, and by assigning differing costs and utility values to the terminal nodes of
each individual subtree branch. Expected costs and QALYs for each strategy were subsequently calculated
by summation of the terminal node values, weighted by the conditional branch probabilities.54,56
Patients with ARF are at increased risk of short-term mortality and intubation.6 Therefore, the decision
tree assigned a baseline probability of intubation or death within 30 days for the standard care arm.
Log-ORs for mortality and intubations were used as effectiveness parameters in the model for
prehospital CPAP, and applied to the baseline risks to give intervention arm probabilities. If the
baseline risk is P, then µ is estimated as logit(P) = log[P/(1 – P)]. The absolute probabilities for the
intervention (CPAP) are then estimated as:
P(intervention) = e µ+ dð Þ/½1 + e µ+ dð Þ, (1)
in which d is the log-OR for an intervention relative to standard care.
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Lifetime QALYs were accrued by patients who survived their initial ARF presentation. The model
estimated prognosis by using a 30-day probability of death and probabilities of intubation depending
on the type of treatment. Survivors (i.e. those who avoided the short-term 30-day mortality risk)
accrued QALYs estimated from life expectancy and their utilities for this time period. It was assumed
that the lifetime QALYs were the same for all survivors, irrespective of whether they were in the
standard care or prehospital CPAP arm.
The cost of standard care was assumed as £0. This simplification was made as the analysis is based on
incremental costs (i.e. it was assumed that all initial treatment costs are the same, regardless of whether
or not the patient receives prehospital CPAP).54 The zero costs for standard care relate only to prehospital
and ED treatment and do not include hospitalisation costs, intubation costs or additional lifetime costs
for survivors. This was deemed sensible by the clinical experts on the TMG, as it was assumed that the
proportion of participants who would receive NIV in hospital were similar in both arms, irrespective of
whether or not a participant received prehospital CPAP.
Thus, the only difference in initial treatment costs between standard care and prehospital CPAP was
the additional cost of providing prehospital CPAP. This was determined by sharing out the initial and
ongoing equipment and training costs among the number of patients who would benefit (i.e. the
incidence of ARF patients eligible for CPAP), based on a 5-year depreciation period (i.e. assuming new
prehospital CPAP equipment will be required in 5 years).
Subsequent hospital treatment costs were dependent on the probability of needing intubation. Lifetime
health-care costs accrued among survivors according to their life expectancy. It was assumed that the
lifetime costs were the same for all survivors, irrespective of whether they were in the standard care
or prehospital CPAP arm. The model structure is shown in Figure 4.
Model population and setting
The population consisted of a hypothetical cohort of patients with ARF due to any cause and potentially
suitable for CPAP treatment. The setting was a representative NHS ambulance service, such as WMAS.
Although this cohort could include patients with heterogeneous aetiology for ARF, including acute
cardiogenic pulmonary oedema/heart failure, COPD and pneumonia, for the purposes of modelling
they were treated as a single group.
Parameterisation
The identification, appraisal and selection of evidence to determine model inputs have been previously
described in detail,3 but were updated for this analysis.When possible, parameters, ideally valid evidence
from systematic literature reviews or routine official data sources deemed to be at low risk of systematic
error, were used from the previous HTA model.3 When relevant and unbiased published evidence was
unavailable, parameters were updated using ACUTE trial pilot data or expert opinion of clinical experts
from the ACUTE TMG. Each model input was assigned an average or most likely value, and a probability
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FIGURE 4 Structure of the ACUTE trial decision-analytic model.
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this estimate was defined. Distributional choices were carefully chosen based on theoretical considerations,
logical constraints and the parameter estimation process.60 As model inputs were derived from alternative
sources, with no data available on the covariance structure, it was not possible to account for any correlation
between costs and outcomes.56 The sources, mean values and distributions for each parameter are described
in detail with the economic model results in Chapter 3, Economic analysis results.
Cost-effectiveness analysis
The cost-effectiveness of the different interventions was estimated using both the ICER and the net
monetary benefit (NMB) approaches.61,62 The ICER measures the relative value of two strategies and is
calculated as the mean incremental cost divided by the mean incremental benefits, computed by comparing
to the next most effective alternative. A strategy is dominated when another strategy accrues more
QALYs at a lower cost. The willingness-to-pay threshold (λ) is the amount of money that the decision-
maker is willing to pay to gain 1 additional QALY.63 The usual threshold for decision-making at NICE is
considered to be £20,000 per QALY, as detailed in NICE HTA guidelines.57 The NMB framework transforms
cost-effectiveness results to a linear scale and simplifies interpretation of cost-effectiveness results for
decision-makers. NMB is defined as the number of QALYs multiplied by a value for the QALYs (e.g. £20,000)
minus the costs of obtaining them [i.e. NMB= (QALYs × λ) – cost]. The strategy with the highest expected
incremental NMB is the most cost-effective.54,55
To account for the uncertainty in model inputs, a probabilistic sensitivity analysis (PSA) was conducted
using Monte Carlo simulation to randomly sample from the inverse cumulative distribution function
of each model parameter’s probability density functions.54,55,64 Multiple model runs were performed,
each with a random draw from every parameter’s distribution, thus evaluating the full range of
cost-effectiveness results possible, given current uncertainty on the true values of model inputs. Mean
ICERs calculated from the average expected costs and effects over all model runs were computed
and compared with cost-effectiveness thresholds to inform adoption decisions. The number of PSA
iterations to produce a stable mean estimate of incremental cost–utility was determined by visual
inspections of the mean cost per QALY plotted against the number of trial PSA simulations.56
The incremental costs and QALYs of each model run were also depicted graphically on a cost-effectiveness
plane. The cost-effectiveness plane shows the incremental costs (y-axis) and incremental QALYs (x-axis)
compared with usual care. In this chart, if a model run for a strategy had exactly the same costs and
QALYs as usual care, then the ‘sample’ for that model run would appear at the origin. Samples plotted to
the right of the y-axis have more QALYs than usual care and samples plotted above the x-axis have more
costs. Samples plotted to the right of a straight line with slope λ passing through the origin are cost-
effective, whereas those plotted to the left are not. The mean NMB was also calculated for a defined
threshold value of λ= £20,000.54,55
A cost-effectiveness acceptability curve, plotting a relevant range of λ values against the probability that
each intervention was the most cost-effective, was additionally graphed to summarise the uncertainty of
PSA results.65 The cost-effectiveness acceptability curve is derived from the joint density of individual
incremental costs and incremental effects calculated for competing treatment options during a PSA and
shows the proportion of model runs for which each strategy is cost-effective over a range of potential
willingness-to-pay thresholds (i.e. λ). The probability of a treatment being the most cost-effective
corresponds to the proportion of the joint density of incremental costs and effects that result in the
highest NMB at a given λ.
Model uncertainty and sensitivity analyses
Uncertainty can arise in decision models due to variability, heterogeneity, parameter uncertainty and
structural uncertainty. Variability arises from random differences between individuals with similar
characteristics.66 Heterogeneity refers to the differences in costs and effects explained by particular
METHODS
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patient characteristics. Parameter uncertainty will occur as model inputs are estimates, with a
probability distribution denoting the relative likelihood of alternative values. Finally, structural
uncertainty relates to the assumptions imposed by the structure, scope or other methodological
decisions taken during the modelling process.
As a cohort model was implemented with examination of mean values, an examination of variability
is extraneous. Furthermore, a prehospital CPAP service is a population-level intervention, which
will be implemented for any patient presenting with suspected ARF, meaning that examination of
heterogeneity is superfluous. Parameter uncertainty (i.e. uncertainty surrounding the true value of a
model input within the specified probability distribution) was fully explored in the PSA.56,64
To examine structural uncertainty and ensure that the correct statistical form has been specified for
the probability distribution of important parameters, a number of sensitivity analyses were planned.
Two different scenario analyses were performed using different effectiveness parameters. In the base
case, results from the ACUTE pilot trial were used. The ACUTE pilot trial was not designed to test
effectiveness, but the clinical experts felt that it provided the only genuinely representative data for
routine NHS practice. It was felt that an imprecise but representative estimate of effectiveness was
more appropriate for the base case than a more precise estimate based on meta-analysis that included
selected populations and practice that differed markedly from the UK. A scenario analysis was
undertaken in which the effectiveness parameters were based on a network meta-analysis synthesising
previously published experimental data, updated with results from the ACUTE trial using identical
methods to those previously reported.3 Included studies were predominantly from non-UK settings,
and the pooled effect estimate may reflect the efficacy of CPAP achievable in more developed EMS systems.
The incidence of ARF was identified as an influential parameter in the original economic analysis
and a further scenario analysis was planned to explore the effect of extreme estimates.3 However,
developments in CPAP technology dramatically reduced the cost of providing prehospital CPAP from
that estimated in the previous analysis (see Chapter 3, Prehospital costs),44 thus removing the potential
means by which the incidence of ARF could influence cost-effectiveness. Therefore, we did not proceed
with this scenario analysis.
Expected value-of-information analysis
Using estimates of the probability of making the wrong decision, together with the ensuing opportunity
costs of error, the expected opportunity loss surrounding a decision can be estimated.54,56,67 A rational
decision-maker, aiming to maximise health within a fixed budget, should be willing to spend up to this
value for additional evidence to remove decision uncertainty, a figure termed the population expected
value of perfect information (i.e. EVPI). This can be thought of as the maximum that the health-care
system should be willing to pay for additional evidence to inform the decision in the future.54,67
The population EVPI places an upper limit on the total value of additional research relating to a specific
decision problem, but does not indicate where future research may be beneficial. The population EVPPI
is the difference between expected value with perfect and current information about particular model
inputs, for all future patients. There will be a large value in improving the precision of estimates of
parameters, or groups of parameters, with high EVPPI, which may suggest using particular study
designs (e.g. commissioning a cohort study to obtain estimates of disease incidence or a clinical trial
to investigate effectiveness).54,67,68
Individual-level expected value-of-information metrics were initially calculated for both the base-case
and updated meta-analysis scenario analyses. Assumptions on ARF incidence (11,000 patients per year
in England and Wales), discount rates (3.5%) and health technology lifespan (5 years) were then used
to compute population-level statistics. EVPI for individual patients was calculated directly from the
model PSA output using standard formulas.54 Individual EVPPIs were estimated by using two-level
Monte Carlo simulation techniques.68 Ten parameters, reflecting targets for potential future research
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designs, were considered in EVPPI analyses: baseline mortality, baseline risks, relative effectiveness for
mortality, relative effectiveness for intubation, cost of prehospital CPAP, cost of hospitalisation, cost of
intubation, cost of long-term survival, life expectancy and lifetime quality of life.
Model implementation
The decision-analytic model was programmed in the R statistical package. Internal testing was
performed throughout model development to ensure that mathematical calculations accurately
represented model specifications and were correctly implemented. Debugging techniques included
reimplementation in Excel, null and extreme input values; setting equal values across comparators;
fixed distributions; and line-by-line checking of syntax. Model validation was performed by comparing
model outputs with published estimates from the ARF literature,6,8 including the costs and life
expectancy predicted from the model.69–71
Acute respiratory failure incidence study
A pre-planned cross-sectional study was conducted to estimate the incidence of ARF suitable for
prehospital CPAP treatment. ARF was defined as respiratory distress (e.g. raised respiratory rate or
use of accessary muscles of respiration), with peripheral oxygen saturation below BTS target levels
(88% for patients with COPD, 94% for other conditions) despite supplemental oxygen (titrated low-
flow oxygen for COPD or titrated high-flow oxygen for other conditions).14 Suitability for CPAP was
determined by whether or not cases met the ACUTE trial eligibility criteria.
The source population consisted of adult patients, aged ≥ 18 years, presenting to WMAS between
1 August 2017 and 31 July 2018. EPRs from this period were searched with an electronic filter to
identify potential ARF patients. The filter excluded any patients with peripheral oxygen saturations of
≥ 94% recorded during the prehospital interval; no oxygen treatment provided; normal respiratory
rate (13–20 breaths per minute); non-conveyance to hospital (except for cardiac arrest); primary
diagnostic impressions not consistent with ARF (e.g. gastrointestinal bleeding or haematuria); or a
clear contraindication to CPAP recorded, including vomiting, epistaxis or pneumothorax. The EPRs of
all remaining cases were manually reviewed by a research paramedic and presentations meeting the
ACUTE trial clinical eligibility criteria were identified to provide the final study sample. Inter-rater
agreement was checked with a second research paramedic, who independently examined a random
subsample of 10% of filtered cases each month. Any disagreements were resolved by negotiation.
Derivation of the study sample was described and monthly incidence rates presented graphically. Overall
incidence rate with 95% CIs was then calculated for patients with ARF suitable for CPAP for the entire
WMAS region. Separate incidence estimates were calculated using a population denominator determined
fromWMAS, Office for National Statistics census72 and Office for National Statistics labour market data.73
The number of ACUTE trial eligible, but unenrolled, patients presenting to ACUTE trial-trained paramedics
was also determined. Inter-rater agreement was evaluated by calculating raw agreement.74
Acute respiratory failure diagnosis study
A nested, pre-planned, diagnostic accuracy and agreement study was conducted to compare
prehospital clinical impression with the final hospital discharge diagnosis. Study conduct and reporting
was performed in accordance with standards for the reporting of diagnostic accuracy studies (STARD),
and Guidelines for Reporting Reliability and Agreement Studies (GRRAS), recommendations for
diagnostic accuracy and reliability studies.75,76
The index test under consideration was the ambulance service clinician’s clinical impression of the
aetiology of ARF. After enrolment of a patient into the ACUTE trial, both the most likely clinical
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diagnosis and the presence of any contributing conditions were recorded using CRF A, contained within
each equipment box. A six-category nominal variable was used to classify the suspected diagnosis,
comprising ‘heart failure’, ‘asthma’, ‘lower respiratory tract infection’ (LRTI), ‘COPD’, ‘PE’ or ‘other’.
These categories were chosen based on the most common causes of ARF and conditions benefiting from
specific treatment strategies.2,6,7,9 Diseases specified in the free-text ‘other’ option were coded post hoc
by ACUTE trial co-investigators, with any disagreements resolved by discussion, to achieve a consensus
decision. The reference standard was the final hospital diagnosis accounting for presenting respiratory
distress. This was identified by research paramedics from the hospital case notes or discharge summary
and recorded using CRF B using the same nominal categories.
The statistical analysis proceeded in three stages. First, sample characteristics were described using
summary statistics, cross-tabulation and a mosaic plot. Second, agreement between prehospital and
hospital diagnostic assessments was evaluated. Raw agreement was initially calculated as the proportion
of cases with an identical prehospital and hospital diagnosis.77,78 To account for the possibility that
some agreement might be expected due to chance, the Gwet’s AC1 coefficient was also determined.
This statistic was chosen in preference to Cohen’s kappa statistic, as it does not depend on an assumption
of independence between different ratings, is robust to marginal probabilities and is less affected by rating
prevalence. Landis and Koch’s79 benchmark values were used to interpret the magnitude of agreement
coefficients, with 0.00–0.20 indicating slight, 0.21–0.40 indicating fair, 0.41–0.60 indicating moderate,
0.61–0.80 indicating substantial and 0.81–1.00 indicating almost perfect agreement. Agreement was
calculated for the primary diagnoses alone and for combined primary and secondary diagnoses, ignoring
the precedence placed on each condition and counting any match. Third, the prehospital primary clinical
impressions (index tests) were compared with the final hospital diagnosis (reference standard), with
sensitivity and specificity calculated for the most common diagnostic categories.80 All results were
calculated with their 95% CIs. Complete-case analyses were conducted, with missing or non-interpretable
data highlighted when relevant. Statistical analyses were carried out in Stata® version 15 (StataCorp LP,
College Station, TX, USA).
Study of the perceptions of recruiting clinicians
The experiences of ambulance service clinicians participating in the ACUTE trial were examined in a
pre-planned mixed-methods study, consisting of a survey and focus groups.
Recruiting ambulance service clinicians were invited to complete a short, anonymous, web-based
questionnaire to examine their experience of providing prehospital CPAP after each patient was
enrolled. Closed questions explored a range of trial-related topics, including identification and diagnosis
of ARF, assessment of capacity, obtaining verbal consent and enrolment of participants, use of CPAP
and prehospital trial data collection. Responses were recorded using a five-point Likert-type scale, for
which respondents specified their level of agreement or disagreement on a symmetric agree–disagree
scale, with a statement included in each question.81 Additional open questions were offered for each
topic and at the end of the survey, to capture any further issues. Data were collected using Google
Forms (Google Inc., Mountain View, CA, USA), with data downloaded to Excel for analysis. Categorical
numerical responses to closed questions were described using percentages. Answers to free-text open
questions were processed and coded, with subsequent identification of important themes.82
All WMAS ambulance service clinicians recruiting to the trial were also invited to participate in focus
groups to further explore trial issues. Three meetings were held, facilitated by a research paramedic
using an interview guide to conduct semistructured discussions.83 Sessions were remunerated at
overtime rates, and used training materials, a demonstration box, a CPAP mask and demonstration
CRFs as stimuli for discussion. Proceedings were digitally recorded (supplemented with hand-written
notes), transcribed and analysed using NVivo software, version 12 (QSR International, Warrington, UK).
Findings were tabulated and key themes were identified.
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Allocation concealment study
The robustness of allocation concealment using equipment boxes was investigated in a post hoc, cross-
sectional study after closure of ACUTE trial recruitment (substantial amendment 3, 16 February 2018).
A convenience sample of ambulance service clinicians from Yorkshire Ambulance Service (YAS) and
WMAS, who did not participate in the ACUTE trial, were recruited at educational events and during
clinical shifts between August and September 2018. Each participant was presented with a pair of
ACUTE trial equipment boxes, one from the CPAP intervention arm and one from the standard oxygen
control arm, randomly selected from the residual pool of trial boxes. Ambulance service clinicians were
then allowed up to 60 seconds to identify any differences between the two boxes. If a difference was
identified, they were asked to indicate which box was thought to contain CPAP equipment, quantify
their certainty [scaled from 0 (complete guess) to 10 (absolute certainty)] and detail the detected
difference(s). The pairs of boxes tested by each paramedic were selected from a pool of three sets of
boxes according to a pre-generated randomisation schedule, stratified by ambulance service, determined
centrally at Sheffield CTRU. Following completion, recruitment boxes were examined for any differences.
The proportion (with a 95% CI) of ambulance service clinicians who claimed to be able to detect a
difference between the boxes, and the proportion who were able to correctly identify the box
containing CPAP equipment, were examined. The certainty of guesses, if a difference was identified,
was summarised using medians and IQRs. These results were calculated for the whole sample and
stratified by ambulance service. The free-text reasons reported for indicating differences between
boxes were coded and grouped into common themes. The sample size was determined on the basis of
convenience and the willingness of ambulance service clinicians to participate, but it was estimated a
priori that a sample of 100 participants was feasible and would provide estimates that were precise
enough to determine whether or not there was a potential threat to allocation concealment.
METHODS





The Stoke ambulance service hub commenced recruitment as planned on the 1 August 2017. Owing to
delayed research approvals, the remaining ambulance hubs became active later (Stafford, 17 August
2017; Lichfield, 11 September 2017; and Erdington, 6 October 2017). Across the hubs, 204 ambulance
service clinicians, representing 13% of available staff, completed trial training. Seventy-three staff
attended the face-to-face ACUTE trial training event and 131 completed the online educational package.
Over the recruitment period up to 30 August 2018, approximately 364 patients with ARF meeting the
ACUTE trial eligibility criteria presented from the 1.5 million population of four participating WMAS hubs.
Of those patients, 161 (44.2%) were attended by ACUTE trial-trained ambulance service clinicians and
could potentially have been recruited. Of these 161 patients, 77 (47.8%) were enrolled in the trial, by
41 individual ambulance service clinicians, equating to a recruitment rate of 5.1 per 100,000 persons
per year (95% CI 4.1 to 6.4 per 100,000 persons per year). The remaining 84 patients (52.2%) presented
to participating ambulance service clinicians, but were not enrolled. Although the attending clinician had
signed out an ACUTE trial equipment box, the patient was not enrolled in 18 of these cases, for unknown
reasons. In the remaining 66 cases, the participating ambulance service clinician had failed to carry an
ACUTE trial equipment box and was therefore unable to recruit an eligible patient. This occurred either
because the clinician forgot to collect an equipment box or because they withdrew from participation in
the study. No patients assessed to have capacity at the scene and invited to enrol in the trial declined
verbal consent for participation.
The recruitment rate was broadly similar across the four participating hubs. Enrolment showed a
marked seasonal variation, with an increased rate between October and February and fewer patients
included over spring and summer months. Overall, recruitment did not meet the feasibility target of
120, with a much lower enrolment rate than target over the closing summer months of the trial.
The target and actual recruitment figures are shown in Figure 5, corrected for the staged start in hub








































































































FIGURE 5 Recruitment rate by month compared with the target rate.
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TABLE 1 Recruitment numbers by month across participating ambulance hubs
Hub
2017 2018
TotalAugust September October November December January February March April May June July August
Erdington 0 0 1 1 8 1 0 1 2 0 0 0 0 14
Lichfield 0 2 2 0 3 0 2 2 1 2 3 1 0 18
Stafford 1 0 7 1 2 7 2 1 0 1 2 0 0 24
Stoke 2 2 1 4 2 7 0 1 0 0 0 2 0 21





























Weekly audit of trial boxes was unremarkable until week 10 of recruitment when it was noted that some
of the intervention arm boxes had begun to ‘rattle’. Further examination revealed that the CPAP mask
had been packaged under tension and, over time, the cushion seal had slightly deflated. All equipment
boxes were immediately returned to the CTRU, replaced using a revised technique that no longer placed
the CPAP masks under pressure and redistributed to WMAS. The original randomisation schedule was
used and box assembly otherwise followed the initially used protocol. For the remainder of the trial, no
issues were noted during box audits. A post hoc allocation concealment study was subsequently conducted
as described in Chapter 2, Allocation concealment study, to explore the robustness of randomisation using
equipment boxes.
Participant flow
The majority of patients were able to provide verbal consent for participation in the trial (59/77, 76.6%);
however, 18 patients (23.4%) were incapacitated at the scene of incident and enrolled after a best-
interests assessment by the attending ambulance service clinician. All patients were transported
to hospital. Informed consent for further participation was confirmed by research paramedics for
51 patients (66.2%, 46 individual patient consent, five personal consultee). This allowed retention of
prehospital data, collection of hospital and clinical outcome information, and invitation to complete the
30-day quality-of-life and resource use follow-up questionnaire. None of these patients withdrew from
the trial at a later date due to subsequent removal of consent, losing capacity and a consultee declining
further participation, or regaining capacity and over-ruling preceding consultee consent.
Consent for further data collection was declined by nine patients (11.7%), resulting in retention of
prehospital data and collection of anonymised 30-day mortality data only. Seventeen patients (22.1%) died
before a research paramedic could approach them for consent. In accordance with research approvals,
prehospital data were retained, and anonymised collection of hospital and clinical outcome information
was conducted; however, 30-day questionnaire follow-up was not possible. ED and inpatient information
were unavailable for two patients owing to absence of research approvals to access data, secondary to
the reorganisation and merger of one hospital. Of the 51 participants who were consented for follow-up,
41 completed the questionnaire at 30 days (80.4%). Four participants died between consent and follow-up
and six participants did not complete the questionnaire despite providing consent for follow-up.
Figure 6 presents the participant flow for the trial, with follow-up figures presented at each relevant
time point. Table 2 summarises the consent, data collection and follow-up.
Baseline characteristics
A small number of data were missing for baseline characteristics, secondary to not being recorded in
CRF A or routine EPRs, including clinician’s assessment of patient’s breathlessness (1/77), systolic
blood pressure (7/77), diastolic blood pressure (7/77), peripheral oxygen saturations (1/77) and pulse
rate (2/77). The final hospital diagnosis was missing for 12 patients (nine patients declining consent for
data collection, one patient for whom no clear primary diagnosis was apparent and two patients for
whom clinical records were unavailable).
Of the 77 recruited patients, slightly more participants were randomised to the CPAP intervention
arm (42 cases), than to the standard oxygen control arm (35 cases). The trial population was elderly
(median age 71 years), predominantly male (62.3%) and severely unwell (median VAS breathlessness
score 9/10, median pulse 115 beats per minute, median respiratory rate 34 breaths per minute and
median initial peripheral oxygen saturations of 78.5%). The most common final primary diagnoses were
COPD (21/65, 32.3%) and LRTI (28/65, 43.1%). A minority of cases (4/65, 6.2%) had non-respiratory
primary diagnosis, comprising abdominal aortic aneurysm, myocardial infarction, sepsis (not further
specified) and liver failure (ascites). Secondary conditions accounting for ARF were diagnosed in
27 out of 65 patients (41.5%), with COPD (16/65) and LRTIs (14/65) being the most common concomitant
conditions. Pre-randomisation characteristics were similar across trial arms, as summarised in Table 3.
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• Received CPAP, n = 38
• Did not received CPAP, n = 4
    • Patient refused, n = 1
    • Not tolerated, n = 1
    • Other, n = 2
• Received standard oxygen therapy, n = 34
• Did not received standard oxygen therapy, n = 1
   • Own CPAP, n = 1
• Died prior to written consent, n = 11
• Declined, n = 5
• Died prior to written consent, n = 6
• Declined, n = 4
Reason follow-up not completed:
• Died within 30 days, n = 1
• Missing, n = 2
Reason follow-up not completed:
• Died within 30 days, n = 3
• Missing, n = 4
Attending clinician not trained to recruit
(n = 203)
No equipment box on board the attending ambulance
(n = 66)
Unknown reason not enrolled
(n = 18)
Reasons for being ineligible
• Non-time critical/improved, n = 343
• Hypotension, n = 115
• DNAR/respect form/palliative, n = 48
• Cardiac arrest, n = 21
• Other, n = 75
Ineligible
(n = 602)
• Patient lacked capacity, n = 18
Verbal consent given
(n = 59)






















FIGURE 6 Consolidated Standards of Reporting Trials (CONSORT) diagram of participants’ flow through the ACUTE
pilot trial. DNAR, do not attempt resuscitation.
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TABLE 2 The ACUTE pilot trial consent, data collection and follow-up
Follow-up variable Total (N= 77), n (%)
Consent at scene





Personal consultee 5 (6.5)
Declinedb 9 (11.7)
Died prior to approachc 17 (22.1)
30-day follow-up questionnaire
Returned 41 (53.2)
Not returned 36 (46.8)
Died 21 (27.3)
Declined consent for follow-up 9 (11.7)
Not completed 6 (7.8)
a Full data collection subsequently possible.
b Prehospital and 30-day mortality data collection only.
c Prehospital, hospital and 30-day mortality data collection.
TABLE 3 Baseline characteristics of ACUTE trial participants by arm
Baseline variable
Descriptive
statistic CPAP (N= 42)
Standard oxygen
therapy (N= 35) Total (N= 77)
Age Median (IQR) 70.0 (60.5–76.8) 73 (65.0–77.0) 71 (62.0–77.0)
Sex Male, n (%) 27 (64.3) 21 (60.0) 48 (62.3)




Yes, n (%) 35 (83.3) 26 (74.3) 61 (79.2)
No, n (%) 7 (16.7) 9 (25.7) 16 (20.8)
Hospital ARF
diagnosisa
n 36 30 65
Asthma, n (%) 1 (2.8) 1 (2.9) 2 (3.0)
COPD, n (%) 10 (27.8) 11 (36.7) 21 (31.8)
Heart failure, n (%) 4 (11.1) 2 (6.7) 6 (9.1)
LRTI, n (%) 17 (47.2) 11 (36.7) 28 (42.4)
PE, n (%) 1 (2.8) 0 (0.0) 1 (1.5)





n 41 35 76
Median (IQR) 9.0 (8.0–10.0) 9.0 (8.0–9.5) 9.0 (8.0–10.0)
First systolic blood
pressure (mmHg)
n 40 30 70
Median (IQR) 136.0 (115.2–150.5) 126.5 (112.0–152.0) 134.5 (112.2–152.0)
continued
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Delivery of interventions
Continuous positive airway pressure was fully delivered as planned (i.e. administered until hospital arrival or
discontinued as a result of patient improvement after successful treatment) in 73.8% (31/42) of intervention
arm participants. CPAP was commenced in 90.5% of participants (38/42), with two participants refusing
to wear the mask, one participant spontaneously improving and a fourth participant having a cardiac
arrest prior to commencement. Of participants commencing CPAP, 31 (81.6%) continued with CPAP until
they arrived at hospital (six did not tolerate CPAP and the remaining participant was transferred to a
standard oxygen non-rebreather mask owing to non-improvement). CPAP administration in the intervention
arm is detailed in Table 4.
Standard oxygen therapy was delivered using a range of devices, either individually or in combination,
consisting of bag–valve–mask apparatus, high-flow non-breather masks, Venturi masks, nebuliser masks and,
in one case, the patient’s own CPAP machine. High-flow non-breather mask used alone was the commonest
treatment (10/35, 28.6%), with treatment with various combinations of non-breather mask, Venturi mask
and nebuliser mask also being common. Oxygen therapy in the control arm is summarised in Table 5.
No participants underwent intubation during the prehospital interval, but 6 of 77 participants (7.8%,
two in the CPAP arm and four in the control arm) required assisted bag–mask ventilation. Ancillary
disease-specific treatments were administered to 61 of 77 (74.3%, 35 in the CPAP arm and 26 in the
control arm) participants. Table 6 summarises the additional treatments administered by ambulance
service clinicians.
TABLE 3 Baseline characteristics of ACUTE trial participants by arm (continued )
Baseline variable
Descriptive
statistic CPAP (N= 42)
Standard oxygen
therapy (N= 35) Total (N= 77)
First diastolic blood
pressure (mmHg)
n 40 30 70
Median (IQR) 75.5 (68.5–84.2) 77.0 (66.5–90.0) 76.0 (67.2–88.2)
First Glasgow Coma
Scale score
n 42 35 77
Median (IQR) 15.0 (14.0–15.0) 15 (14.5–15.0) 15 (14.0–15.0)
First oxygen
saturations (%)
n 41 35 76
Median (IQR) 78 (74.0–85.0) 82 (75.5–86.0) 78.5 (74.8–86.0)
First pulse rate (b.p.m.) n 42 33 75
Median (IQR) 117.0 (105.0–125.8) 111 (92.0–121.0) 115 (100.0–124.0)
First respiratory rate
(breaths/minute)
n 42 35 77
Median (IQR) 36.0 (30.5–40.0) 32 (24.0–40.0) 34 (28.0–40.0)
Duration between 999
call and arrival at
scene (minutes)
Median (IQR) 12.50 (8.00–15.75) 12.00 (8.50–14.50) 12.00 (8.00–15.00)
Duration between
arrival at scene and
departure to hospital
(minutes)
Median (IQR) 43.00 (34.00–49.75) 36.00 (32.50–46.50) 40.00 (34.00–49.00)
Duration between
leaving the scene and
arriving at hospital
(minutes)
Median (IQR) 13.00 (9.00–18.75) 15.00 (10.00 –20.50) 13.00 (10.00–20.00)
Baseline hospital
EQ-5D-5L score
Median (IQR) 0.59 (0.43–0.90) 0.63 (0.44–0.74) 0.63 (0.43–0.83)
b.p.m., beats per minute.
a Consent was declined for data collection in nine cases, clinical records were unavailable in two cases and, in one case,
there was no clear underlying diagnosis apparent in the notes.
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TABLE 4 Adherence to CPAP
CPAP adherence Descriptive statistic Total (N= 42)
CPAP commenced Yes, n (%) 38 (90.5)
Reason CPAP not commenced n 4
Patient refused, n (%) 2 (50)
Cardiac arrest, n (%) 1 (25)
Improved, n (%) 1 (25)
Maximum level of CPAP delivered (LO2/minute)
a n 37
Mean (SD) 9.78 (2.70)
Median (IQR) 9 (8.00–10.00)
Minimum, maximum 6, 15
CPAP continued until arrival in hospital n 38
Yes, n (%) 31 (81.6)
No, n (%) 7 (18.4)
Reason for discontinuing CPAP n 7
Not tolerated, n (%) 6 (85.7)
Lack of improvement, n (%) 1 (14.3)
Duration of CPAP among participants who discontinued before
arriving at hospital (minutes)
n 7
Median (IQR) 12.0 (3–15)
Duration of CPAP among participants who continued CPAP until
arrival at hospital (minutes)
n 31
Median (IQR) 22.0 (15–29)
LO2, litres of oxygen; SD, standard deviation.
a Data not recorded for one participant.
TABLE 5 Details of combinations of oxygen therapy given in the control arm
Standard oxygen therapy method Total (N= 35), n (%)
Bag–mask ventilation and non-rebreather mask 3 (8.6)
Bag–mask ventilation and non-rebreather mask and nebuliser mask 1 (2.9)
Non-rebreather mask only 10 (28.6)
Non-rebreather mask and Venturi mask 4 (11.4)
Non-rebreather mask, Venturi mask and nebuliser mask 4 (11.4)
Non-rebreather mask and nebuliser mask 3 (8.6)
Nebuliser mask 2 (5.7)
Own CPAP machine 1 (2.9)
Venturi mask only 4 (11.4)
Venturi mask and nebuliser mask 3 (8.6)
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Arterial blood gas results, sampled in the ED after arrival, were recorded for 45 participants. Data
were unavailable for 14 cases (nine participants declined consent, two participants had absent research
approvals, and notes were unavailable for three participants). For the remaining 18 cases, an arterial
blood gas procedure was not documented in the clinical records. The median values indicated type II
respiratory failure, with acidaemia secondary to uncompensated acute respiratory acidosis. ED NIV or
CPAP was performed on a minority of participants [13/52 (25.0%) data were missing for 25 participants].
Tables 7 and 8 details ED investigation and management.
Feasibility outcomes
Feasibility outcomes, compared with the prespecified target, are summarised in Table 9.









Bag-mask ventilation required 2 (4.8) 4 (11.4) 6 (7.8)
Intubation required 0 (0.0) 0 (0.0) 0 (0.0)
Ancillary disease-specific treatment required 35 (83.3) 26 (74.3) 61 (79.2)
Salbutamol nebuliser 29 (69.0) 16 (45.7) 45 (58.4)
Ipratropium nebuliser 10 (23.8) 12 (34.3) 22 (28.6)
Adrenaline 3 (7.1) 2 (5.7) 5 (6.5)
Furosemide 5 (11.9) 3 (8.6) 8 (10.4)
Sublingual GTN 6 (14.3) 5 (14.3) 11 (14.3)
Othera 19 (45.2) 11 (31.4) 30 (39.0)
GTN, glyceryl trinitrate.
a Other additional treatments given by ambulance clinicians were i.v. glucose (n = 2); aspirin (n= 2); atropine (n = 2);
glucagon (n= 1); hydrocortisone (n= 6); i.v. 0.9% saline (n= 20); naloxone (n= 1); ondansetron (n= 1); and paracetamol
(n= 5). Note that participants could receive multiple ‘other’ treatments.
TABLE 7 Emergency department arterial blood gas results
Arterial blood gas variable
Descriptive
statistic CPAP (N= 34)
Standard oxygen
therapy (N= 29) Total (N= 63a)
Arterial blood gases sampled n (%) 27 (79.4) 18 (62.1) 45 (71.4)
pH (normal 7.38–7.42)b Median (IQR) 7.31 (7.23–7.38) 7.33 (7.29–7.38) 7.31 (7.23–7.38)
PaO2 (kPa, normal 10.5–13.5)
c Median (IQR) 8.35 (5.62–9.70) 7.05 (6.80–8.20) 7.45 (5.68–9.70)
PaCO2 (kPa, normal 5.1–5.6) Median (IQR) 6.30 (5.50–8.45) 7.30 (6.15–9.00) 6.50 (5.60–9.00)
Standard bicarbonate (mmol/l,
normal 22–28)d
Median (IQR) 22.95 (20.80–26.18) 24.90 (22.70–30.50) 24.70 (21.75–28.20)
PaO2, partial pressure of oxygen.
a Data not available for 14 cases, secondary to lack of research approvals (n = 2), consent for data collection declined
(n = 9) or case notes unavailable (n = 3).
b Data in case notes missing or unclear for two further cases.
c Data in case notes missing or unclear for one further case.
d Data in case notes missing or unclear for 10 further cases.
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Recruitment rate
The sample size of 77 enrolled participants resulted in a recruitment rate of 5.1 (95% CI 4.1 to 6.4)
per 100,000 persons per year, falling short of the feasibility target of 8 per 100,000 persons per year
(i.e. 120 patients).
Major or minor non-compliances
All participants were recruited appropriately, with no major protocol non-compliances. A single minor
protocol non-compliance (1/77, 1.3%) was recorded when it was reported that a control arm standard
oxygen mask did not work, necessitating substitution of another mask. However, when formally tested
by the supplier, no abnormality was found. This compared favourably with feasibility targets for minor
or major non-compliances of ≤ 10% and 0%, respectively.
TABLE 8 Emergency department management
ED NIV/CPAP CPAP arm (N= 32), n (%) Standard oxygen arm (N= 20), n (%) Total (N= 52), n (%)a
None 22 (68.8) 17 (85) 39 (75)
O-Two CPAP continued 9 (28.1) 0 (0) 9 (17.3)
ED CPAP 0 (0.0) 0 (0) 0 (0)
ED BIPAP 1 (3.1) 3 (15) 4 (7.7)
a Data in case notes missing or unclear for 14 cases (data not available owing to lack of research approvals for two
cases and consent for data collection declined for nine cases).
TABLE 9 Summary of feasibility results
Feasibility outcome Target Result
Recruitment rate 8 per 100,000 persons per year
(i.e. 120 patients recruited)
l 5.1 (95% CI 4.1 to 6.4) per 100,000
persons per year
l 77 enrolled participants
Major and minor non-compliances 0% and ≤ 10% l 0% major non-compliances
l 1.3% minor non-compliance
Adherence to the allocation
schedule
Target ≥ 90% l 100% adherence to allocation schedule
Adherence to treatment in the
CPAP arm
Target ≥ 75% l 74%: CPAP fully delivered as planned
Retention at 30 days Target ≥ 90% l 100% follow-up for all feasibility end
points and 30-day mortality
Data completeness Target ≥ 90% Data completeness for outcomes:
l 100% – feasibility outcomes
l 100% – 30-day mortality
l 81% – 30-day intubation
l 84% – admission to critical care
l 99% – clinician assessed breathlessness
l 86% – length of hospital stay
l 85% – baseline EQ-5D-5L scorea
l 71% – 30-day EQ-5D-5L scorea
l 73% – 30-day resource usea
a Of alive participants.
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Adherence to the allocation schedule
There was full adherence to the allocation schedule (feasibility target ≥ 90%). Treatment with CPAP
was attempted in all participants enrolled in the intervention arm. All participants received appropriate
standard oxygen management in the control arm, although one participant was enrolled who used their
own CPAP machine.
Adherence to treatment in the continuous positive airway pressure arm
Continuous positive airway pressure was fully delivered as planned (i.e. administered until hospital arrival,
or discontinued because of patient improvement after successful treatment) in 74% (31/42) of participants
in the intervention arm, as described in Delivery of interventions. This compared favourably with the feasibility
target of 75%.
Retention at 30 days and data completeness
Full data were available for key outcomes, including all feasibility end points and vital status at 30 days,
which meets the feasibility targets of ≥ 90% retention at 30 days and ≥ 90% data completeness. A small
number (< 1%) of prehospital data describing baseline patient characteristics were not available because
of missing values. The difference in clinician-reported VAS dyspnoea scores was unavailable for one
participant secondary to prehospital cardiac arrest (n = 77, 1.3%).
A larger proportion of hospital data were missing secondary to lack of consent for collection (n = 9, 11.7%),
absence of local research approvals to access hospital data (n = 2, 2.6%) or unclear or absent information
in the hospital clinical records [differing across variables, ranging from n = 0 (0%) for hospital length of
stay to n = 25 (32.5%) for ED management]. Across the prespecified secondary hospital outcomes, data
were missing for:
l endotracheal intubation by 30 days (15/77, 19.5%)
l admission to critical care at any point up to 30 days (12/77, 15.6%)
l mean and median lengths of hospital stay (11/77, 14.3%).
Baseline EQ-5D-5L score was unavailable for 26 participants (33.8%) in total: for nine (11.7%), there was
a lack of consent for collection, and the remaining 17 (22.1%) died prior to research paramedic approach
for measurement. Of participants alive at 30 days (n = 56), 30-day follow-up questionnaires examining
quality of life and post-discharge health resource use were fully completed by 40 participants (71.4%),
with partial completion by one participant of health resource use only. Consent for further data collection
was declined by nine participants and a further seven participants did not complete the questionnaire,
despite providing consent for follow-up.
Effectiveness outcomes
Secondary effectiveness outcomes are summarised in Table 10.
TABLE 10 Summary of effectiveness outcomes
Effectiveness outcome CPAP (N= 42)
Standard oxygen
therapy (N= 35) Total (N= 77)
30-day mortality (N) 42 35 77
n 12 9 21
% 28.6 25.7 27.3
Intubated (N) 33 29 62
n 2 1 3
% 6.1 3.4 4.8
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Proportion surviving to 30 days
Overall mortality of the trial population was higher than expected, with 27.3% (21/77) of participants
dying by 30 days.3 A total of 28.6% (12/42) of participants in the CPAP arm and 25.7% (9/35) in the
standard oxygen arm (expected 12%) died by 30 days. Two participants in each arm died on the day of
enrolment, with the remainder dying between 1 and 28 days post hospital admission. The median
time to death among those who died was 4 days overall (2.5 days for CPAP arm and 10 days for the
standard oxygen arm). Survival of enrolled participants, stratified by trial arm, is presented using a
Kaplan–Meier graph in Figure 7.
An unplanned descriptive analysis of the deceased participants was undertaken to explore the circumstances
for the unexpectedly high mortality rate. Data were not available for two cases owing to lack of research
approvals to access data, and two participants died from non-cardiorespiratory conditions not amenable to
NIV (ruptured abdominal aneurysm and liver failure). Of the remaining 17 cases, six participants (35.3%)
received hospital NIV (5/17, 29.4%) or mechanical ventilation (1/17, 5.9%) and the other 11 participants
had explicit ceiling-of-treatment decisions documented in hospital that excluded hospital NIV and critical
care management (5/17, 29.4%), or appeared to have implicit limits on treatment level and died without
NIV or critical care intervention (6/17, 35.3%).
TABLE 10 Summary of effectiveness outcomes (continued )
Effectiveness outcome CPAP (N= 42)
Standard oxygen
therapy (N= 35) Total (N= 77)
Admission to critical care (N) 35 30 65
n 4 2 6
% 11.4 6.5 9.2
Length of stay (days) (n) 22 22 44
Median 10.0 7.0 8
IQR 6.5 to 12.0 5.0 to 9.8 5.5 to 11.2
Patient-reported breathlessness over prehospital
interval (VAS score) (n)
18 18 36
Change in VAS score –3 –2 –2.5
IQR –4 to –2 –4 to –1 –4 to –1
Change in
Clinician-assessed breathlessness over prehospital
interval (VAS score) (n)
41 35 76
Change in VAS score –3 –2 –2
IQR –5 to –1 –3.5 to 1 –4 to –1
30-day EQ-5D-5L score (n) 22 18 40
EQ-5D-5L score 0.82 0.73 0.76
IQR 0.58 to 0.95 0.43 to 0.89 0.48 to 0.92
Change in EQ-5D-5L score (n) 22 18 40
Median change 0.09 0.10 0.09
IQR –0.01 to 0.16 –0.06 to 0.19 –0.02 to 0.18
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Proportion undergoing endotracheal intubation by 30 days
The overall risk of intubation was low, occurring for only three of the 62 participants with follow-up
data (4.8%). Two participants in the CPAP arm were intubated (n = 33, 6.1%), and one participant in the
standard oxygen therapy arm was intubated (n = 29, 3.4%).
Proportion admitted to critical care at any point up to 30 days
A small proportion of participants were admitted to higher levels of care, with six participants receiving
critical care-based management (n = 65, 9.2%). Four participants in the CPAP arm (n = 35, 11.4%)
received intensive care unit care, with two of these also receiving high-dependency or respiratory support
unit treatment. The median length of critical care stay for these participants was 6.5 days (IQR 4.0–8.75 days,
range 1–11 days). Two out of 30 participants in the standard oxygen arm (6.7%) were managed entirely
in an intensive care unit, with no preceding/subsequent level 2 critical care. The median length of critical
care stay in the control arm was 15 days (IQR 11.0–19.0 days, range 7–23 days).
Mean and median lengths of hospital stay
Overall, 44 out of 66 participants were discharged after their initial admission (66.7%); 17 participants
died during their index presentation (25.8%) and five participants remained in hospital for the
duration of the 30-day follow-up period (7.8%). The overall median length of initial stay was 8 days
(IQR 5.8–12.0 days, range 1–28 days). Length of stay was similar for both trial arms, with a median
of 10.0 days (IQR 6.5–12.0 days) in the CPAP arm and 7.0 days (IQR 5.0–9.8 days) in the standard
oxygen therapy arm.
Change in visual analogue scale dyspnoea score from initial presentation to immediately
before emergency department arrival
Breathlessness, evaluated by patient-reported and clinician-assessed VAS score, was measured at
enrolment and after arrival at hospital. There was an improvement in both patient-reported and
clinician-assessed breathlessness over the prehospital interval. The overall median VAS score for initial
breathlessness was 9 out of 10 (IQR 8–10) for both patient-reported (n = 37) and clinician-assessed
measurements (n = 76). The VAS score for breathlessness on arrival at hospital improved to a median
of 5.5 (n = 48, IQR 4–8) for patient-reported measurements and 6.0 (n = 76, IQR 5–8) for clinician-
assessed values. Initial and hospital-arrival VAS breathlessness scores were similar across trial arms for



















Group = standard oxygen therapy
Strata
FIGURE 7 Kaplan–Meier plot showing post-randomisation survival. Line represents survival curve estimate. Shaded areas
represent 95% CI.
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Mean EuroQol-5 Dimensions, five-level version, score
Baseline quality of life, measured using the EQ-5D-5L, was relatively poor overall, with a median score
of 0.63 (n = 51, IQR 0.43–0.83, range –0.027 to 1). Baseline EQ-5D-5L scores were similar across trial
arms, with median scores of 0.59 (n = 26, IQR 0.43–0.90) and 0.63 (n = 25, IQR 0.44–0.74) in the
intervention and control arms, respectively. Follow-up EQ-5D-5L data were available for 40 participants,
demonstrating improved quality of life with an increased overall median score of 0.76 (IQR 0.48–0.92).
Follow-up scores were higher in the CPAP arm [median score 0.82 (n = 22, IQR 0.58–0.95) than in the
standard oxygen therapy arm [median score 0.73 (n = 18, IQR 0.43–0.89)].
Key elements of health-care resource use up to 30 days
Of participants who were discharged after their initial admission, 11 were re-admitted to hospital during
the 30-day follow-up period (n = 44, 25.0%). A high proportion of respondents to the 30-day health care
resource use questionnaire consulted other health-care services (28/41, 68.3%), with the commonest
providers including general practitioners (15/41, 53.6%), EDs (7/41, 25.0%) and physiotherapists
(5/41, 17.9%). Post-discharge health-care resource use is summarised in Table 11.
Safety
In total, 47 AEs (in 40 participants) were reported, of which 39 (in 34 participants) were classified as SAEs.
The proportion of participants experiencing AEs and SAEs across trial arms were, respectively, 54.8%
and 45.2% for the CPAP arm, and 48.6% and 42.9% for the standard oxygen therapy arm. The non-SAEs
comprised claustrophobia or distress associated with CPAP mask use (n = 5), a non-rebreather mask in
the control arm not inflating (n= 1, mask subsequently confirmed as functional by supplier) and non-specific
mild worsening of condition (n= 2). The majority of SAEs were deaths (20/39, 51.2%) or re-admission to
hospital within 30 days (13/39, 33.3%). There were no unexpected related SAEs. Two patients (one
intervention arm participant not receiving CPAP and one control arm participant) were categorised as having
experienced related expected SAEs following diagnosis with pneumothoraces requiring intercostal drainage
after hospital admission. The remaining SAEs were all unrelated and included an inpatient fall resulting in a
fractured neck of femur, cardiac arrest prior to administration of prehospital CPAP, social care re-admission
and a stroke. AEs and SAEs are summarised in Table 12 and detailed individually in Appendix 5.
TABLE 11 Post-discharge health-care resource use







Discharged after index admission N 36 30 66
n (%) 22 (61.1) 22 (73.3) 44 (66.7)
Re-admission for any reason N 22 22 44
n (%) 5 (22.7) 6 (27.3) 11 (25.0)
Health-care provider consulted N 23 18 41
n (%) 14 (60.9) 14 (77.8) 28 (68.3)
Health-care provider seen GP, n (%) 7 (50.0) 8 (57.1) 15 (53.6)
Practice or district nurse, n (%) 7 (50.0) 5 (35.7) 12 (42.9)
ED, n (%) 4 (28.6) 3 (21.4) 7 (25.0)
Physiotherapist (out of hospital),
n (%)
2 (14.3) 3 (21.4) 5 (17.9)
Other, n (%)a 3 (21.4) 7 (50.0) 10 (35.7)
GP, general practitioner.
a Other health-care providers seen were oxygen supplier, care workers, community respiratory team, dentist, heart
failure nurse, occupational therapy, outpatient appointment, outpatient X-ray, pharmacist, social worker. Some
participants saw multiple other health-care providers.
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The decision-analytic model assigned the standard oxygen therapy cohort with a baseline probability of
death and intubation. The risks of death and intubation for prehospital CPAP were estimated by applying
the ORs from the ACUTE trial and updated HTA network meta-analysis3 to the baseline risks of mortality
and intubation. Costs were based on the prehospital treatment received, the probability of intubation and
life expectancy. QALYs accrued according to the probability of mortality, life expectancy and utility values.
The model parameters are described in Baseline risks, Effectiveness and Lifetime quality-adjusted life-years.
and summarised in Table 13. Costs are detailed in Table 14.
TABLE 12 Summary of the number of AEs and SAEs, as well as the proportion of participants experiencing at least one





Number of participants 42 35 77
Number of AEs 27 20 47
Number (%) of individuals with an AE 23 (54.8) 17 (48.6) 40 (51.9)
Number of SAEs 22 17 39
Number (%) of individuals with a SAE 19 (45.2) 15 (42.9) 34 (44.2)
TABLE 13 Summary of model parameters
Parameter Mean Distribution (95% CI) Source
Baseline risk
Risk of mortality 0.257 Beta (9 to 26) ACUTE trial
Risk of intubation 0.034 Beta (1 to 28) ACUTE trial
OR for prehospital CPAP
Base-case scenario (effectiveness parameters from ACUTE trial)
Log-(mortality OR) 0.145 Normal (0.145 to 0.521) ACUTE trial
Log-(intubation OR) 0.591 Normal (0.591 to 1.403) ACUTE trial
Scenario using effectiveness parameters from the network meta-analysis
Log-(mortality OR) –0.916 Samples ACUTE trial, HTA meta-analysis3
Log-(intubation OR) –1.050 Samples ACUTE trial, HTA meta-analysis3
Life expectancy of patients
Lifetime years 2.67 years Normal (2.67 to 0.16) 3CPO trial,22 clinical opinion
Health-related quality of life
Utility 0.6 Beta (640 to 425) 3CPO trial,22 clinical opinion
Costs (£)
Prehospital CPAP 33 Normal (33 to 3.30) O-Two/SP Services (UK) Ltd (Telford, UK),44
WMAS, expert opinion
Hospitalisation 3200 Gamma (80 to 40) NHS reference costs84
Intubation 3600 Gamma (90 to 40) HCHS index,85 clinical opinion
Annual costs 6000 Gamma (60 to 100) 3CPO trial,22 HCHS index,85 clinical opinion
HCHS, Hospital and Community Health Service.
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Baseline risks
The baseline risk of mortality was modelled using the 30-day mortality data from the control arm of the
ACUTE pilot trial, which reported nine deaths [n = 35 (25.7%), complete-case, modified intention-to-treat
analysis set]. The uncertainty in the baseline risk was represented in the model as a beta distribution,
with an alpha of 9 and a beta of 26. A key secondary outcome measure of interest was the intubation risk,
which determines whether or not critical care admission is required. This parameter was also modelled




























£17.25 × 5 × 1017
Total cost of the device (£) 97,204
Staff costs








0.5 × £21.76 × 1384
Technicians,
n= 1002
Band 5: 17.42 0.5 × £17.42 × 1002
Student technicians,
n= 816
Band 4: 14.40 0.5 × £14.40 × 816
Total cost (£) 29,660
Costs of ongoing
training for new staff




Technicians, n = 90
per year
Band 5: 17.42 0.5 × £17.42 × 5 × 90
Student technicians,
n= 280 per year
Band 4: 14.40 0.5 × £14.40 × 5 × 280
Total cost (£) 14,129
Refresher training for
existing staff (using
10% attrition rate to
account for promotion,
retirement, leavers, etc.)




Paramedics, n= 1245 Band 6: 21.76 0.5 × £21.76 × 1245
Technicians, n = 902 Band 5: 17.42 0.5 × £17.42 × 902
Student technicians,
n= 735
Band 4: 14.40 0.5 × £14.40 × 735
Total (£) 26,695
Total staff costs (£) 70,484
Total costs of prehospital CPAP (£) 167,688
Number of patients in 5 years (5 years × 1017 patients per year) 5085
Cost of prehospital CPAP per patient (£) 33
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using the data from the control arm of the ACUTE trial, which reported one intubation [n = 29 (3.4%),
complete-case, modified intention-to-treat analysis set]. Uncertainty in the intubation risk was represented
as a beta distribution, with an alpha of 1 and a beta of 28.
Effectiveness
The base-case cost-effectiveness analysis used relative effectiveness results from the ACUTE pilot trial
for mortality and intubation. The ORs for effectiveness of CPAP for reducing mortality and intubation
were 1.2 (95% CI 0.4 to 3.2) and 1.8 (95% CI 0.2 to 40.1), respectively. Both ORs were calculated using
the intention-to-treat principle, but the OR for intubation only used patients for whom in-hospital
intubation data were available.
A scenario analysis was also performed using different effectiveness parameters from a preceding
HTA-funded evidence synthesis.3 The network meta-analysis was revised with results from the ACUTE
trial, using identical methods to those previously reported. The ORs with 95% CrIs for reducing
mortality and intubation were 0.5 (95% CrI 0.2 to 1.4) and 0.4 (95% CrI 0.1 to 0.9), respectively.
Lifetime quality-adjusted life-years
Lifetime QALYs were estimated by multiplying the life-years with representative quality of life. The same
estimates for life expectancy and quality of life were used as in the previous economic model, both
derived from the 3CPO trial.22 Discounted life expectancy was estimated at 2.67 years, parameterised as
a normal distribution with a mean of 2.67 years and standard deviation of 0.16 years. The mean utility
value was 0.6, represented as a beta distribution with an alpha of 640 and a beta of 425.
Prehospital costs
The cost of standard care was assumed as £0. There are a number of costs involved in providing
prehospital CPAP, namely initial and ongoing training and equipment costs. These total costs were
converted into a cost per patient based on a 5-year depreciation period (i.e. assuming new prehospital
CPAP equipment will be required in 5 years) and sharing the overall costs out among the number of
patients who would benefit from the service over this time period.
There is a paucity of data on the total costs of providing prehospital CPAP and, thus, bottom-up costing
methods were used, updating the previous economic model values with more relevant and contemporary
data. The resulting costs were much lower than in the previous analysis because a newer CPAP device
was used [O-Two vs. Boussignac CPAP system (Vygon, Paris, France)]. This was much cheaper and required
less training, so that the reduced cost was roughly half attributable to reduced device cost and half
attributable to reduced training costs.
Training costs for initial and new staff to use prehospital CPAP were provided by expert opinion from
WMAS. The estimate of £70,484 was, again, lower than the previous economic model, but was informed
by the training model used in the ACUTE pilot trial. This assumed an initial half-hour training session,
with one further refresher session during the 5-year technology lifespan.
Prehospital CPAP device costs were dependent on the number of ambulances that would need to be
equipped with CPAP devices, the incidence of ARF and the cost of disposable CPAP devices. An estimate
of 550 ambulances was provided by WMAS. A CPAP device cost of £17.25 was quoted from SP Services,
the UK suppliers of the O-Two unit. The unit cost for the Boussignac CPAP system used in the previous
model was £513.49. The incidence of ARF patients who will benefit from prehospital CPAP is one of
the key parameters in the model, as the unit cost of prehospital CPAP is estimated by dividing the total
costs to the ambulance service of a prehospital CPAP by the number of CPAP devices used. The mean
incidence rate reported in the ACUTE trial was 18.2 per 100,000 persons per year (95% CI 17.1 to 19.3
per 100,000 persons per year). Uncertainty in the cost of delivering prehospital CPAP per patient was
estimated by changing the cost of the device by £5 in either direction, and by using a range of incidences
(17.1–19.3 per 100,000) based on the 95% confidence limits of the incidence estimate.
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This resulted in a final CPAP cost per patient ranging from £26.53 to £39.57. This was assumed to be
normally distributed around the mean of £33.00, with a standard deviation of £3.30.
Intubation costs
The cost of intubation was estimated in the previous HTA economic model3 by multiplying intensive
care unit costs by the average length of stay for intubation (assumed to be 5 days). In the previous
model,3 the mean intubation costs were estimated as £3500. These costs were inflated using the ratio
of Hospital and Community Health Service (HCHS) indices for 2016/17 and 2014/15, which were
302.3 and 293.1, respectively. This resulted in a mean annual cost of £3600. In the model, this cost was
parameterised as a gamma distribution, with an alpha of 90 and a beta of 40, after consultation with
ACUTE trial clinical experts.
Hospitalisation costs
The cost of ED care was assumed as £0 in both arms. Length of hospitalisation is dependent on whether
or not a patient needs intubation, as length of stay is longer for patients who undergo intubation. The
same estimate from the previous economic model, informed by Hubble and colleagues,86 was used,
which reported that the mean hospital length of stay for patients without intubation is 5.84 days.
The non-intubated participants in the ACUTE trial can be classified into those that received NIV in
hospital (approximately 42.5% between both arms) and those that did not. ACUTE trial clinical advisors
suggested that non-intubated patients with no NIV/critical care matched closely with patients with code
DZ27S (respiratory failure without interventions, with complication and comorbidity score 11+) and
those with no intubation but who did get NIV in hospital matched closely to the patients with code DZ27P
(respiratory failure with single intervention, with complication and comorbidity score 11+) reported in
NHS reference costs for 2017/18.84 Thus, the mean inpatient admission cost for hospitalisations was
calculated as the weighted average of the costs of patients with DZ27S and DZ27P, from the NHS
reference costs for 2016/17.84 The hospitalisation cost used in the model, with a mean cost of £3200,
was represented as gamma distribution, with an alpha of 80 and a beta of 40.
Lifetime costs
Lifetime costs of survivors were estimated using the annual costs and the discounted life expectancy of
patients captured from the 3CPO trial. In the previous HTA model,3 the mean annual costs were estimated
as £5300, based on the 3CPO study published in 2009. These costs were inflated using the ratio of
HCHS indices for 2016/17 and 2008/9, which were 302.3 and 267, respectively. This resulted in a mean
annual cost of £6000. In the model, this annual cost was parameterised as a gamma distribution, with an
alpha of 60 and a beta of 100, after discussions with ACUTE trial clinical experts. It was assumed that the
lifetime costs were the same for all survivors, irrespective of whether they were in the standard care or
prehospital CPAP arm.
Base-case cost-effectiveness results: ACUTE pilot trial effectiveness estimates
The base-case analysis used effectiveness estimates from the ACUTE pilot trial, representing NHS
implementation of prehospital CPAP. Exploratory analyses indicated that 10,000 PSA runs were
sufficient to sample fully from parameter probability distributions and achieve stable estimates of
incremental cost-effectiveness. This analysis indicated that the prehospital CPAP strategy was cheaper
and less effective than standard care. The ICER was therefore interpreted as the incremental costs and
QALYs of standard care compared with CPAP (as the ICER is calculated by comparing with the next
most effective alternative).
Incremental expected costs and QALYs from the PSA are shown in Figure 8 for standard oxygen therapy
compared with the ‘baseline’ strategy of prehospital CPAP. Each PSA simulation, representing a realisation
of the joint distribution of possible model inputs, is depicted by a single point on the cost-effectiveness
plane. It is apparent that there is a large degree of uncertainty in incremental costs and effects,
reflected in the dispersal of PSA simulations, falling in both the north-east and south-west quadrants
of the cost-effectiveness plane. On average, the standard oxygen therapy strategy was more effective
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(mean incremental QALYs of 0.062), but also more expensive (mean incremental costs of £351) than
prehospital CPAP. The mean ICER, estimated as standard care compared with CPAP, was £5685 per
QALY. Given the typical NICE threshold of £20,000 per QALY, the base-case analysis indicates that
standard care is cost-effective because it gains QALYs with an acceptable ICER, compared with CPAP.
The mean expected costs of standard oxygen therapy and prehospital CPAP were £15,201 and £14,850,
respectively. The corresponding mean expected QALYs were 1.190 and 1.128. The NMB of standard oxygen
therapy and prehospital CPAP were, therefore, £8598 and £7715, with an incremental NMB of £883 for
standard oxygen therapy compared with prehospital CPAP, assuming a threshold value of £20,000 per QALY.
Table 15 summarises the mean expected costs and QALYs, ICERs and NMB for the base-case analysis.
The base-case cost-effectiveness acceptability curve is shown in Figure 9, presenting the proportion
of model runs for which each strategy is cost-effective over a range of potential willingness-to-pay
thresholds. At thresholds of < £5000 per QALY, prehospital CPAP was the most cost-effective strategy
in the majority of model runs, although the probability of cost-effectiveness remained close to 50%.
However, at thresholds of > £5000 per QALY, standard care has more probability of being cost-effective.























FIGURE 8 Cost-effectiveness plane showing incremental costs and QALYs for standard oxygen therapy compared with
prehospital CPAP for the base-case analysis using ACUTE trial effectiveness data. Individual points depict a single PSA
simulation (n= 10,000 PSA simulations). Solid line represents willingness-to-pay threshold of £20,000. Triangle corresponds
to mean ICER.














Base case: ACUTE pilot trial effectiveness data
Standard care 15,201 1.190 5685b 8598 883b 0.67
Prehospital CPAP 14,850 1.128 7715 0.33
Scenario analysis: updated network meta-analysis effectiveness estimates
Standard care 15,201 1.19 8598 0.06
Prehospital CPAP 16,722 1.35 9712c 10,209 1612c 0.94
a Assuming a threshold value of £20,000 per QALY.
b Mean ICER/incremental NMB estimated as standard care compared with CPAP.
c Mean ICER/incremental NMB estimated as CPAP compared with standard care.
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Scenario analysis cost-effectiveness results: updated network meta-analysis effectiveness estimates
A scenario analysis used effectiveness estimates from a previous HTA network meta-analysis,3 which
synthesised previously published experimental data, updated with results from the ACUTE trial. The
pooled effect estimate reflects the efficacy of CPAP that might be achievable in more developed EMS
systems. Exploratory analyses indicated that 10,000 PSA runs were sufficient to sample fully from
parameter probability distributions and to achieve stable estimates of incremental cost-effectiveness.
This analysis indicated that the prehospital CPAP strategy was more expensive and more effective than
standard care. The ICER was therefore interpreted as the incremental costs and QALYs of prehospital
CPAP compared with standard care (because the ICER is calculated by comparing with the next most
effective alternative).
Incremental expected costs and QALYs from the PSA are shown in Figure 10 for prehospital CPAP
compared with the ‘baseline’ strategy of standard oxygen therapy. The model was re-run 10,000 times,
each time with different values for the ORs, costs and utilities sampled from the probability distributions,
indicating less uncertainty than the base case, with incremental expected costs and effects clustering in
the north-east quadrant of the cost-effectiveness plane. On average, the prehospital CPAP strategy was




































FIGURE 9 Cost-effectiveness acceptability curve for the base-case analysis using ACUTE trial effectiveness data.



























FIGURE 10 Cost-effectiveness plane showing incremental costs and QALYs for prehospital CPAP compared with standard
oxygen therapy in the updated network meta-analysis scenario analysis (n= 10,000 PSA simulations).
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£1522) than standard care. The mean ICER, estimated as prehospital CPAP compared with standard
care, was £9712 per QALY. Given the typical NICE threshold of £20,000 per QALY, in this analysis it
would be concluded that prehospital CPAP is cost-effective because it gains QALYs with an acceptable
ICER, compared with standard care.
The mean expected costs of standard oxygen therapy and prehospital CPAP were £15,201 and £16,722,
respectively. The corresponding mean expected QALYs were 1.19 and 1.35, respectively. The NMB of
standard oxygen therapy and prehospital CPAP were £8598 and £10,209, respectively, with an
incremental NMB of £1612, assuming a threshold value of £20,000 per QALY. Table 15 summarises
the mean expected costs and QALYs, ICERs and NMB for this scenario analysis.
The updated meta-analysis scenario analysis cost-effectiveness acceptability curve is shown in Figure 11.
The percentage of model runs in which prehospital CPAP was the most cost-effective strategy did not
exceed 50% at thresholds of < £10,000 per QALY. At the £20,000-per-QALY threshold, prehospital
CPAP was highly likely to be the most cost-effective strategy (94%).
Value-of-information analyses
Expected value of perfect information
Reflecting the uncertainty in effectiveness of prehospital CPAP, together with the large, potential,
opportunity losses from making the incorrect adoption decision, base-case individual EVPI was considerable
at the NICE willingness-to-pay threshold: £300 at λ= £20,000. Given the relatively large annual population
with ARF eligible for prehospital CPAP treatment (11,000 across England and Wales), and the long time
period over which the technology is likely to be applicable (5 years), base-case population EVPI was also
correspondingly large in the base-case analysis: £16.5M at λ = £20,000 per QALY. This indicated that it
would be worth spending up to £16.5M on research investigating the effectiveness of prehospital CPAP
for ARF. Population EVPI was substantial at thresholds of < £8000, but decreased to a minimum at a
threshold of £10,000 per QALY, for which there was little uncertainty about whether to adopt or reject
CPAP based on existing evidence. Population EVPI continued to increase at higher cost-effectiveness
thresholds, representing rising uncertainty. The base-case population EVPI is presented in Figure 12.
For the updated network meta-analysis scenario analysis, individual EVPI was also appreciable at
λ = £20,000: £67.60, corresponding to a population EVPI of £3.72M. The population EVPI for this




































FIGURE 11 Cost-effectiveness acceptability curve for the updated meta-analysis scenario analysis. MAICER, maximum
acceptable incremental cost-effectiveness ratio.
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Expected value of partial perfect information
The population EVPI places an upper limit on the total value of additional research relating to a specific
decision problem, but does not indicate where future research may be beneficial. The population EVPPI
indicates the value of reducing the uncertainty surrounding particular input parameters in the decision
model. Ten parameters, reflecting targets for potential future research designs, were considered in the
EVPPI analyses: baseline mortality and risks; relative effectiveness for mortality and intubation; costs
of prehospital CPAP, hospitalisation, intubation and long-term survival; life expectancy; and lifetime
quality of life.
The EVPPIs associated with each of these parameters in the base case are illustrated in Figure 14. At the
threshold of £20,000 per QALY, the individual EVPPI associated with the effectiveness of CPAP in
reducing mortality was £299.60, and individual EVPPIs for all the other parameters were zero. The
population EVPPI for CPAP effectiveness on mortality in the base case was £16.5M.
The EVPPIs for model parameters in the updated meta-analysis scenario analysis are illustrated in Figure 15.
At the threshold of £20,000 per QALY, the individual EVPPI associated with the effectiveness of CPAP
in reducing mortality was £67.60, and EVPPIs for all the other parameters were zero. The population
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FIGURE 13 Updated network meta-analysis scenario population EVPI. MAICER, maximum acceptable incremental
cost-effectiveness ratio.
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Acute respiratory failure incidence study
Between 1 August 2017 and 31 July 2018, the WMAS attended 90,232 adult 999 emergency calls.
After application of a search filter to the EPR database, 4526 patients were identified with presentations
possibly consistent with ARF and no clear contraindication to CPAP. Further detailed research paramedic
review of case records confirmed that 2980 of these patients had ARF and that 1017 of these (34.1%)
were assessed as potentially being eligible for the ACUTE pilot trial. The most common reasons for
ineligibility were rapid patient improvement (n = 1075, 54.8%), hypotension (n = 401, 20.4%) and a pre-
existing ceiling-of-treatment decision, for example respect form (n= 326, 16.6%). Inter-rater reproducibility,
with re-assessment of a random 10% sample of cases, was excellent, with raw agreement of 86%. Table 16.
details reasons for non-eligibility. Figure 16 presents the monthly cumulative incidence, demonstrating a
mild seasonal variation of eligible ARF cases, with an increased incidence rate evident over autumn and
winter months. The overall incidence rate of eligible ARF patients in theWest Midlands region was 17.4 per
100,000 persons per year (95% CI 16.3 to 18.5 per 100,000 persons per year) in the base-case estimate
using a WMAS population denominator estimate. Incidence estimates were very similar in sensitivity
estimates using Office for National Statistics’ census and Office for National Statistics’ labour market data,

















































































































































































































FIGURE 15 Updated network meta-analysis scenario EVPPIs at a £20,000 per QALY cost-effectiveness threshold.
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TABLE 16 Reasons for ACUTE trial ineligibility in WMAS patients identified as having ARF
Ineligibility variable Patients (N= 1963), n (%)
Rapid improvement with standard management 1075 (54.8)
Hypotension 401 (20.4)
DNAR/respect form/palliative care 326 (16.6)
Pre-existing lack of capacity 73 (3.7)
Cardiac arrest 55 (2.8)
Possible pneumothorax 10 (0.5)
Epistaxis/vomiting 24 (1.2)
O2 alert card 14 (0.7)
O2 not administered 4 (0.2)
Other 204 (10.4)






























































































FIGURE 16 Cumulative incidence of ARF cases eligible for the ACUTE trial across the WMAS.
TABLE 17 Incidence rate of ARF (per 100,000 persons per year) for different estimates of the population covered
by WMAS
Source Population estimate (n) Number of eligible patients Incidence rate (95% CI)
WMAS 5,600,000 1017 18.161 (17.062 to 19.312)
ONS census 5,860,706 1017 17.353 (16.303 to 18.453)
NOMIS labour market 5,860,700 1017 17.353 (16.303 to 18.453)
ONS, Office for National Statistics; NOMIS, National Online Manpower Information System.
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Acute respiratory failure diagnosis study
Sample characteristics
A valid prehospital primary diagnosis was available for 76 out of 77 patients. For one case, the primary
clinical impression was recorded as ‘other’, but lacked interpretable information to assign an underlying
aetiology for ARF. COPD (25/76, 32.9%) and LRTI (25/76, 32.9%) were the most commonly suspected
primary prehospital diagnoses. In six out of 76 cases (7.9%), a non-respiratory primary diagnosis was
recorded: ruptured abdominal aortic aneurysm (n = 1), liver failure (n = 1), sepsis (not specified further,
n= 2) and urinary tract infection (n= 2). A secondary diagnosis was recorded for 36 patients (N= 77, 46.8%),
with a single contributory condition suspected in 29 patients (N = 77, 37.7%) and two supplementary
diagnoses made for seven patients (N = 77, 9.1%). LRTI (9/77, 11.7%) and heart failure (10/77, 13.0%)
were the most common concomitantly diagnosed conditions.
A final hospital primary diagnosis was available for 65 patients. Consent was declined for data collection
in nine cases, clinical records were unavailable in two cases and in one case there was no clear underlying
diagnosis apparent in the notes. The most common final diagnoses were COPD (21/65, 32.3%) and LRTI
(n = 28/65, 43.1%). For four cases, a non-respiratory final diagnosis was given: myocardial infarction,
ruptured abdominal, liver failure and sepsis (not specified further). Secondary conditions accounting for
ARF were diagnosed in 27 patients (N = 65, 41.5%), with one additional condition recorded for 23 cases,
two contributory diseases given for three cases and three further supporting diagnoses for one case.
The most common secondary diagnoses were COPD (7/65, 10.8%) and heart failure (8/65, 12.3%).
Notably, two patients were diagnosed with a pneumothorax in hospital (one primary diagnosis and one
secondary diagnosis, both requiring intercostal drains). Prehospital and final hospital diagnoses are
summarised in Table 18.
TABLE 18 Prehospital and hospital ARF diagnosis
Diagnosis Total, n (%) Notes
Primary prehospital ARF diagnosis (N= 76)
COPD 25 (32.9)
LRTI 25 (32.9)
Heart failure 14 (18.4)
Asthma 4 (5.3)
Pulmonary fibrosis 2 (2.6)
Other 6 (2.6) Sepsis (n = 2); AAA (n = 1);
liver failure (n = 1); UTI (n = 2)




Heart failure 10 (13.0)
Asthma 5 (6.5)
Pulmonary fibrosis 1 (1.3)
Other 6 (7.8) PE (n = 1); sepsis (n = 1);
myocardial infarction (n = 1);
pericarditis (n = 1); Guillain–Barré
syndrome (n= 1); overdose (n = 1)
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Agreement
There was limited reproducibility between the primary prehospital and hospital diagnoses, with raw
agreement of 58.5% (38/65). However, if both primary and secondary diagnoses were considered
together, counting any match and ignoring the precedence placed on each condition, there was
higher raw agreement of 76.9% on at least one causative disease for ARF (50/65). Chance-corrected
agreement between prehospital and hospital primary diagnosis was moderate, as demonstrated by a
Gwet’s AC1 coefficient of 0.56 (95% CI 0.43 to 0.69). When both primary and secondary diagnoses
were assessed together, there was substantial chance-corrected agreement on at least one condition,
with a Gwet’s AC1 coefficient of 0.75 (95% CI 0.64 to 0.87). Agreement between prehospital and
hospital diagnoses is summarised in Table 19 and Figure 17.
Diagnostic accuracy
The performance of ambulance service clinicians’ assessment was then investigated by calculating diagnostic
accuracy metrics for the most prevalent conditions (COPD, LRTI and heart failure). Other conditions
were not evaluated because of small sample sizes, with consequent imprecision and intractability.
Although each condition was identified correctly more often than not, all three were commonly missed
as the primary diagnosis: the sensitivities for COPD, LRTI and heart failure were 71%, 54% and 67%,
respectively. The specificity (‘rule-out’) was higher (COPD, 84.1%; LRTI, 86.8%; and heart failure, 86.7%).
When both primary and secondary diagnoses were assessed together, diagnostic accuracy improved.
Considering the index test and reference standard to be positive if the condition was recorded in either
the primary or secondary diagnosis gave sensitivities of 95.2% for COPD, 69.2% for LRTI and 85.7% for
heart failure, meaning that all three conditions were typically identified, even if not as the primary
diagnosis. Specificities in this contingency were COPD, 84.1%; LRTI, 92.3%; and heart failure, 96.6%.
Diagnostic accuracy metrics are summarised in Table 20.
TABLE 18 Prehospital and hospital ARF diagnosis (continued )
Diagnosis Total, n (%) Notes
Primary final hospital ARF diagnosis (N= 65)
COPD 21 (32.3)
LRTI 28 (43.1)
Heart failure 6 (9.2)
Asthma 2 (3.1)
Pulmonary fibrosis 1 (1.5)
Other 7 (10.8) Sepsis (n= 1); PE (n= 1); AAA
(n= 1); liver failure (n= 1); lung
cancer (n= 1); myocardial infarction
(n= 1); pneumothorax (n= 1)




Heart failure 8 (12.3)
Asthma 3 (4.6)
Pulmonary fibrosis 1 (1.5)
Other 9 (3.8) Sepsis (n = 2); lung cancer
(n = 2); bronchiectasis (n = 1);
pneumothorax (n= 1); morbid
obesity (n= 2); anaemia (n = 1)
AAA, abdominal aortic aneurysm; UTI, urinary tract infection.
a More than one secondary contributory diagnosis possible.
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TABLE 19 Prehospital and final hospital primary ARF diagnoses
Prehospital ARF
diagnosis
Final ARF diagnosis (n)
Total (n)Asthma COPD
Heart









Asthma 2 0 0 0 2 0 0 0 0 0 0 0 0 4
COPD 0 15 0 0 5 0 0 0 1 0 1 0 0 22
Heart failure 0 4 4 0 3 0 0 0 0 1 0 0 0 12
PE 0 0 0 0 0 0 0 0 0 0 0 0 0 0
LRTI 0 2 2 0 15 0 0 0 0 0 0 1 0 20
Sepsis 0 0 0 0 2 0 0 0 0 0 0 0 0 2
AAA 0 0 0 0 0 0 1 0 0 0 0 0 0 1
Liver failure 0 0 0 0 0 0 0 1 0 0 0 0 0 1
Lung cancer 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Myocardial
infarction
0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pneumothorax 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Pulmonary fibrosis 0 0 0 0 0 1 0 0 0 0 0 0 0 1
UTI 0 0 0 1 1 0 0 0 0 0 0 0 0 2
Total 2 21 6 1 28 1 1 1 1 1 1 1 0 65




























Study of the perceptions of recruiting clinicians
Ambulance service clinician survey
Ambulance service clinicians were invited to complete a survey after each new participant enrolment.
Responses were received in 40 cases (n = 77, 52%). Personal identifiable data were not collected, in line
with ethics permission; therefore, it was not possible to confirm whether or not repeat surveys were
completed by the 41 individual recruiters. Quantitative responses to survey questions are summarised




















































































































FIGURE 17 A mosaic plot of prehospital and final primary diagnoses. AAA, abdominal aortic aneurysm; UTI, urinary
tract infection.
TABLE 20 Diagnostic accuracy metrics of prehospital primary diagnosis
Prehospital
primary

































FN, false negative; FP, false positive; NPV, negative predictive value; PPV, positive predictive value; TN, true negative;
TP, true positive.
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10 20 30 40 50 60 70 80 90 100
I was comfortable providing treatment with prehospital CPAP (n = 26)a
Prehospital CPAP appeared to be acceptable to patients (n = 26)a
I was confident in managing ARF with standard oxygen therapy (n = 14)b
Being able to use CPAP increases my confidence in managing ARF (n = 26)a
If CPAP had been available, I would have used it to treat this patient (n = 14)b
I would like CPAP to be available for patients in the control arm of the ACUTE trial (n = 14)b
There were no problems with delivering prehospital CPAP (n = 26)a
Using CPAP delayed patient transport to hospital (n = 26)a
It was straightforward to titrate the level of CPAP (n = 26)a
The CPAP mask correctly fitted the patient (n = 26)a
Overall, the CPAP equipment was easy to use (n = 26)a
My training allowed me to administer prehospital CPAP appropriately (n = 26)a
I was confident identifying patients eligible for the ACUTE trial (n = 40)
I was confident diagnosing ARF (n = 40)
Strongly agree
Agree
Neither agree nor disagree
Disagree
Strongly disagree
FIGURE 18 Cumulative bar charts summarising responses to the ambulance service clinician survey. a, Question asked only if patient was randomised to CPAP arm; and b, question




























Clinicians were confident in both the diagnosis of ARF (98% agreed or strongly agreed) and determining
whether or not potential patients were eligible to be recruited to the ACUTE trial (98% agreed or strongly
agreed). Respondents from the standard care arm were less confident in managing ARF (36% strongly
agreed) than those in the CPAP arm (73% strongly agreed).
Standard oxygen therapy arm clinicians presented mixed views on CPAP treatment, with only 43%
strongly agreeing that they would have liked to have had CPAP available. One clinician indicated a lack
of evidence, stating:
I understand for control purposes that comparison must be made by using standard therapy.
Conversely, one clinician felt that CPAP should have been available, stating:
I struggle with talking to the PT [patient] about CPAP and then finding only 02 mask in the box [sic].
Clinicians who were assigned to the CPAP arm were overwhelmingly positive with regard to their
experiences with the intervention, with a large majority (> 75%) agreeing or strongly agreeing that
training allowed appropriate use of CPAP; CPAP was easy to use; the CPAP mask correctly fitted; it
was straightforward to titrate CPAP; CPAP did not delay transport; and there were no problems with
delivering prehospital CPAP. Although respondents were positive about training and the equipment,
they did suggest some practical improvements that could be made in a future trial:
A bit more training on the practical training aspect could have been added in to the training day, e.g. how
to fit one on properly. Perhaps you could have demonstrated on the stage during the training day.
A diagram showing how it goes together on the patient may be helpful for staff who have not used it for
a while and may have forgotten.
Difficulty with handover at hospital, nursing staff unaware of trial and whether patient should remain on
CPAP or have it removed.
Clinicians were very comfortable with the amount of prehospital data collection, with 95% considering
it ‘about right’. There was only one specific data collection concern regarding the patient-reported VAS
breathlessness score, with a respondent stating:
Scale of 1–10 for how breathless a patient feels doesn’t seem appropriate as the vast majority are never
going to be able to give a rating.
Intervention arm respondents were generally positive about how their patients perceived CPAP, with
> 85% agreeing or strongly agreeing that CPAP was acceptable to patients and that they were comfortable
administering this treatment to patients. Clinicians suggested that those patients who found it less
acceptable did not tolerate the mask or the increased airway pressure, whereas one respondent who
strongly agreed with both questions offered the following practical advice:
Letting the patient feel the pressure delivery on their face first is probably vital to a successful application,
instead of applying the mask and then turning it on.
There were no significant issues raised in the closing general open question of the survey. Of note,
there were no comments regarding allocation concealment.
Focus groups
Nine ACUTE trial-trained ambulance service clinicians took part in three focus groups, comprising six staff
who had recruited to the trial, one who had not and two who had withdrawn from trial participation.
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Seven staff had attended the face-to-face ACUTE trial training event, whereas two had trained using
web-based training videos.
Participants described a range of facilitators that helped participation in the ACUTE trial. Specific
themes included the following.
Clear eligibility on equipment boxes
The trial boxes included lists of inclusion criteria and exclusion criteria (see Figure 3). Focus group
participants described these as straightforward and clear:
I looked at the green and I looked at the red and I went ‘oh ok, I can’t’. So I think having it on the box
was the best way to do it. I couldn’t remember.
Multichannel promotion of the trial
Social media were actively used throughout the trial to make ambulance staff aware of the trial and
options to participate. This was indicated to be an effective means of raising awareness, for example:
I literally use Twitter [Twitter, Inc., San Francisco, CA, USA] for, from a work perspective really and then
the sort of CPD [continuing professional development] side, type of thing that’s really good for getting
stuff off there, and a lot of people commented when, about prehospital CPAP, I saw a lot of the feeds.
Staff who had used continuous positive airway pressure described telling their colleagues about their
experiences. As the study was not blinded, this did, at times, include assertions of treatment efficacy:
Once I’d used it once I was like saying to everybody, ‘God, this thing’s amazing’ and then people were
starting to get interested then.
Documentation
Case report form A was designed to avoid duplication in collection of routinely recorded data, and its
simplicity was highlighted by several clinicians, for example:
It didn’t really bother me filling out the form. It took 5 minutes.
The form itself was really quick and easy to fill in. It wasn’t, it wasn’t a big deal to fill it in.
Training methods
Both the face-to-face ACUTE trial training day and the web-based video training package were
described favourably by respondents:
It was a good day, wasn’t it.
It makes everything so simple.
I don’t remember [the video] being difficult. I don’t remember it being sort of boring, or ending like that,
so it must have been good.
I think it’s quite straight to the point really.
Almost all participants described the opportunity to try out assembling and fitting the intervention CPAP
masks as important. Staff who trained via video said they would have preferred this opportunity, and,
although the ambulance hubs had demonstration masks available, in at least one location these were
noted to have become unavailable over the course of the trial. A representative comment included:
. . . I was quite lucky that you were, you were here whilst I was on, on shift as well, so got the added
bonus of having a look at it.
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Brief consent
Clinicians indicated that, in almost all cases, verbal consent at the scene consisted of an abbreviated
discussion or a recognition that the patient lacked capacity at that time and recruitment was in their
best interests. A typical comment was as follows:
I always tend to keep it really really brief. I’ll say like ‘you are obviously really, really struggling with your
breathing. There’s this trial available. However, it’s a 50–50 chance that you’ll get this, one that I think
will benefit you. This will do this. The other one will do this. Do you want to trial and see if you get the
better option OK’, and they normally say ‘yeah, I’ll try it, I’ll try anything’.
Relevance to practice
The high incidence of respiratory problems in participating hubs was cited as a reason clinicians took
part in the trial. For example one participant stated:
We have a lot of COPD patients and breathing problems, so obviously we thought we’d probably be more
exposed to use it.
Repeated recruitment
Exposure to eligible patients was stated to be infrequent. However, clinicians who repeatedly recruited
patients described all trial processes becoming more straightforward:
. . . when it happened the second time again I was more confident with CSD [clinical support desk, which
accepted telephone calls to register patient recruitment] to say ‘Right, this is what actually you need to
do’, ’cause they sort of fumbled around a bit, so . . .
Conversely, participants also noted a number of barriers to successful participation in the trial.
Important themes included the following.
Limitations of training
The delay between the ACUTE trial face-to-face training event and the trial going live was highlighted
as problematic:
It was a long time between doing the face to face and then first recruiting. I think there was a gap
between the face-to-face one and getting them on station.
The voluntary nature of participation in the pilot trial, with lack of payment or protected time, was also
noted to be a limiting factor in completing online training, for example:
Control just wouldn’t give us the day and time to do this . . . they never give you downtime to get things
signed and done, and stuff. There’s always something more urgent . . .
Finally, some staff opted to train for the trial on workplace computing facilities during shifts; however,
the noisy environments and lack of speakers on workplace computers made this challenging. It was
suggested that trial training videos should incorporate subtitling options to mitigate the latter difficulty.
Lack of blinding or control arm sham treatment
Clinicians indicated that they found it unsettling to randomise a patient to the standard care arm.
One participant described it thus:
Yeah, you helped even if it felt rubbish to not have . . . But that, that particular moment on the back of the
truck, it felt dreadful . . .
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Focus group participants also indicated that patients could also be distressed by the realisation that
they would not receive CPAP. The clinicians explained that enrolled patients appeared to be well
informed about their health condition and the usual care available to them, and realised when they
had been assigned to continue with standard care. Representative comments included:
I was standing there going ‘uh uh uh uh’ thinking ‘I hope to God this has got a CPAP in it’ yeah because
otherwise, and especially with her because she would have known the difference.
I think the thing I struggled with was a lot of the people that you’re offering this to are not silly people.
They know the difference between a CPAP and a 100%. They’ve had breathing difficulties for long enough,
haven’t they, to know the equipment that comes around their condition and I opened the box and it was
the 100%, and the lady herself went [big sigh] and I felt dreadful then.
Equipment boxes
Many of the focus group participants complained that accessing trial equipment boxes from the
designated hub research cabinet was challenging because of difficulties obtaining the key safe:
. . . you could never get the key back in.
. . . yeah, you can’t ever get the key back in the slot and by that time, you’re then 10, 10–15 minutes . . .
Moreover, staff made multiple comments about the practicalities of carrying the trial equipment boxes,
particularly the difficulties of carrying additional paraphernalia onto ambulances and the fact that
ambulance vehicles did not have a specific place for storage. These factors forced staff to improvise
with varying degrees of success. Comments included:
. . . especially on the new vehicles, it’s more difficult but on the older, on the older style of vehicles you
could move a bit of linen about and put ‘em in there.
. . . mine just laid on me bag.
. . . mine used to live with the drugs cupboard.
Notably, two focus group participants withdrew from the trial, secondary to frustrations with carrying
the equipment boxes, stating:
I stopped taking the box out ’cause I was that annoyed of having to carry my bag, my drugs . . .
. . . there’s a lot to carry, isn’t there.
Patient-reported breathlessness
Some focus group participants felt that it was unfair to use a patient-reported outcome during a
critical illness:
It’s, it was a bit subjective and as well because you’re with someone that’s acutely ill, you don’t wanna be
like ‘can you grade your breathing out of 10?’ with a weird mask on their face; they don’t wanna talk to
you about what their breathing is like out of 10.
Submission of case report form A data
Many participants said this system of calling the central clinical support desk worked well. However,
on occasion, delays in getting through were noted, with the potential to negatively affect ambulance
operations. A typical comment was:
. . . sometimes it takes 2 seconds, sometimes it takes 2 days.
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Authority gradient
It was noted that, on occasion, trial-trained technicians could work with non-trial-trained paramedics.
Some focus group participants felt that this did not cause any issues, but for at least one, there was the
suggestion that the more senior paramedic might veto the otherwise appropriate recruitment of a patient:
. . . some of the paras [paramedics] I worked with were like ‘what’s that?’. So I’d, I’d explain to them and
they’d say ‘Oh we won’t need that’.
Hospital awareness and attitudes
Despite research paramedic visits and ED posters, participants reported that some hospital staff did
not seem to be aware of the trial, particularly if patients were conveyed to hospitals distant from their
base hubs:
Every time you went in, it was a different member of staff, so it, even though it was up on the wall, that
the trial was on going, nobody seem to be aware of it.
The first words out of the nurse’s mouth, and she’s, she was an experienced, she is an experienced nurse
and probably the one nurse you’d, you’d wanna see in resus[citation] if you were going in there poorly,
and the first thing she said to me was ‘What the hell is that?’.
Allocation concealment was also discussed in the focus groups. One focus group participant stated
that, on one occasion, they had noticed a difference between similar boxes when they had shaken
them, but were unable to deduce the trial arm and had found no further differences between boxes
later in the trial. One other clinician indicated a ‘system’ for selecting boxes, choosing boxes with shrink
wrap in the best condition. All other participants stated that they had not noticed any differences and
that all boxes had been selected at random:
. . . whatever was there to be honest.
. . . not a specific decision to take one.
. . . literally randomly.
Allocation concealment study
A total of 278 ambulance service clinicians participated in the allocation concealment substudy (WMAS,
n = 128; YAS, n = 150). A total of 163 (58.6%) participants stated that they were unable to determine
any difference between boxes. The remaining 115 (41.4%) participants felt that they were able to tell
which box contained CPAP equipment, with a median certainty of 5 (moderate certainty, IQR 4–7).
Of these 81 paramedics, 70.4% (95% CI 61.1%, 78.4%) chose correctly. Stratified by ambulance service,
WMAS participants were less likely to indicate that they could tell a difference between the boxes
[29.7% (38/128)] than YAS participants [51.3% (77/150)]. WMAS and YAS clinicians identified the correct
box in 24 (63.2%) and 57 (74.0%) cases, respectively.
The most common reasons informing clinicians’ selection of equipment boxes were ‘heavier weight’,
‘sounds different when percussed’ or ‘different’ (not specified further). When re-examined after
completion of the trial, a CPAP box used in the YAS subgroup was found to weigh > 40 g than its
paired standard oxygen arm box. All other pairs of boxes were deemed indistinguishable. Results of
the allocation concealment substudy are summarised in Table 21.
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TABLE 21 Results of the ACUTE trial allocation concealment substudy
Result Descriptive statistic WMAS (N= 128) YAS (N= 150) Total (N= 278)
Felt able to guess which box
contained CPAP?
Yes, n (%) 38 (29.7) 77 (51.3) 115 (41.4)
If yes, how confident were they? n 38 77 115
Median (IQR) 5.00 (4.25, 6.75) 6.00 (4.00, 7.00) 5.00 (4.00, 7.00)
If yes, were they correct? No, n (%) 14 (36.8) 20 (26.0) 34 (29.6)
Yes, n (%) 24 (63.2) 57 (74.0) 81 (70.4)
RESULTS





The ACUTE pilot trial enrolled 77 participants over 12 months, below the recruitment target of
120 participants. CPAP was fully delivered as planned in 74% (31/42) of intervention arm participants,
compared with the feasibility target of 75%. There were no major protocol violations/non-compliances.
Full data were available for key outcomes, including all feasibility end points and vital status at 30 days,
compared with the feasibility targets of ≥ 90% retention at 30 days and ≥ 90% data completeness.
However, data were missing on other hospital variables and follow-up outcomes owing to declined
consent, lack of research approvals to access data, non-interpretable clinical records and non-completion
of questionnaires (ranging from 0% to 29%).
Mortality was higher than expected, with 28.6% (12/42) of participants in the CPAP arm and 25.7% (9/35)
of participants in the standard oxygen arm dying by 30 days. Of the deceased patients, 68% (13/19 with
available data, n = 21) either did not have a respiratory condition or had explicit or implicit ceiling-of-
treatment decisions, which excluded hospital NIV or critical care. The risk of intubation was low (3/62, 4.8%):
two participants in the CPAP arm (n= 33, 6.1%) and one participant in the standard oxygen therapy arm
(n= 29, 3.4%) were intubated. A small proportion of participants were admitted to critical care (6/65, 9.2%),
with risks of 11.4% and 6.7% in participants treated with CPAP (4/35) and standard oxygen therapy
(2/30), respectively. Hospital length of stay was similar for both trial arms, with a median of 10.0 days
(IQR 5.8–12.0 days) in the CPAP arm and 7.0 days (IQR 5.0–9.8 days) in the standard oxygen therapy
arm (n = 44). Breathlessness, evaluated by ambulance service clinician-assessed VAS score, was similar
across trial arms, and improved over the prehospital interval from an initial median of 9 out of 10
(n = 76, IQR 8–10) to 6 out of 10 (n = 76, IQR 5–8) on arrival at hospital. Median follow-up EQ-5D-5L
scores at 30 days were 0.82 (n = 22, IQR 0.58–0.95) for participants allocated to CPAP and 0.73 (n = 18,
IQR 0.43–0.89) for those allocated to standard oxygen therapy.
Adverse events related to CPAP comprised mild claustrophobia or distress associated with CPAP mask
use. Two participants were diagnosed with pneumothorax in the ED, which were reported as expected
related SAEs (one participant in the intervention arm not receiving CPAP and one participant in the
control arm; both required intercostal drainage). There were no other expected or unexpected related
SAEs. During week 10 of recruitment, some intervention arm equipment boxes began to ‘rattle’, due to
packaging of CPAP face masks under tension and deflation of the CPAP mask air cushion seal. After
repackaging and redistribution, no further concerns were noted during equipment box audits. No other
feasibility issues were evident.
Economic evaluation
The base-case analysis, using CPAP effectiveness estimates from the ACUTE pilot trial representative for
the NHS setting, indicated that the standard oxygen therapy strategy was more effective (mean incremental
QALYs of 0.062), but also more expensive (mean incremental costs of £351), than prehospital CPAP.
The mean ICER, estimated as standard care compared with CPAP, was £5685 per QALY. At the £20,000-
per-QALY threshold, standard care was most likely to be cost-effective (67%).
A scenario analysis, using effectiveness estimates from an updated meta-analysis typical of non-NHS
settings with more developed EMS systems,3 suggested that prehospital CPAP was more effective
(mean incremental QALYs of 0.157), but also more expensive (mean incremental costs of £1522), than
standard care. The mean ICER, estimated as prehospital CPAP compared with standard care, was £9712
per QALY. At the £20,000-per-QALY threshold, prehospital CPAP was highly likely to be the most
cost-effective strategy (94%).
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Values of information analyses demonstrated that there was considerable uncertainty about whether
or not to adopt prehospital CPAP. In the base-case analysis, the population EVPI indicated that it
would be worth spending up to £16.5M on research investigating the effectiveness of prehospital
CPAP for ARF. This compared with a population EVPI of £3.72M in the updated meta-analysis scenario
analysis. EVPPI analyses indicated that effectiveness of prehospital CPAP on mortality was the only
important variable for future research, with population EVPPIs of £16.5M and £3.72M, respectively,
in the base case and updated meta-analysis scenario analysis.
Acute respiratory failure incidence study
Between 1 August 2017 and 31 July 2018, 1017 patients were identified from the WMAS with ARF,
and were eligible for the ACUTE pilot trial, giving an overall incidence rate of 17.4 per 100,000
persons per year (95% CI 16.3 to 18.5 per 100,000 persons per year). A mild seasonal variation was
apparent, with an increased incidence rate during autumn and winter months.
Acute respiratory failure diagnostic accuracy study
Chronic obstructive pulmonary disease (25/76, 32.9%) and LRTI (25/76, 32.9%) were the most frequently
suspected primary prehospital diagnoses for ARF, with secondary contributory conditions recorded in
36 out of 77 participants (46.8%). The most common final hospital diagnoses were also COPD (21/65,
32.3%) and LRTI (28/65, 43.1%). In seven cases, a final diagnosis was made for which CPAP would not be
expected to be effective or could be harmful, including myocardial infarction, ruptured abdominal aortic
aneurysm, liver failure, sepsis and pneumothorax (7/65, 10.8%). Secondary conditions accounting for ARF
were diagnosed in 27 participants (n = 65, 41.5%). There was moderate agreement between the primary
prehospital and hospital diagnoses, with raw agreement of 58.5% (38/65) and a Gwet’s AC1 coefficient of
0.56 (95% CI 0.43 to 0.69).
Clinicians’ views: mixed-methods study
The post-recruitment survey demonstrated that ambulance service clinicians felt confident in the diagnosis
of ARF and in determining trial eligibility. Respondents assigned to the intervention arm were positive
regarding clinician and patient experiences with CPAP. The amount of prehospital data collection was
considered to be ‘about right’. Focus group participants identified a number of facilitators that aided
participation in the ACUTE trial, including uncomplicated equipment boxes, successful multimedia promotion
of the trial, ease of use of trial documentation, simplicity of consent processes and the importance of the
research question. Conversely, lack of awareness of the ACUTE trial in receiving hospitals, problems in
measuring patient-reported breathlessness, difficulties in completing web-based trial training and a
desire to provide CPAP treatment were highlighted as important challenges. No issues were raised in the
post-recruitment survey or focus groups regarding allocation concealment.
Allocation concealment substudy
Of the ambulance service clinicians participating in the allocation concealment substudy, 58.6% were
unable to distinguish a difference between control and intervention arm boxes (163/278). The participants
who felt that they were able to tell which box contained CPAP equipment (115/278, 41.4%) indicated a
median certainty of 5 (moderate certainty, IQR 4–7), with 70.4% choosing box contents correctly (81/115,
95% CI 61.1% to 78.4%).
Interpretation of findings
Evidence of feasibility
Feasibility studies are stand-alone investigations completed before the start of a definitive RCT,
investigating whether or not a large-scale trial can be done, whether or not it should be done and,
if so, how it should be conducted.48 Pilot trials, a subset of feasibility studies, additionally test the
proposed main trial procedures in miniature to determine whether or not the components of the
main trial work together.51,52 The ACUTE pilot trial recruited only 21% of the potentially eligible
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patients (77/364) and achieved only 64% of its recruitment target (77/120); therefore, feasibility
was not demonstrated. Nevertheless, a number of issues were successfully addressed. Patients were
appropriately recruited using a deferred consent model, with no reported issues with using verbal consent
for recruitment of patients with capacity. There were no major protocol violations/non-compliances and
only one minor non-compliance. Adherence to the allocation schedule was complete: commencement
of CPAP was attempted in all intervention arm participants and control arm participants received
appropriate standard oxygen therapy. Full data were available for key outcomes, including all feasibility
end points and vital status at 30 days. Furthermore, ambulance service clinicians were able to recognise
ARF, enrol patients and use the CPAP equipment.
The recruitment rate could be improved by addressing a number of remediable factors. Ambulance
service clinician participation was voluntary and the majority of potentially eligible cases presented to
non-trial-trained staff (203/364). Therefore, it is likely that recruitment could be improved if, consistent
with some previous prehospital studies,87,88 a full trial mandated participation of all ambulance service
personnel. Focus groups revealed a number of solvable issues, including improving access to hub
research cabinets and providing designated storage space on ambulances for trial equipment boxes.
However, determining the impact of these interventions would require further piloting.
Several other issues identified in the pilot trial would need to be addressed before considering a full
trial. First, a relatively large number of patients (9/77, 12%) declined consent for further participation
and data collection when approached in hospital for confirmation of previously provided prehospital
verbal consent. Although the primary clinical outcome of 30-day mortality was available, important
secondary end points were, consequently, missing. These patients were less unwell than incapacitated
patients included following consultee consent, and selection bias would be a risk if there were an
association between trial arm and the probability of providing consent. No issues with the provision
of initial verbal consent were reported by patients or participating clinicians, but informal feedback to
research paramedics later during the consent process suggested that withdrawal occurred as patients
did not wish to complete the 30-day follow-up questionnaires. To mitigate this problem, any future trial
could offer tiered consent, allowing participants to opt out of 30-day follow-up questionnaires, but to
agree to collection of hospital data and secondary clinical outcomes from their records.
Second, although the main feasibility and clinical outcomes had complete follow-up, some hospital data
were missing because of failure to gain research approvals in two hospitals. In one case, this occurred
after unanticipated patient conveyance to an out-of-area hospital. Challenges arising from transport
across regional and ambulance service boundaries have been noted in previous prehospital trials and
could be magnified in a scaled-up definitive trial.89 In the second case, it was not possible to engage
the research and development department because of an ongoing merger between separate hospital
trusts. The secondary care landscape is undergoing considerable evolution and, as pressures on acute care
services continue, similar problems might be expected in the future.33 However, the number of missing
data was very small and such challenges would not present a significant barrier to a definitive trial.
Third, a novel prehospital method of randomisation using identically sealed equipment boxes was
piloted, which could have been unreliable. Correctly implemented, randomisation results in balanced
comparison groups that at baseline differ only by chance in potentially confounding variables.90
A valid randomisation process requires two essential and independent components: generation of an
unpredictable random allocation sequence and concealed implementation, with irreversible assignment
to trial arms without foreknowledge of the allocation when enrolling patients in the study.38 If the
expected trial arm is known in advance, then the decision to accept or reject potential participants may
be influenced by personal prejudices, resulting in patients with better prognosis being assigned to one
arm rather than the other. Selection bias in effect estimates will subsequently occur secondary to
imbalance in baseline prognostic variables.91
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The importance of secure allocation concealment in the ACUTE trial is highlighted by the focus
group findings that clinicians and patients were uncomfortable with randomisation to standard care,
for example:
. . . I hope to God this has got a CPAP in it . . .
I opened the box and it was the 100%, and the lady herself went [big sigh] and I felt dreadful then.
Systematic reviews have consistently demonstrated that trials using inadequate or unclear allocation
concealment methods report greater heterogeneity in results, providing evidence of bias that may
result in either exaggerated effect estimates or failure to identify a true treatment effect.
Prehospital trials pose unique barriers to randomisation.92,93 The environment is uncontrolled, with
recruitment potentially occurring away from ambulances at the scene of the incident. The location of
enrolment may be out of radio, telephone or internet signal, and emergency, time-critical conditions
are often studied. Individual randomisation options are, therefore, limited, as central randomisation
(e.g. web- or telephone-based randomisation) is often not practical, and sequentially numbered opaque
sealed envelopes have well-known limitations.94 Scratch cards have recently been proposed as a novel
randomisation method for prehospital trials, although there is limited experience with this method.92
Cluster randomisation offers one potential way to avoid these problems, with recruiting centres,
ambulances or clinicians (rather than patients) being randomised to delivering either the intervention
or control to all their trial participants.95,96 This inevitably leads to advance knowledge of the treatment
a future participant would receive and is therefore prone to post-randomisation recruitment bias,
whereby different types of participants are recruited in the trial arms.95,96 Therefore, undertaking a
valid randomised trial in a prehospital setting requires a different approach.
Sequential, identical medicine containers are recommended in the CONSORT statement for allocation
concealment.37 Similarly, identical equipment boxes seem to offer a promising method for randomisation
in medical device trials. Ensuring that medications are indistinguishable across arms is likely to be
straightforward, as they can be specifically manufactured to be identical.37,91 However, medical device
trials pose a greater challenge, as it will often not be possible, or desired, in pragmatic trials to use a
‘mock’ device in the control arm. The difficulties of ensuring that all containers are identical is highlighted
by the unexpected development of ‘rattling’ in the intervention arm boxes 10 weeks into the trial and
the weight discrepancy detected in an equipment box used in the allocation concealment substudy.
Although a loss of allocation concealment cannot be entirely ruled out, there is no evidence that any
subversion of allocation actually occurred. The problem of boxes ‘rattling’ was quickly detected and
immediately rectified. No further issues were subsequently observed during careful weekly audits.
Post-recruitment surveys and clinician focus groups did not suggest any issues with randomisation.
The number of patients recruited per arm, and baseline characteristics, were also reassuringly similar.
Furthermore, the allocation concealment substudy results were inconclusive, with only 29% of
participants indicating that they could tell a difference between boxes and correctly identifying the
treatment arm (81/278). Regardless of any problems with box randomisation, the other feasibility
findings of the pilot trial will remain unaffected.
Given the finding that randomisation using equipment boxes in medical device trials may be unreliable,
it would be important that any future definitive trial implementing this technique uses rigorous quality
control processes to avoid potential selection bias. Scratch card randomisation is an alternative method
that could be used in a definitive ACUTE trial.92,97 This method has its own limitations, most obviously
damaged cards, which may arise through wear and tear, but could also be perceived as an attempt to
decipher future allocations. A further problem would arise if several potentially eligible cases presented
on a given shift, as it would be difficult to verify the order in which allocations were given (and, in
particular, whether these were manipulated dependent on the revealed allocation). Nevertheless, the
relatively low incidence of ARF means that this is unlikely to present a limitation in this setting.
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Cost-effectiveness of prehospital continuous positive airway pressure
The decision-analytic model shows that the key determinant of cost-effectiveness is whether or not
prehospital CPAP is effective in reducing mortality. This contrasts with the preceding HTA economic
model,3 which suggested that the incidence of ARF was very important, secondary to its influence on
prehospital CPAP costs.3 The O-Two CPAP device used in the ACUTE trial is much cheaper and requires
less training than the system previously examined, meaning that the costs of providing prehospital
CPAP, and thus the incidence of ARF, are no longer critical in determining cost-effectiveness.44
The base-case analysis, using ACUTE pilot trial effectiveness data, suggested that prehospital CPAP was
cheaper than standard care. This arises from increased short-term mortality, with fewer patients incurring
critical care or lifetime health costs. However, this also results in fewer lifetime QALYs, and, at the
conventional £20,000 threshold, there is a 67% probability that standard care is the most cost-effective
option. The ACUTE pilot trial should be more representative of NHS ambulance services, but the low
sample size gives very imprecise effectiveness estimates and leaves considerable uncertainty around
cost-effectiveness, reflected in the large population EVPPI for the mortality effectiveness parameter.
In addition to ‘second-order’ sampling uncertainty, there is also significant uncertainty around what is the
most valid and applicable effectiveness estimate for prehospital CPAP. The scenario analysis, using updated
meta-analysis effectiveness data, gives the opposite conclusion to the base case and suggests that CPAP
is highly likely to be cost-effective at a threshold of £20,000, although population EVPI and EVPPI for
CPAP effectiveness still remain high. Overall, the economic evaluation indicates that cost-effectiveness is
principally dependent on the clinical effectiveness of CPAP, and expected value-of-information analyses
are favourable, supporting the commissioning of a large pragmatic effectiveness trial, providing feasibility
and plausibility conditions are met.
Other insights from the ACUTE pilot trial
The ACUTE pilot trial failed to achieve its recruitment target, but cost-effectiveness analysis and value-
of-information analysis suggested that a large pragmatic trial to determine the effectiveness of CPAP
could still be worthwhile. This could be delivered if the remedial actions identified above were successful
or if the trial recruited across a large number of sites. Alternatively, given that the mortality rate in the
ACUTE pilot trial was higher than expected, a smaller sample size than previously anticipated could
detect a potentially important absolute difference in mortality.
External pilot trials are not designed or powered to generate estimates of clinical effect that should be
used for decision-making.48,51,52 We have therefore drawn no conclusions from comparisons of outcomes
between CPAP and standard care. However, a number of findings from the ACUTE pilot trial can be used
to inform a judgement regarding whether or not it would be plausible for a large trial to detect an effect
from CPAP on mortality and, therefore, whether or not a trial might be worthwhile.
First, the diagnostic accuracy study indicated that prehospital assessment of ARF is difficult and identifying
patients with the potential to benefit from CPAP may be challenging. Respiratory distress with low oxygen
saturations is common to many conditions, with symptoms and clinical signs shared between a range of
differential diagnoses, including non-respiratory conditions.2,7 It is therefore unsurprising that agreement
between the primary prehospital clinical impression and primary final hospital diagnosis was limited.
COPD, LRTI and heart failure were the most commonly identified conditions, and it is notable that, in
many cases, these diseases were given concurrently as supplementary diagnoses.When both primary and
secondary diagnoses were assessed together, counting any match and ignoring the precedence placed
on each condition, raw agreement on at least one causative disease for ARF improved substantially from
58% to 77%. However, difficulties in prehospital diagnosis inevitably reduce our ability to target patients
for CPAP appropriately.
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Given that the most important treatment for ARF is provision of oxygen and that other treatment
modalities currently available to NHS ambulance service clinicians (e.g. nebulisers) have few side
effects, it could argued that an exact prehospital diagnosis is unnecessary prior to definitive hospital
care.2,7,11,14 The most important factor, therefore, is to recognise conditions when CPAP would not be
beneficial and identify any contraindications. In the ACUTE pilot trial, a small, but significant, minority
of cases (4/65, 6%) were ultimately diagnosed with conditions for which CPAP could not conceivably
be beneficial. A further two participants were ultimately found to be suffering from asthma, for
which the evidence base for definitive care with CPAP is uncertain.98 It is also concerning that two
participants were diagnosed in the ED with clinically significant pneumothorax, which required
intercostal drainage. Although neither participant received prehospital CPAP, the potential for
iatrogenic harm if these cases had been allocated to the intervention arm is conspicuous.
Second, delivery of CPAP was relatively limited, with only 74% of intervention arm participants continuing
treatment to hospital as planned, just below the lower limit of the feasibility criterion of > 75% usage.
Almost one-fifth of participants either refused to commence CPAP or did not tolerate treatment (8/42, 19%).
Although CPAP may be efficacious, the potential to demonstrate effectiveness would be restricted by
lack of treatment compliance. Feedback from the post-recruitment survey suggested that unhurried and
gentle application of the mask was ‘vital to successful application’. However, such an approach may not
be practical in the emergent and confused prehospital setting.
Third, a key rationale for the implementation of prehospital CPAP is that earlier instigation of treatment
will improve outcomes over and above the availability of hospital NIV.24 In the pilot trial, relatively short
on-scene times and conveyance times were recorded (median of 40 minutes and 13 minutes, respectively).
It could be argued that, in urban or semirural settings, the potential time saved from prehospital
administration of CPAP is likely to be too small to produce meaningful benefit.
Fourth, only a small proportion of participants (28%) received CPAP or NIV after arrival at hospital.
Clinical improvement during the EMS interval, secondary to prehospital CPAP, and lack of familiarity
with the O-Two device among ED staff are possible reasons underpinning this observation in the
intervention arm. However, although the majority of hospitals had access to ED NIV, no standard care
arm participants received CPAP and only a very small number were treated with BIPAP (15%). This
could suggest that enrolled participants were satisfactorily treated by current prehospital practice,
or would not be expected to benefit from NIV.
Finally, illness severity was much higher than anticipated. The increased overall 30-day mortality risk of
27.3% might initially appear to offer a definitive trial a greater opportunity to detect a clinically relevant
survival benefit. However, despite designing eligibility criteria to exclude those for whom critical care
interventions may be inappropriate, many enrolled participants had apparent treatment limitation decisions
for ward-level hospital care only [11/17 (65%) with explicit or implicit ceiling-of-treatment decisions that
excluded hospital NIV or critical care for respiratory illness]. The observed risk of intubation and admission
to critical care was consequently low, at 4.8% (3/62) and 9.2% (6/65), respectively. The fact that NIV and
higher levels of treatment were considered inappropriate for many enrolled cases indicates a study
population with a high prevalence of end-stage cardiorespiratory disease, multiple severe comorbidities or
very poor pre-morbid performance status, for which more aggressive treatment might be futile and overly
burdensome.99,100 Given the problems in establishing this information at the scene, prehospital CPAP would
be unlikely to provide benefit in such a contingency.
In summary, although the higher than expected mortality rate might suggest increased potential to detect
an absolute difference in mortality, the challenges of providing prehospital CPAP and the characteristics
of the patients who would benefit from CPAP, suggest limited potential to improve survival. It therefore
appears unlikely that a trial powered to detect a plausible effect size could be designed.
DISCUSSION




The purpose of a feasibility study is to determine if a large-scale trial can be performed. Therefore,
challenges that might be interpreted as weaknesses when appraising a definitive RCT actually represent
important learning points in the feasibility setting.48,51,52 In addition to the previously discussed issues,
a number of other factors were noted during the pilot study that would help inform the design of any
definitive trial. Modification of eligibility criteria to specify the presence of a primary cardiorespiratory
diagnosis as an inclusion criterion, and exclusion of patients with home CPAP machines or reduced level
of consciousness, would ensure that a more appropriate trial population is selected. Recording level of
consciousness using the Alert, Voice, Pain, Unresponsive (AVPU) scale would also help improve data
completeness for this domain. Designing ‘carbon-copy’ consent forms in triplicate was also identified
as a potential method to reduce the research burden on patients and recruiting clinicians.
The ACUTE pilot trial followed best practice research conduct and reporting recommendations.37,38
However, a weakness was that hospital data collection was reliant, to some extent, on retrospective
case note review. This approach improved the efficiency of data collection, but is associated with
well-recognised limitations that could have resulted in inaccurate measurement of trial end points.101,102
If information was not present, it was not possible to be certain whether it was not recorded or whether
the variable value was genuinely null. Subjective variables could also potentially be misinterpreted.
However, data collection rules, such as using the first recorded value, should have minimised any
information bias, and feasibility and clinical outcomes represented routinely collected objective end
points, robust to misclassification.
Health economics
The economic evaluation updated a previously published decision-analytic model and followed NICE
base-case recommendations.3,103 Taking the perspective of the NHS in England and Wales, valued
outcomes, such as QALYs, used a lifetime horizon and included PSA.54,55,64 Other strengths included
detailed costing at the level of the ambulance service, and use of relevant existing data sources to
estimate key population, cost and outcome parameters. Decision uncertainty was explored in scenario
analyses using different effectiveness estimates and the potential benefit of future research was
evaluated in expected value-of-information analyses. Using ACUTE trial data directly relevant to
NHS practice for key ARF and effectiveness parameters in the base case helped overcome the main
limitations of the preceding HTA economic analysis,3 which was reliant on potentially non-generalisable
and biased estimates.
However, there are limitations in the model design and parameterisation, which could challenge the
internal validity of results. The model assumed that the proportion of patients who would receive NIV
in hospital was similar in both arms, irrespective of whether or not a patient received prehospital
CPAP. This appears plausible based on the limited pilot data, but it is conceivable that there could be
an association between the effectiveness of treatment during the EMS interval and ED management.
It was also assumed that the lifetime QALYs were same for all survivors, irrespective of whether they
were in the standard care or prehospital CPAP arm. Although unproven, this appears to be reasonable,
as CPAP would be expected to help with acute presentations and short-term outcomes only, rather
than modify underlying chronic diseases. No information was available on the covariance between
individual model parameters. Treating these variables as independent in the PSA is a further possible
limitation of the model structure.
Within the modelled population, there will be a considerable diversity of patients with differing
characteristics, underlying diagnoses and prognoses. Applying a cohort methodology, with consequent
use of mean values, impeded an examination of uncertainty due to heterogeneity. However, competing
management strategies are service-level interventions and, hence, would be applied to the entire
population presenting with ARF and ostensibly eligible for CPAP. Exploration of heterogeneity,
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for example the cost-effectiveness in different underlying diseases, is therefore less relevant. Finally,
there was a limited evidence base available to parameterise lifetime QALYs and costs of care, with data
provided by the 3CPO trial.22 This trial enrolled patients with pulmonary oedema receiving ED NIV,
rather than the undifferentiated EMS ARF cases relevant for prehospital CPAP. However, baseline
characteristics of participants in the 3CPO trial22 appear similar to those included in the ACUTE trial.
Finally, an EVSI analysis was not undertaken.104 EVSI extends the value-of-information methodological
framework to establish the expected value of conducting studies with different designs and sample
sizes. The expected benefits of a given study sample (the population EVSI) can be compared with the
expected costs of collecting these data, with the difference denoting the expected net benefit of
sampling (ENBS), measuring the societal reward from conducting additional research. ENBS values
> 0 demonstrate that the marginal benefits of gathering further evidence exceed the marginal costs,
with higher ENBS values representing more efficient study designs.104 However, although the population
EVPPI result suggests that a pragmatic trial would represent value for money, as expounded above, it
does not seem credible that a clinically significant effect size could be demonstrated, which suggests that
the computationally expensive EVSI analysis is redundant.
Ancillary substudies
The ARF diagnostic accuracy and agreement study has a number of strengths, including the prospective
prehospital data collection and defined nominal categorisation for ARF. The index tests and reference
standard were also independently applied, with no possibility of incorporation, partial or differential
verification biases.75,105–107 However, there was the potential for reference standard misclassification,
as the final diagnosis was recorded from the hospital record or discharge letter, rather than determined
through formal expert case review.108 Although comparing favourably with other published reproducibility
small studies,109,110 the sample size was relatively low, resulting in imprecise results consistent with either
fair or substantial agreement. This sample size constraint also prevented modelling of any clustering
effects arising from ambulance service clinicians and hospitals assessing multiple patients. Furthermore,
some reference standard data were missing. Although this represented a relatively small number of
patients, with similar characteristics to included cases, selection bias is possible if excluded patients
differed systematically from the trial population. Finally, the relatively liberal Landis and Koch79 scale
was used for benchmarking agreement coefficients. Although well established and widely used, this may
overstate agreement compared with other benchmarks (e.g. Fleiss’s111 or McHugh’s112 proposed scales).
The remaining ACUTE trial substudies also had strengths and weaknesses. The allocation concealment
substudy tested a large sample of ambulance services clinicians using random pairs of ACUTE trial
equipment boxes. However, some informative details about allocation concealment were not available,
and the exact weights of all trial equipment boxes during, and at the end of, the trial were not recorded.
The ARF incidence study was reliant on electronic filtering of the WMAS database followed by patient
record review. Although a census sample of cases was studied, and inter-rater agreement examined,
the findings are similarly limited by problems arising from retrospective clinical note review,101,102 as
discussed in Pilot trial. Determining whether or not a patient improved rapidly with supplemental
oxygen, or met the definition of ARF with low peripheral oxygen saturations despite treatment, was
particularly difficult to deduce using this approach. It is therefore possible that the reported incidence of
ARF is underestimated. Finally, the response rate of the post-recruitment survey was low and omission
of a personnel identifier prevented e-mail reminders being sent to non-completers and the identification
of repeat recruiters.
Generalisability
On a continuum, a RCT can, at one extreme, investigate whether or not a treatment could work in
ideal circumstances (explanatory), or, at the other extreme, whether or not it would work in everyday
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practice (pragmatic).113 Pragmatic trials, such as the ACUTE trial, approximate the reality of clinical practice
and therefore provide more meaningful information on which to base health-care decision-making.
The external validity of the pilot trial’s clinical findings will be dependent on whether or not the trial
population and intervention delivery are similar to usual practice in the setting in which the treatment
is adopted. Although enrolment of patients with ARF was not consecutive or random, eligibility criteria
were broad, excluding only patients for whom CPAP was contraindicated (e.g. vomiting), for whom
entry would probably not be appropriate (e.g. those with a do not attempt resuscitation form or pre-
existing loss of capacity), or when verbal consent was not possible (e.g. language barrier). The clinical
findings reported herein, and any similar definitive trial, should therefore have strong generalisability
to patients presenting with ARF in NHS ambulance services.
Conversely, extrapolation of effectiveness data is less certain. Trial treatments were provided by staff
who had volunteered to take part in ACUTE trial, who, therefore, might be expected to have higher levels
of interest and knowledge in managing ARF than non-trial-trained clinicians. Furthermore, a novel CPAP
device was chosen as the intervention for the ACUTE pilot trial.44 Although there are considerable
advantages to the studied O-Two unit, including small size, low cost and simplicity, there may also be
limitations compared with other more complex prehospital CPAP systems. As an open system, inspired
gases in the O-Two unit are a combination of the applied oxygen and entrained ambient air. Patients in
respiratory distress with high inspiratory flows could theoretically exceed the device flow rate, diluting
the fraction of inspired oxygen (FiO2) and reducing the level of CPAP. Furthermore, the FiO2 and CPAP
level are jointly determined by the oxygen flow rate in the O-Two device. This precludes separate
optimisation of lung mechanics and titration to desired oxygen saturations, by independently altering
each of these parameters. Finally, the maximum FiO2 and maximum CPAP were 0.67 and 15 cmH2O,
respectively. Consequently, efficacy could differ with other methods of delivering prehospital CPAP.
West Midlands Ambulance Service ambulance hubs serve a mixed rural, semirural and urban population,
and the trial population for the ARF incidence study should be typical of many NHS ambulance services.
Regions with varying socioeconomic conditions, demographics, smoking rates and urban–rural balance
would be expected to have different ARF incidence. As highlighted, clinical trial populations may not
be fully representative after application of eligibility criteria and consent procedures.114 The ACUTE
trial population specifically excluded patients with pre-existing lack of capacity and those unable to
communicate with trial ambulance service clinicians. These are subgroups for whom prehospital diagnosis is
likely to be even more challenging, and agreement and diagnostic accuracy results for ARF could be lower.
Prehospital diagnosis might be better in systems with physician, rather than paramedic, assessment, and
spectrum effects could also occur in settings where disease prevalence varies.115
The economic model consciously focused on simulating management within a UK NHS ambulance service.
Any generalisation of results to other populations should therefore be circumspect. The allocation
concealment substudy enrolled a large number of ambulance service clinicians and examined a range of
boxes packaged for use in the pilot trial. However, the test conditions did not fully reflect the experiences
of clinicians on duty in the pilot trial. Participants were specifically looking to find a difference and may
have subjected the boxes to greater scrutiny than during the ACUTE trial (e.g. percussing boxes). On the
other hand, the time period for examination of boxes might have been less than that available during a
clinical shift (e.g. during breaks).
Comparison with existing literature
A series of recent observational studies have also demonstrated that CPAP can be implemented by
EMS.116–121 These studies are consistent with the ACUTE trial experience of submaximal CPAP
adherence and difficult prehospital diagnosis, including treatment of patients with pneumothoraces.
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However, different trial populations and implementation of prehospital CPAP with physician support
contrasted markedly with the ACUTE trial. For example, the largest reported cohort describes the
experience of 177 patients in a regional CPAP service in north Denmark.116 CPAP was discontinued
in 4% of cases and one SAE was reported: a suspected pneumothorax treated in the field by an
anaesthesiologist. The study population appeared less unwell, with higher initial peripheral oxygen
saturations (median of 87%) and a higher prevalence of COPD (57%). A larger proportion of patients
(27%) were admitted to an intensive care unit, with lower pre-discharge mortality of 14%.
An updated literature search did not reveal any further experimental evidence examining prehospital
CPAP since a 2015 evidence synthesis.3 The protocol of an unpublished RCT in Australia was identified
(registered in 2015), but its status was unclear, with the national trial registry suggesting that ethics
approval remains pending.122 The previous review identified 10 trials and quasi-randomised studies
comparing prehospital NIV (including CPAP) with standard oxygen therapy. Network meta-analysis suggested
that prehospital CPAP is an effective treatment for ARF, with evidence that it reduces mortality (OR 0.41,
95% CrI 0.20 to 0.77) and intubation rate (OR 0.32, 95% CrI 0.17 to 0.62) compared with standard care.3
However, some included studies were at risk of selection bias from lack of allocation concealment and
information bias, secondary to unblinded outcome assessment. Furthermore, the meta-analysis findings
have doubtful external validity to routine prehospital practice. Only one trial included undifferentiated
respiratory failure patients, and the methods used to deliver prehospital CPAP (physician or paramedics
with online physician support) are not routine in many prehospital care systems. The ACUTE trial results
are consistent with the meta-analysis pooled effectiveness estimate, and secondary to the low sample
size, updating the meta-analysis with results of the pilot trial did not substantively change findings.
Only one previous economic evaluation of prehospital NIV for patients with ARF is available.86
Unfortunately, a number of limitations prevent meaningful comparison with the ACUTE trial: in-hospital
effectiveness data were used rather than prehospital data, outcomes were valued as lives saved rather
than QALYs, the setting was the US health-care system and US cost estimates were used, the model only
used a 1-year time horizon, and a PSA was not performed.
The ACUTE trial diagnostic study provides the first evidence for the accuracy of diagnostic assessment of
undifferentiated patients with ARF presenting to EMS. Previous literature has focused on less unwell,
dyspnoeic patients or examined specific diseases, including COPD, asthma or heart failure.25,123,124
Although limited by retrospective chart review designs, this body of research demonstrates similar
findings to the current study. Christie and colleagues25 reported only moderate agreement between
paramedic and hospital diagnosis in a New Zealand cohort, with many cases having no clearly documented
working diagnosis. The sensitivity for prehospital heart failure, asthma and COPD diagnoses was only
29%, 66% and 39%, respectively, in Australian EMS studies by Williams and colleagues123,124
The incidence of patients with ARF who could benefit from prehospital CPAP is a key variable
influencing whether or not the sample size for a definitive trial could be delivered and for deciding
cost-effectiveness, as the unit cost of prehospital CPAP is determined by dividing the total costs to the
ambulance service of prehospital CPAP by the number of patients treated. The previous HTA economic
evaluation identified a variety of estimates, ranging from 3.5 to 40.8 eligible patients per 100,000 per
year.3 Higher estimates were reported in audit data relating to in-hospital NIV, which includes patients
who develop ARF in hospital, and so may be overestimated.125 Lower estimates were provided from
services that have introduced prehospital CPAP; however, implementation was limited to selected
providers and/or patients in these settings, so these are likely to be underestimated.3,126,127 The ARF
rate of 17.4 per 100,000 persons per year reported in the ACUTE trial incidence study has face
validity, lying between these extremes.
No literature was found examining allocation concealment in emergency or prehospital trials, or for
qualitative research examining ARF or prehospital CPAP.
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Chapter 5 Conclusions
Implications for policy-makers, health professionals and people with acute
respiratory failure
As a feasibility study, the ACUTE pilot trial results are principally intended to inform future research
and should not be used to guide service provision or policy. No conclusions can be made about the
clinical effectiveness of CPAP, but there are implications for the NHS prehospital management of
patients with ARF arising from this investigation. Identification of patients who might benefit from
prehospital CPAP was challenging. It appeared difficult to exclude conditions for which CPAP would
not work, or might be harmful, and to select patients for whom there was a meaningful chance of
CPAP being successful, or for whom the potential advantages of prehospital CPAP would outweigh
the burdens of more advanced and aggressive treatment.
These findings might argue against routine implementation of CPAP into EMS, but would not be at
variance with a CPAP service provided by clinicians with extended training (e.g. critical care paramedics,
British Association for Immediate Care teams), whose more advanced diagnostic and clinical reasoning
skills might allow selective targeting of treatment to an appropriate subgroup of patients. Furthermore,
increased use of Recommended Summary Plan for Emergency Care and Treatment (RESPECT) forms
would be particularly helpful to support treatment decisions in the demanding prehospital setting.
Research recommendations
The ACUTE pilot trial demonstrated a recruitment rate that was below the target rate considered a
priori necessary to deliver a definitive pragmatic trial. Therefore, in spite of identifying potentially
remediable recruitment barriers and achieving other feasibility targets, we conclude that feasibility was
not demonstrated. The economic evaluation showed that a large definitive trial could represent value
for money, and the higher than expected mortality rate might superficially suggest a smaller trial than
anticipated is required to detect a minimum clinically important difference. However, proceeding to a
large-scale pragmatic trial is predicated on the expectation that a clinically significant effect size is
plausible. The limited compliance with treatment in the intervention arm and the trial population,
including a significant proportion of patients who could not benefit from CPAP, indicate that this
assumption is unlikely to be tenable. We therefore do not recommend proceeding to a large-scale,
definitive effectiveness trial of CPAP in the NHS.
A number of alternative research questions are raised by the ACUTE trial. The difficulty in selecting
appropriate patients for CPAP suggests that further research into prehospital diagnosis and
personalisation of care is indicated. For example, point-of-care ultrasonography is a novel modality
that might be helpful in identifying pulmonary oedema and excluding pneumothorax, although its
complexity would restrict its use to clinicians with extended skills. Qualitative research exploring
ambulance service and patient views on treatment limitation decisions would also be informative.
The probability that the clinical effectiveness of prehospital CPAP could be convincingly demonstrated
in a future trial is likely to increase if applied to a more appropriate subgroup, although recruitment
would subsequently become more difficult.
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,




We gratefully acknowledge the hard work, support and advice from the following individualsand groups.
Patient and public involvement
The Breathe Easy PPI group, Sheffield Teaching Hospitals Cardiovascular PPI group, Sheffield
Emergency Care Forum, Asthma UK, Barnsley PPI and the ACUTE trial service user advisory group
(Jo Bishop, Katy Meegan, Carol Hurst, Julie Ardron, Paul Hague, Tom O’Brien, Mary Scott, Bob Scott,
Lynne Barnsley, Derek Platts and Margaret M Marsh).
Continuous positive airway pressure
O-Two Medical Technologies: Kevin Bowden.
SP Services: Paul Watts.
West Midlands Ambulance Service
Rhiannon Boldy and Jenny Lumley-Holmes.
Local hospital trust points of contact
University Hospital of North Midlands NHS Trust: Adrian Butler.
Burton Hospitals NHS Foundation Trust: Dr James Crampton and Mr Eddie Oforka.
The Royal Wolverhampton NHS Trust: Mr Chieh-Min Lin.
Heart of England NHS Foundation Trust: Dr Sajeel Mustafa and Dr Susan Dorrian.
Derby Teaching Hospitals NHS Foundation Trust: Dr Graham Johnson.
East Cheshire NHS Trust: Dr Thomas Bartram.
University Hospitals Birmingham NHS Foundation Trust: Dr David Yeo.
Sandwell and West Birmingham Hospitals NHS Trust: Brian Gammon.
University Hospitals Coventry and Warwickshire NHS Trust: Catherine Morgan.
George Eliot Hospital NHS Trust: Dr Rahul Bhat.
Yorkshire Ambulance Service
Fiona Bell, Richard Pilberry, Kelly Hird and Jamie Miles.
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
69
Medical students
Thomas McKenzie, Helena Davies and Caitlin Borowsky.
The University of Sheffield Clinical Trials Research Unit, Data Management
Tim Chater, Emily Turton and Chris Turtle.
We offer special thanks to the members of our TSC and DMEC.
Trial Steering Committee
Professor Alasdair Gray (chairperson, Royal Infirmary of Edinburgh), Professor Jason Smith (Derriford
Hospital), Dr Nicholas Hart (Guy’s and St Thomas’ Hospital), Ms Helen Pocock (South Central Ambulance
Service), Mr Nigel Rees (Welsh Ambulance Service), Ms Diana Charles (PPI representative, Sheffield
Emergency Care Forum), Mr Richard Barrass (PPI representative, Sheffield Cardiovascular Group) and
Dr Martyn Lewis (Keele University).
Data Monitoring and Ethics Committee
Professor Anthony Gordon (chairperson, Charing Cross Hospital), Ms Laura Blair (North East
Ambulance Service) and Professor Catherine Hewitt (University of York).
Contributions of authors
Gordon W Fuller (https://orcid.org/0000-0001-8532-3500) (Chief Investigator) drafted the report;
conceived of, or designed, the work; was involved in the analysis and the interpretation of data for
the work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
Samuel Keating (https://orcid.org/0000-0003-3685-2849) (Trial Manager) drafted the report;
conceived of, or designed, the work; was involved in the analysis and the interpretation of data for
the work; contributed to the management and conduct of the trial; revised the work critically for
important intellectual content and was involved in the final approval of the version to be published.
Steve Goodacre (https://orcid.org/0000-0003-0803-8444) (Co-chief Investigator) drafted the report;
conceived of, or designed, the work; was involved in the analysis and the interpretation of data for
the work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
Esther Herbert (https://orcid.org/0000-0002-1224-5457) (Statistician) drafted the report; was
involved in the analysis and the interpretation of data for the work; revised the work critically for
important intellectual content and was involved in the final approval of the version to be published.
Gavin D Perkins (https://orcid.org/0000-0003-3027-7548) (Co-applicant) conceived of, or designed,
the work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
70
Andy Rosser (https://orcid.org/0000-0002-5477-4269) (Lead Research Paramedic) was involved in the
acquisition of data for the work; contributed to the management and conduct of the trial; revised the
work critically for important intellectual content and was involved in the final approval of the version
to be published.
Imogen Gunson (https://orcid.org/0000-0001-8335-3335) (Research Paramedic) was involved in the
acquisition of data for the work; was involved in the analysis and the interpretation of data for the
work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
Joshua Miller (https://orcid.org/0000-0003-1990-4029) (Research Paramedic) drafted the report; was
involved in the acquisition of data for the work; was involved in the analysis and the interpretation of
data for the work; revised the work critically for important intellectual content and was involved in the
final approval of the version to be published.
Matthew Ward (https://orcid.org/0000-0003-4565-2339) (Co-applicant) conceived of, or designed,
the work; was involved in the acquisition of data for the work; contributed to the management and
conduct of the trial; revised the work critically for important intellectual content and was involved in
the final approval of the version to be published.
Mike Bradburn (https://orcid.org/0000-0002-3783-9761) (Co-applicant, Statistician) drafted the
report; conceived of, or designed, the work; was involved in the analysis and the interpretation of data
for the work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
Praveen Thokala (https://orcid.org/0000-0003-4122-2366) (Co-applicant, Health Economist) drafted
the report; conceived of, or designed, the work; was involved in the analysis and the interpretation of
data for the work; revised the work critically for important intellectual content and was involved in the
final approval of the version to be published.
Tim Harris (https://orcid.org/0000-0001-9628-130X) (Co-applicant) conceived of, or designed, the
work; revised the work critically for important intellectual content and was involved in the final
approval of the version to be published.
Margaret M Marsh (https://orcid.org/0000-0001-9881-0105) (Co-applicant, PPI Representative)
drafted the report; conceived of, or designed, the work; was involved in the analysis and the interpretation
of data for the work; revised the work critically for important intellectual content and was involved in the
final approval of the version to be published.
Alexander J Scott (https://orcid.org/0000-0001-7426-7099) (Qualitative Researcher) drafted the
report; was involved in the analysis and the interpretation of data for the work; revised the work
critically for important intellectual content and was involved in the final approval of the version to
be published.
Cindy Cooper (https://orcid.org/0000-0002-2995-5447) (Co-applicant; CTRU Director) conceived of,
or designed, the work; revised the work critically for important intellectual content and was involved in
the final approval of the version to be published.
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
71
Publications
Fuller GW, Goodacre S, Keating S, Perkins G, Ward M, Rosser A. The ACUTE (Ambulance CPAP: Use,
Treatment effect and economics) feasibility study: a pilot randomised controlled trial of prehospital
CPAP for acute respiratory failure. Pilot Feasibility Stud 2018;4:86.
Fuller G, Keating S, Goodacre S, Herbert E, Perkins G, Rosser A, et al. Is a definitive trial of prehospital
continuous positive airway pressure versus standard oxygen therapy for acute respiratory failure
indicated? The ACUTE pilot randomised controlled trial. BMJ Open 2020;10:e035915.
Thokala P, Fuller GW, Keating S, Herbert E, Rosser A, Gunson A, et al. Cost-effectiveness of out-of-
hospital continuous positive airway pressure for acute respiratory failure: decision analytic modelling
using data from a feasibility trial. BMC Emerg Med 2021. In press.
Data-sharing statement
All data requests should be submitted to the corresponding author for consideration. Access to
anonymised data may be granted following review.
Patient data
This work uses data provided by patients and collected by the NHS as part of their care and support.
Using patient data is vital to improve health and care for everyone. There is huge potential to make
better use of information from people’s patient records, to understand more about disease, develop
new treatments, monitor safety, and plan NHS services. Patient data should be kept safe and secure,
to protect everyone’s privacy, and it’s important that there are safeguards to make sure that it is
stored and used responsibly. Everyone should be able to find out about how patient data are
used. #datasaveslives You can find out more about the background to this citation here:
https://understandingpatientdata.org.uk/data-citation.
ACKNOWLEDGEMENTS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
72
References
1. Fuller G, Keating S, Goodacre S, Herbert E, Perkins G, Rosser A, et al. Is a definitive trial of
prehospital continuous positive airway pressure versus standard oxygen therapy for acute
respiratory failure indicated? The ACUTE pilot randomised controlled trial. BMJ Open
2020;10:e035915. https://doi.org/10.1136/bmjopen-2019-035915
2. Creagh-Brown B. Respiratory failure. Medicine 2016;44:342–5. https://doi.org/10.1016/
j.mpmed.2016.03.005
3. Pandor A, Thokala P, Goodacre S, Poku E, Stevens JW, Ren S, et al. Pre-hospital non-invasive
ventilation for acute respiratory failure: a systematic review and cost-effectiveness evaluation.
Health Technol Assess 2015;19(42). https://doi.org/10.3310/hta19420
4. Widmaier EP, Raff H, Strang KT. Vander’s Human Physiology: The Mechanisms of Body Function.
9th edn. Boston, MA: McGraw-Hill Higher Education; 2004.
5. Barrett K, Barman S, Boitano S, Brooks H. Ganong’s Review of Medical Physiology. 25th edn.
Boston, MA: McGraw-Hill Higher Education; 2016.
6. Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Steingrub JS, Lagu T, Lindenauer PK.
Epidemiology and outcomes of acute respiratory failure in the United States, 2001 to 2009:
a national survey. J Hosp Med 2013;8:76–82. https://doi.org/10.1002/jhm.2004
7. Roussos C, Koutsoukou A. Respiratory failure. Eur Respir J Suppl 2003;47:3s–14s. https://doi.org/
10.1183/09031936.03.00038503
8. Delerme S, Ray P. Acute respiratory failure in the elderly: diagnosis and prognosis. Age Ageing
2008;37:251–7. https://doi.org/10.1093/ageing/afn060
9. Ray P, Birolleau S, Lefort Y, Becquemin MH, Beigelman C, Isnard R, et al. Acute respiratory
failure in the elderly: etiology, emergency diagnosis and prognosis. Crit Care 2006;10:R82.
https://doi.org/10.1186/cc4926
10. Department of Health and Social Care. Hospital Episode Statistics. 2014. URL: www.hesonline.
nhs.uk (accessed 20 August 2014).
11. Association of Ambulance Chief Executives and Joint Royal Colleges Ambulance Liaison
Committee. UK Ambulance Services Clinical Practice Guidelines: 2013. Somerset: Class
Professional Publishing; 2013.
12. Abdo WF, Heunks LM. Oxygen-induced hypercapnia in COPD: myths and facts. Crit Care
2012;16:323. https://doi.org/10.1186/cc11475
13. Brill SE, Wedzicha JA. Oxygen therapy in acute exacerbations of chronic obstructive
pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014;9:1241–52. https://doi.org/10.2147/
COPD.S41476
14. O’Driscoll BR, Howard LS, Earis J, Mak V. BTS guideline for oxygen use in adults in healthcare
and emergency settings. Thorax 2017;72:ii1–ii90. https://doi.org/10.1136/thoraxjnl-2016-
209729
15. Bello G, De Pascale G, Antonelli M. Noninvasive ventilation. Clin Chest Med 2016;37:711–21.
https://doi.org/10.1016/j.ccm.2016.07.011
16. Baudouin S, Blumenthal S, Cooper B, Davidson C, Elliot M, Kinnear W, et al. Non-invasive
ventilation in acute respiratory failure. Thorax 2002;57:192–211. https://doi.org/10.1136/
thorax.57.3.192
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
73
17. Poulton EP. Left-sided heart failure with pulmonary oedema: its treatment with the
‘Pulmonary Plus Pressure Machine’. Lancet 1936;228:981–3. https://doi.org/10.1016/
S0140-6736(00)47948-1
18. Cross AM. Review of the role of non-invasive ventilation in the emergency department.
J Accid Emerg Med 2000;17:79–85. https://doi.org/10.1136/emj.17.2.79
19. Mas A, Masip J. Noninvasive ventilation in acute respiratory failure. Int J Chron Obstruct
Pulmon Dis 2014;9:837–52. https://doi.org/10.2147/COPD.S42664
20. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation
to treat respiratory failure resulting from exacerbations of chronic obstructive pulmonary
disease: Cochrane systematic review and meta-analysis. BMJ 2003;326:185. https://doi.org/
10.1136/bmj.326.7382.185
21. Vital FM, Ladeira MT, Atallah AN. Non-invasive positive pressure ventilation (CPAP or bilevel
NPPV) for cardiogenic pulmonary oedema. Cochrane Database Syst Rev 2013;5:CD005351.
https://doi.org/10.1002/14651858.CD005351.pub3
22. Gray AJ, Goodacre S, Newby DE, Masson MA, Sampson F, Dixon S, et al. A multicentre
randomised controlled trial of the use of continuous positive airway pressure and non-invasive
positive pressure ventilation in the early treatment of patients presenting to the emergency
department with severe acute cardiogenic pulmonary oedema: the 3CPO trial. Health Technol
Assess 2009;13(33). https://doi.org/10.3310/hta13330
23. Masip J, Roque M, Sánchez B, Fernández R, Subirana M, Expósito JA. Noninvasive ventilation
in acute cardiogenic pulmonary edema: systematic review and meta-analysis. JAMA
2005;294:3124–30. https://doi.org/10.1001/jama.294.24.3124
24. Plaisance P, Pirracchio R, Berton C, Vicaut E, Payen D. A randomized study of out-of-hospital
continuous positive airway pressure for acute cardiogenic pulmonary oedema: physiological
and clinical effects. Eur Heart J 2007;28:2895–901. https://doi.org/10.1093/eurheartj/ehm502
25. Christie A, Costa-Scorse B, Nicholls M, Jones P, Howie G. Accuracy of working diagnosis by
paramedics for patients presenting with dyspnoea. Emerg Med Australas 2016;28:525–30.
https://doi.org/10.1111/1742-6723.12618
26. Goodacre S, Stevens JW, Pandor A, Poku E, Ren S, Cantrell A, et al. Prehospital noninvasive
ventilation for acute respiratory failure: systematic review, network meta-analysis, and individual
patient data meta-analysis. Acad Emerg Med 2014;21:960–70. https://doi.org/10.1111/
acem.12466
27. Simpson PM, Bendall JC. Prehospital non-invasive ventilation for acute cardiogenic pulmonary
oedema: an evidence-based review. Emerg Med J 2011;28:609–12. https://doi.org/10.1136/
emj.2010.092296
28. Rees N. Prehospital continuous positive airway pressure ventilation in ACPO: part 2.
J Paramed Pract 2011;3:179–85. https://doi.org/10.12968/jpar.2011.3.4.179
29. Williams B, Boyle M, Robertson N, Giddings C. When pressure is positive: a literature review
of the prehospital use of continuous positive airway pressure. Prehosp Disaster Med
2013;28:52–60. https://doi.org/10.1017/S1049023X12001562
30. Williams TA, Finn J, Perkins GD, Jacobs IG. Prehospital continuous positive airway pressure
for acute respiratory failure: a systematic review and meta-analysis. Prehosp Emerg Care
2013;17:261–73. https://doi.org/10.3109/10903127.2012.749967
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
74
31. Mal S, McLeod S, Iansavichene A, Dukelow A, Lewell M. Effect of out-of-hospital noninvasive
positive-pressure support ventilation in adult patients with severe respiratory distress: a
systematic review and meta-analysis. Ann Emerg Med 2014;63:600–7.e1. https://doi.org/
10.1016/j.annemergmed.2013.11.013
32. Thokala P, Goodacre S, Ward M, Penn-Ashman J, Perkins GD. Cost-effectiveness of out-of-
hospital continuous positive airway pressure for acute respiratory failure. Ann Emerg Med
2015;65:556–63.e6. https://doi.org/10.1016/j.annemergmed.2014.12.028
33. Mungall IJ. Trend towards centralisation of hospital services, and its effect on access to care
for rural and remote communities in the UK. Rural Remote Health 2005;5:390.
34. Nicholl J, West J, Goodacre S, Turner J. The relationship between distance to hospital and
patient mortality in emergencies: an observational study. Emerg Med J 2007;24:665–8.
https://doi.org/10.1136/emj.2007.047654
35. Snooks H, Evans A, Wells B, Peconi J, Thomas M, Woollard M, et al. What are the highest
priorities for research in emergency prehospital care? Emerg Med J 2009;26:549–50.
https://doi.org/10.1136/emj.2008.065862
36. Fuller GW, Goodacre S, Keating S, Perkins G, Ward M, Rosser A, et al. The ACUTE (Ambulance
CPAP: Use, Treatment effect and economics) feasibility study: a pilot randomised controlled
trial of prehospital CPAP for acute respiratory failure. Pilot Feasibility Stud 2018;4:86.
https://doi.org/10.1186/s40814-018-0281-9
37. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated
guidelines for reporting parallel group randomised trials. BMJ 2010;340:c332. https://doi.org/
10.1136/bmj.c332
38. Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, et al. CONSORT 2010
statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239.
https://doi.org/10.1136/bmj.i5239
39. World Medical Association. Declaration of Helsinki: ethical principles for medical research
involving human subjects. JAMA 2013;310:2191–4. https://doi.org/10.1001/jama.2013.281053
40. Johnston C, Liddle J. The Mental Capacity Act 2005: a new framework for healthcare decision
making. J Med Ethics 2007;33:94–7. https://doi.org/10.1136/jme.2006.016972
41. Dixon JR. The International Conference on Harmonization Good Clinical Practice guideline.
Qual Assur 1998;6:65–74. https://doi.org/10.1080/105294199277860
42. Davies H, Shakur H, Padkin A, Roberts I, Slowther AM, Perkins GD. Guide to the design and
review of emergency research when it is proposed that consent and consultation be waived.
Emerg Med J 2014;31:794–5. https://doi.org/10.1136/emermed-2014-203675
43. Coats TJ, Ng G, Shakur H. Consent in emergency research. Emerg Med J 2006;23:489–90.
https://doi.org/10.1136/emj.2005.031005
44. O-Two Medical Technologies Inc. Single Use CPAP. 2018. URL: http://otwo.com/emergency-cpap/
o_two-single-use-cpap/ (accessed 10 January 2018).
45. Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and
preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res
2011;20:1727–36. https://doi.org/10.1007/s11136-011-9903-x
46. Boyd P. Health research and the Data Protection Act 1998. J Health Serv Res Policy
2003;8(Suppl. 1):1:24–7. https://doi.org/10.1258/135581903766468846
47. Chico V. The impact of the General Data Protection Regulation on health research. Br Med Bull
2018;128:109–18. https://doi.org/10.1093/bmb/ldy038
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
75
48. Arain M, Campbell MJ, Cooper CL, Lancaster GA. What is a pilot or feasibility study? A review
of current practice and editorial policy. BMC Med Res Methodol 2010;10:67. https://doi.org/
10.1186/1471-2288-10-67
49. Teare MD, Dimairo M, Shephard N, Hayman A, Whitehead A, Walters SJ. Sample size
requirements to estimate key design parameters from external pilot randomised controlled
trials: a simulation study. Trials 2014;15:264. https://doi.org/10.1186/1745-6215-15-264
50. Wilson EB. Probable inference, the law of succession, and statistical inference. J Am Stat Assoc
1927;22:209–12. https://doi.org/10.2307/2276774
51. Leon AC, Davis LL, Kraemer HC. The role and interpretation of pilot studies in clinical research.
J Psychiatr Res 2011;45:626–9. https://doi.org/10.1016/j.jpsychires.2010.10.008
52. Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, et al. A tutorial on pilot studies: the what,
why and how. BMC Med Res Methodol 2010;10:1. https://doi.org/10.1186/1471-2288-10-1
53. Kruse RL, Alper BS, Reust C, Stevermer JJ, Shannon S, Williams RH. Intention-to-treat analysis:
who is in? Who is out? J Fam Pract 2002;51:969–71.
54. Briggs AH, Claxton K, Sculpher MJ. Decision Modelling for Health Economic Evaluation. Oxford:
Oxford University Press; 2006.
55. Drummond MF. Methods for the Economic Evaluation of Health Care Programmes. 3rd edn.
Oxford: Oxford University Press; 2005.
56. Fuller G. The Clinical and Cost-Effectiveness of Prehospital Triage and Bypass for Adults with
Suspected Significant Traumatic Brain Injury. Sheffield: University of Sheffield; 2014.
57. National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology
Appraisal 2013. London: NICE; 2013.
58. Office for National Statistics. Source Dataset: Consumer Price Inflation Time Series (MM23).
URL: www.ons.gov.uk/economy/inflationandpriceindices/timeseries/l55o/mm23 (accessed
22 April 2020).
59. Weinstein MC, Torrance G, McGuire A. QALYs: the basics. Value Health 2009;12(Suppl. 1):5–9.
https://doi.org/10.1111/j.1524-4733.2009.00515.x
60. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD, ISPOR-SMDM
Modeling Good Research Practices Task Force. Model parameter estimation and uncertainty
analysis: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force
Working Group-6. Med Decis Making 2012;32:722–32. https://doi.org/10.1177/
0272989X12458348
61. Cohen DJ, Reynolds MR. Interpreting the results of cost-effectiveness studies. J Am Coll Cardiol
2008;52:2119–26. https://doi.org/10.1016/j.jacc.2008.09.018
62. Trippoli S. Incremental cost-effectiveness ratio and net monetary benefit: current use in
pharmacoeconomics and future perspectives. Eur J Intern Med 2017;43:e36. https://doi.org/
10.1016/j.ejim.2017.05.015
63. McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what
that means. PharmacoEconomics 2008;26:733–44. https://doi.org/10.2165/00019053-
200826090-00004
64. Claxton K, Sculpher M, McCabe C, Briggs A, Akehurst R, Buxton M, et al. Probabilistic
sensitivity analysis for NICE technology assessment: not an optional extra. Health Econ
2005;14:339–47. https://doi.org/10.1002/hec.985
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
76
65. Fenwick E, O’Brien BJ, Briggs A. Cost-effectiveness acceptability curves – facts, fallacies and
frequently asked questions. Health Econ 2004;13:405–15. https://doi.org/10.1002/hec.903
66. Briggs AH. Handling uncertainty in cost-effectiveness models. PharmacoEconomics
2000;17:479–500. https://doi.org/10.2165/00019053-200017050-00006
67. Eckermann S, Willan AR. Expected value of information and decision making in HTA. Health Econ
2007;16:195–209. https://doi.org/10.1002/hec.1161
68. Brennan A, Kharroubi S, O’hagan A, Chilcott J. Calculating partial expected value of perfect
information via Monte Carlo sampling algorithms. Med Decis Making 2007;27:448–70.
https://doi.org/10.1177/0272989X07302555
69. Ho JY, Hendi AS. Recent trends in life expectancy across high income countries: retrospective
observational study. BMJ 2018;362:k2562. https://doi.org/10.1136/bmj.k2562
70. Shavelle RM, Paculdo DR, Kush SJ, Mannino DM, Strauss DJ. Life expectancy and years of life
lost in chronic obstructive pulmonary disease: findings from the NHANES III follow-up study.
Int J Chron Obstruct Pulmon Dis 2009;4:137–48. https://doi.org/10.2147/COPD.S5237
71. Office for National Statistics. England, Interim Life Tables 1980–82 to 2006–2008. Newport:
Office for National Statistics; 2009.
72. Office for National Statistics. 2011 Census Aggregate Data. 2016. URL: https://discover.
ukdataservice.ac.uk/doi/2011-census-aggregate (accessed 3 December 2019).
73. Office for National Statistics. NOMIS: Official Labour Market Statistics Ward Profile. Newport:
Office for National Statistics; 2016.
74. Agresti A. An Introduction to Categorical Data Analysis. New York, NY: Wiley; 1996.
75. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an
updated list of essential items for reporting diagnostic accuracy studies. BMJ 2015;351:h5527.
https://doi.org/10.1136/bmj.h5527
76. Kottner J, Audigé L, Brorson S, Donner A, Gajewski BJ, Hróbjartsson A, et al. Guidelines for
Reporting Reliability and Agreement Studies (GRRAS) were proposed. J Clin Epidemiol
2011;64:96–106. https://doi.org/10.1016/j.jclinepi.2010.03.002
77. Gwet KL. Computing inter-rater reliability and its variance in the presence of high agreement.
Br J Math Stat Psychol 2008;61:29–48. https://doi.org/10.1348/000711006x126600
78. Wongpakaran N, Wongpakaran T, Wedding D, Gwet KL. A comparison of Cohen’s Kappa and
Gwet’s AC1 when calculating inter-rater reliability coefficients: a study conducted with
personality disorder samples. BMC Med Res Methodol 2013;13:61. https://doi.org/10.1186/
1471-2288-13-61
79. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics
1977;33:159–74. https://doi.org/10.2307/2529310
80. Akobeng AK. Understanding diagnostic tests 1: sensitivity, specificity and predictive values.
Acta Paediatr 2007;96:338–41. https://doi.org/10.1111/j.1651-2227.2006.00180.x
81. Sullivan GM, Artino AR. Analyzing and interpreting data from Likert-type scales. J Grad Med Educ
2013;5:541–2. https://doi.org/10.4300/JGME-5-4-18
82. Braun V, Clarke V. Thematic Analysis. In Cooper H, Camic PM, Long DL, Panter AT, Rindskopf D,
Sher K, Neth J, editors. APA Handbook of Research Methods in Psychology, Vol 2: Research Designs:
Quantitative, Qualitative, Neuropsychological, and Biological. Washington, DC: American
Psychological Association; 2012. pp. 57–71. https://doi.org/10.1037/13620-004
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
77
83. Kitzinger J. Qualitative research. Introducing focus groups. BMJ 1995;311:299–302.
https://doi.org/10.1136/bmj.311.7000.299
84. Department of Health and Social Care (DHSC). NHS Reference Costs 2017/2018. London:
DHSC; 2018.
85. Curtis L. Unit Costs of Health and Social Care 2018. Canterbury: PSSRU, University of Kent;
2018.
86. Hubble MW, Richards ME, Wilfong DA. Estimates of cost-effectiveness of prehospital continuous
positive airway pressure in the management of acute pulmonary edema. Prehosp Emerg Care
2008;12:277–85. https://doi.org/10.1080/10903120801949275
87. Perkins GD, Ji C, Deakin CD, Quinn T, Nolan JP, Scomparin C, et al. A randomized trial of
epinephrine in out-of-hospital cardiac arrest. N Engl J Med 2018;379:711–21. https://doi.org/
10.1056/NEJMoa1806842
88. Benger JR, Kirby K, Black S, Brett SJ, Clout M, Lazaroo MJ, et al. Effect of a strategy of a
supraglottic airway device vs tracheal intubation during out-of-hospital cardiac arrest on
functional outcome: the AIRWAYS-2 randomized clinical trial. JAMA 2018;320:779–91.
https://doi.org/10.1001/jama.2018.11597
89. Carron PN, Pantet R, Pasquier M, Hugli O. Mechanical chest compression in the PARAMEDIC
trial. Lancet 2015;386:26. https://doi.org/10.1016/S0140-6736(15)61196-5
90. Altman DG. Randomisation. BMJ 1991;302:1481–2. https://doi.org/10.1136/bmj.302.6791.1481
91. Schulz KF, Grimes DA. Allocation concealment in randomised trials: defending against
deciphering. Lancet 2002;359:614–18. https://doi.org/10.1016/S0140-6736(02)07750-4
92. Keen L, Bulger JK, Rees N, Snooks H, Fegan G, Ford S, et al. Use of scratchcards for allocation
concealment in a prehospital randomised controlled trial. Emerg Med J 2018;35:708–10.
https://doi.org/10.1136/emermed-2018-207881
93. Lecky F, Russell W, Fuller G, McClelland G, Pennington E, Goodacre S, et al. The Head Injury
Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study.
Health Technol Assess 2016;20(1). https://doi.org/10.3310/hta20010
94. Clark L, Fairhurst C, Torgerson DJ. Allocation concealment in randomised controlled trials:
are we getting better? BMJ 2016;355:i5663. https://doi.org/10.1136/bmj.i5663
95. Donner A, Klar NS. Design and Analysis of Cluster Randomisation Trials in Health Research.
London: Arnold; 1999.
96. Hayes RJ, Moulton LH. Cluster Randomised Trials. Boca Raton, FL: CRC Press; 2009.
https://doi.org/10.1201/9781584888178
97. Beksinska ME, Joanis C, Smit JA, Pienaar J, Piaggio G. Using scratch card technology for
random allocation concealment in a clinical trial with a crossover design. Clin Trials
2013;10:125–30. https://doi.org/10.1177/1740774512465496
98. Davidson C, Banham S, Elliott M, Kennedy D, Gelder C, Glossop A, et al. British Thoracic
Society/Intensive Care Society Guideline for the ventilatory management of acute hypercapnic
respiratory failure in adults. BMJ Open Respir Res 2016;3:e000133. https://doi.org/10.1136/
bmjresp-2016-000133
99. Trethewey SP, Edgar RG, Turner AM, Mukherjee R. Ward-based non-invasive ventilation in
acute exacerbations of COPD: a narrative review of current practice and outcomes in the UK.
Healthcare 2018;6:E145. https://doi.org/10.3390/healthcare6040145
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
78
100. Creagh-Brown B, Shee C. Noninvasive ventilation as ceiling of therapy in end-stage chronic
obstructive pulmonary disease. Chron Respir Dis 2008;5:143–8. https://doi.org/10.1177/
1479972308089234
101. Vassar M, Holzmann M. The retrospective chart review: important methodological
considerations. J Educ Eval Health Prof 2013;10:12. https://doi.org/10.3352/jeehp.2013.10.12
102. Gearing RE, Mian IA, Barber J, Ickowicz A. A methodology for conducting retrospective chart
review research in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry
2006;15:126–34.
103. National Institute for Health Research. Guide to the Methods of Technology Appraisal. London:
NICE; 2013.
104. Ades AE, Lu G, Claxton K. Expected value of sample information calculations in medical
decision modeling. Med Decis Making 2004;24:207–27. https://doi.org/10.1177/
0272989X04263162
105. Kohn MA, Carpenter CR, Newman TB. Understanding the direction of bias in studies of
diagnostic test accuracy. Acad Emerg Med 2013;20:1194–206. https://doi.org/10.1111/
acem.12255
106. Schmidt RL, Factor RE. Understanding sources of bias in diagnostic accuracy studies. Arch
Pathol Lab Med 2013;137:558–65. https://doi.org/10.5858/arpa.2012-0198-RA
107. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2:
a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med
2011;155:529–36. https://doi.org/10.7326/0003-4819-155-8-201110180-00009
108. Bertens LC, Broekhuizen BD, Naaktgeboren CA, Rutten FH, Hoes AW, van Mourik Y, et al.
Use of expert panels to define the reference standard in diagnostic research: a systematic
review of published methods and reporting. PLOS Med 2013;10:e1001531. https://doi.org/
10.1371/journal.pmed.1001531
109. Restrepo-Escobar M, Granda-Carvajal PA, Jaimes F. Systematic review of the literature on
reproducibility of the interpretation of renal biopsy in lupus nephritis. Lupus 2017;26:1502–12.
https://doi.org/10.1177/0961203317706556
110. Quader N, Schaeffer EK, Hodgson AJ, Abugharbieh R, Mulpuri K. A systematic review and
meta-analysis on the reproducibility of ultrasound-based metrics for assessing developmental
dysplasia of the hip. J Pediatr Orthop 2018;38:e305–e311. https://doi.org/10.1097/
BPO.0000000000001179
111. Fleiss JL. Measuring nominal scale agreement among many raters. Psychological Bulletin
1971;76:378–382. https://doi.org/10.1037/h0031619
112. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med 2012;22:276–82.
https://doi.org/10.11613/BM.2012.031
113. Thorpe KE, Zwarenstein M, Oxman AD, Treweek S, Furberg CD, Altman DG, et al. A
pragmatic-explanatory continuum indicator summary (PRECIS): a tool to help trial designers.
J Clin Epidemiol 2009;62:464–75. https://doi.org/10.1016/j.jclinepi.2008.12.011
114. Rothwell PM. External validity of randomised controlled trials: ‘to whom do the results of this
trial apply?’. Lancet 2005;365:82–93. https://doi.org/10.1016/S0140-6736(04)17670-8
115. Mulherin SA, Miller WC. Spectrum bias or spectrum effect? Subgroup variation in diagnostic
test evaluation. Ann Intern Med 2002;137:598–602. https://doi.org/10.7326/0003-4819-137-
7-200210010-00011
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
79
116. Nielsen VM, Madsen J, Aasen A, Toft-Petersen AP, Lübcke K, Rasmussen BS, Christensen EF.
Prehospital treatment with continuous positive airway pressure in patients with acute respiratory
failure: a regional observational study. Scand J Trauma Resusc Emerg Med 2016;24:121.
https://doi.org/10.1186/s13049-016-0315-3
117. Hensel M, Strunden MS, Tank S, Gagelmann N, Wirtz S, Kerner T. Prehospital non-invasive
ventilation in acute respiratory failure is justified even if the distance to hospital is short.
Am J Emerg Med 2019;37:651–6. https://doi.org/10.1016/j.ajem.2018.07.001
118. Jacob J, Arranz M, Sancho Ramoneda M, Lopez À, Navarro Sáez MC, Cousiño Chao JR, et al.
[Noninvasive mechanical ventilation in emergency services in Catalonia: the VNICat registry
cohort study.] Emergencias 2017;29:33–8.
119. Luiz T, Kumpch M, Grüttner J, Madler C, Viergutz T. Prehospital CPAP therapy by emergency
physicians in patients with acute respiratory failure due to acute cardiogenic pulmonary
edema or acutely exacerbated COPD. In Vivo 2016;30:133–9.
120. Sahu N, Matthews P, Groner K, Papas MA, Megargel R. Observational study on safety of
prehospital BLS CPAP in dyspnea. Prehosp Disaster Med 2017;32:610–14. https://doi.org/
10.1017/S1049023X17006677
121. Willmore A, Dionne R, Maloney J, Ouston E, Stiell I. Effectiveness and safety of a prehospital
program of continuous positive airway pressure (CPAP) in an urban setting. CJEM
2015;17:609–16. https://doi.org/10.1017/cem.2014.60
122. Williams T. A Randomised Controlled Trial of Continuous Positive Airway Pressure (CPAP) for the
Treatment of Severe Respiratory Distress by Ambulance Paramedics in the Pre-Hospital Setting.
2015. URL: www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=369501 (accessed
1 April 2019).
123. Williams TA, Finn J, Celenza A, Teng TH, Jacobs IG. Paramedic identification of acute pulmonary
edema in a metropolitan ambulance service. Prehosp Emerg Care 2013;17:339–47. https://doi.org/
10.3109/10903127.2013.773114
124. Williams TA, Finn J, Fatovich D, Perkins GD, Summers Q, Jacobs I. Paramedic differentiation
of asthma and COPD in the prehospital setting is difficult. Prehosp Emerg Care 2015;19:535–43.
https://doi.org/10.3109/10903127.2014.995841
125. British Thoracic Society (BTS). National Respiratory Audit Programme Annual Report 2011/2012.
London: BTS; 2012.
126. Luhr OR, Antonsen K, Karlsson M, Aardal S, Thorsteinsson A, Frostell CG, et al. Incidence and
mortality after acute respiratory failure and acute respiratory distress syndrome in Sweden,
Denmark, and Iceland. The ARF Study Group. Am J Respir Crit Care Med 1999;159:1849–61.
https://doi.org/10.1164/ajrccm.159.6.9808136
127. Lewandowski K, Metz J, Deutschmann C, Preiss H, Kuhlen R, Artigas A, Falke KJ. Incidence,
severity, and mortality of acute respiratory failure in Berlin, Germany. Am J Respir Crit Care Med
1995;151:1121–5. https://doi.org/10.1164/ajrccm.151.4.7697241
REFERENCES
NIHR Journals Library www.journalslibrary.nihr.ac.uk
80
Appendix 1 Protocol changes











information sheet and advice
form were created
l Indemnity section added to all
information sheets













l Allocation concealment changed
to reflect that the equipment
boxes will now be prepared by
Sheffield CTRU, not SP Services
l Method of implementation of
allocation schedule further
refined to allow Sheffield CTRU
staff not directly involved in
conduct of the trial to aid in
process of assembling
equipment boxes
l Change to section 8 safety
reporting
l Further refinement of policy
so that AEs related to ‘trial
procedures’ will also be recorded
l ‘Pressure area damage’ added to
discrete list of related AEs that
will be reported





l Addition of allocation
concealment substudy
l Supporting documents for
addition of allocation
concealment substudy
l Changes to collection of data
for patients we are unable to
approach for written consent
(deceased/discharged and unable
to contact in community)
l Addition of one extra field in
survey, to record equipment box
number, used in that particular
enrolment of patient to the trial
(paramedics complete a survey
every time they enrol a new
patient)
l Addition of new trial site to host
the allocation concealment
substudy only
V3 14Dec17 REC, CAG, HRA
DOI: 10.3310/hta25070 Health Technology Assessment 2021 Vol. 25 No. 7
© Queen’s Printer and Controller of HMSO 2021. This work was produced by Fuller et al. under the terms of a commissioning contract issued by the Secretary of State for
Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in
professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial
reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House,
University of Southampton Science Park, Southampton SO16 7NS, UK.
81










l Addition of allocation
concealment substudy
l Supporting documents for
addition of allocation
concealment substudy
l Addition of one extra field in
survey, to record equipment box
number, used in that particular
enrolment of patient to the
trial (paramedics complete a
survey every time they enrol a
new patient)






31 July 2018 l Detailed response to CAG
further requests, related to
change in data collection for
patients we were unable to
approach for written consent
(deceased/discharged and unable
to contact in community)





l Change to section 7. Addition
of qualitative substudy to hold
focus groups with ambulance
clinicians who participated in the
ACUTE trial. Focus groups to
explore issues highlighted in the
ambulance clinician survey and
other topics relevant to the
design/conduct/management of
the trial
l Addition of new documents to
support focus group substudy
l Addition of appendices with
further details of proposed
qualitative substudy
V5 03Aug18 REC, HRA
Minor amendment
number 1
7 June 2017 l ACUTE trial: follow-up
questionnaire v1 18Aug16




l Section 1.a: rewording of
question, addition of hospital
name for clarification
l Section 1.b: adding A&E as
response, reordering of
response categories
l Section 3: rewording question
for further clarification





29 June 2017 l Addition of a new principal
investigator at one of the trial
sites (Andy Rosser at WMAS)
HRA
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3 July 2017 l Addition of several new
trial sites:





17 July 2017 l Changes to the wording in the
ACUTE trial paramedic survey
and ACUTE trial paramedic
survey information sheet, to
reflect that a range of staff
who work for the WMAS will
be recruiting patients to the
trial, not just paramedics
(i.e. ambulance technicians)
HRA
A&E, accident and emergency; CAG, Commissioning Advisory Group; IRAS, Integrated Research Application System.
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Appendix 2 Participating ambulance hubs,
ambulance stations and hospitals
Ambulance hubs Ambulance stations Hospital sites
Erdington Royal Stoke University Hospital
Stoke Leek, Biddulph County Hospital
Stafford Uttoxeter Queen’s Hospital Burton






Macclesfield District General Hospital




Hospital of St Cross
George Eliot Hospital
Russells Hall Hospital
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Appendix 3 The ACUTE pilot trial
follow-up and assessments

































Patient demographics Hospital Research
paramedic
Paper ✗ ✗















Acceptability of CPAP Home/work Ambulance
clinicians
Electronic ✗
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HRA safety report form
Unexpected related SAEs CTRU Chief
investigator
Electronic ✗ ✗ ✗
SAE form
Other SAEs CTRU Chief
investigator
Paper ✗ ✗ ✗
Ceiling-of-treatment form
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Appendix 4 The ACUTE pilot trial safety
reporting procedures
Adverse change in health of acute participant
• Adverse change in health of ACUTE trial participant related to trial




Related SAE Unexpected related SAERelated AE
Reported in aggregate to:
• REC (annual progress report)a
• DMEC (prior to meetings)
• TSC (prior to meetings)
• Sponsor (3 monthly)
Expedited reporting of individual
SAEs within 15 days, using HRA
SAE form, to:
• Sponsor
• WMAS or hospital R&D
• REC
• DMEC
Reported in aggregate to:
• REC (annual progress report)a
• DMEC (prior to meetings)
• TSC (prior to meetings)
• Sponsor (3 monthly)
• Identified by paramedics (prehospital), research paramedics (inpatient) or
    trial manager (follow-up questionnaire)
• Details recorded in
    • the patient’s medical notes
    • the trial CRFs
    • the trial database
• All adverse health changes assessed and classified for relatedness and
    seriousness by an appropriately qualified member of the ACUTE research team
• All AEs reported to the chief investigator; SAEs recorded on SAE from and
    reported to CTRU within 24 hours
• Chief investigator reviews causality, severity and expectedness
FIGURE 19 Flow chart detailing safety reporting procedures for the ACUTE trial. R&D, research and development.
a, Related AEs/SAEs resulting in treatment failure.
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AE An adverse change in health that occurs while a patient is taking part in a study




l prolongation of hospitalisation
l disability or incapacity
l congenital abnormality or birth defect
l other adverse health change resulting in inability to perform routine activities or
significant medical event
Causality
Unrelated An adverse change in health that occurs while a patient is taking part in a study which is
not caused by or related to trial treatments
Related An adverse change in health that occurs while a patient is taking part in a study, which
is caused by or related to trial treatments. An AE or SAE is considered related if the
relationship between the event and trial treatments is:
l possible – there is some evidence to suggest a causal relationship; however, the
influence of other factors may have contributed to the event (e.g. the participant’s
clinical condition, other concomitant treatments)
l probable – there is evidence to suggest a causal relationship and the influence of
other factors is unlikely, or
l definite – there is clear evidence to suggest a causal relationship and other possible
contributing factors can be ruled out
Expectedness
Unexpected Any adverse health change that is not consistent with the known and expected AEs of
trial treatments (i.e. it is not listed in the protocol or related documents/literature as an
expected occurrence)
Expected Any adverse health change that is consistent with the known and expected AEs of trial
treatments
Severitya
Mild An adverse health change that does not interfere with routine activities
Moderate An adverse health change that interferes with routine activities
Severe An adverse health change that makes it impossible to perform routine activities
a The term ‘severity’, is used to describe the intensity and should not be confused with ‘serious’, which is based on
participant/event outcome or action criteria. For example, a headache may be severe but not serious, whereas a
minor stroke is serious but may not be severe.
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Appendix 5 The ACUTE pilot trial
adverse events
Site AE summary AE category Start date End date Serious?
Expected
SAE?
Stoke Headache Other 19 August 2017 19 August 2017 No No





13 September 2017 13 September 2017 Yes No
Lichfield Respiratory arrest Other 17 September 2017 17 September 2017 Yes No




18 September 2017 18 September 2017 Yes No
Stoke Fractured NOF Other 18 October 2017 Yes No
Erdington Social care
readmission
Other 23 October 2017 8 December 2017 Yes No
Lichfield CVA Other 28 October 2017 15 December 2017 Yes No
Stafford Death Cardiorespiratory
arrest
29 October 2017 29 October 2017 Yes Yes
Stafford Death Cardiorespiratory
arrest
29 October 2017 29 October 2017 Yes Yes
Stoke Patient died Cardiorespiratory
arrest
16 November 2017 16 November 2017 Yes No
Stoke Re-admission within
30 days
Other 30 November 2017 30 November 2017 No Yes
Stoke Claustrophobia Claustrophobia 12 December 2017 12 December 2017 No Yes
Erdington Distress at mask Other 15 December 2017 15 December 2017 No Yes
Erdington Died within 30 days Cardiorespiratory
arrest
21 December 2017 21 December 2017 Yes No
Stafford Patient died Cardiorespiratory
arrest
29 December 2017 29 December 2017 Yes Yes




Other 5 January 2018 15 January 2018 Yes Yes
Stafford Re-admission Other 10 January 2018 Yes No
Stoke Death Cardiorespiratory
arrest
14 January 2018 14 January 2018 Yes Yes
Stoke Patient died Cardiorespiratory
arrest
17 January 2018 17 January 2018 Yes Yes




23 January 2018 23 January 2018 Yes Yes




27 January 2018 27 January 2018 Yes Yes










28 January 2018 28 January 2018 No Yes
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6 February 2018 6 February 2018 Yes Yes
Stafford Patient died Cardiorespiratory
arrest
20 February 2018 20 February 2018 Yes Yes









Other 8 March 2018 15 March 2018 Yes Yes










10 March 2018 10 March 2018 Yes Yes




17 March 2018 17 March 2018 Yes Yes




28 March 2018 28 March 2018 Yes Yes
Stoke Patient got worse Vomiting 28 March 2018 28 March 2018 No Yes
Stafford Patient re-admitted,
then died
Other 12 April 2018 15 April 2018 Yes Yes
Lichfield Mask would not
inflate
Other 17 April 2018 17 April 2018 No No
Lichfield Cardiac arrest Cardiorespiratory
arrest
8 May 2018 8 May 2018 Yes Yes
Lichfield Death Cardiorespiratory
arrest
31 May 2018 31 May 2018 Yes Yes




3 June 2018 3 June 2018 Yes Yes
Lichfield Re-admissions within
30 days
Other 30 June 2018 1 July 2018 Yes Yes
Lichfield Re-admission within
30 days




Other 5 July 2018 5 July 2018 No Yes
Lichfield Pneumothorax Other 5 July 2018 27 July 2018 Yes Yes
Stafford Re-admission Other 6 July 2018 Yes Yes




Other 25 July 2018 3 August 2018 Yes Yes
Lichfield Re-admission Other 28 July 2018 Yes Yes
Stoke Death Cardiorespiratory
arrest
22 August 2018 22 August 2018 Yes Yes
CVA, cerebrovascular accident; NOF, neck of femur.
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